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Chapter 1 
INTRODUCTION AND PROBLEM STATEMENT. 
1.1 Some historical and introductory notes 
In 1955 Zollinger and Ellison described a syndrome, consisting 
of a fulminant peptic ulcer diathesis, gastric acid hypersecretion 
and pancreatic non-ß-islet cell tumours ( 1 ) . The relation between 
peptic ulcers and the entity of Multiple Endocrine Adenomatosis 
type I (MEA I) was published one year before ( 2 ) . Five years 
elapsed after the original description of the syndrome before 
gastrin was established as the humoral factor released by these 
tumours (3). Total gastrectomy proved to be the only treatment 
capable of ending the severe ulcer diathesis in these patients 
( 4 ) . 
The diagnosis of the Zol1 inger-El1 i son (ZE) syndrome was based 
on gastric acid hypersecretion and the demonstration of tumours 
at surgery. However, analysis of the parameters of gastric acid 
hypersecretion showed an overlap with the results in non-ZE-
patients ( 5 ) . Moreover, in some patients the tumours appeared to 
be extremely difficult to locate at surgery ( 6 ) . 
The demonstration of elevated serum gastrin concentrations in 
patients with the ZE-syndrome by radioimmunoassay proved to be 
an important diagnostic progress ( 7 ) . Recently different molecular 
forms of gastrin have been discovered and largely characterized 
(8-10). As radioimmunoassay techniques improved and provocation 
tests were developed (11-13), patients with the ZE-syndrome 
were detected with only mild or atypical symptoms. Moreover, 
other entities with the combination of gastric acid hypersecretion 
and hypergastrinemia, such as excluded gastric antrum and antral 
G-cell hyperplasia, were reported (14,15,16). Provocation tests 
proved to be necessary to separate these entities from the ZE-
syndrome (15-17). 
Furthermore newly developed drugs, such as histamine-2-receptor 
antagonists and streptozotocin, might change the way of treatment 
11 
of ZE-patients in the future ( 1 8 , 1 9 ) . 
1.2 Outline of investigations and objectives in this thesis 
The aim of this study is to investigate four main features 
of the ZE-syndrome. 
Firstly, relevant characteristics of the ZE-syndrome are 
analysed by studying clinical, laboratory and radiological data 
and the results of treatment of 18 patients with the ZE-syndrome 
(chapter 2 ) . This analysis is all the more interesting, since 
patients with no or slight complaints are included and the sig-
nificance of newly developed drugs is evaluated. Because serum 
albumin concentration in the patients,studied in chapter 2,was 
often found to be lower than normal, the significance of this 
finding was determined by comparing the results obtained in ZE-
patients with those of patients with duodenal and stomal ulcer 
(chapter 3 ) . Moreover, data about albumin metabolism, studied in 
detail in a small group of ZE-patients, are reported in this 
chapter. 
The most valuable diagnostic tool for the diagnosis of ZE-
syndrome is the determination of serum gastrin levels by radio-
immunoassay. In chapter 4 data about the significance of the 
gastrin assay are presented. 
Another problem, encountered in chapter 4 and in the litera-
ture, is the finding of the combination of hypergastrinemia and hyp-
erchlorhydria in non-ZE-patients as well as the presence of only 
slightly elevated serum gastrin levels in some patients with the 
ZE-syndrome. Stimulation tests have been advocated to separate 
these different entities in equivocal cases. However, no standard-
ized methods for interpretation of the results of stimulation 
tests are available in the literature. Moreover, the proportion 
of ZE-patients and non-ZE-patients with false positive and false 
negative test results has not been determined. The significance 
of the calcium, secretin and meal stimulation test in the diag-
nosis of ZE-syndrome is therefore presented in chapters 5, 6, 
7 and 8. In chapter 7 the effect of a standard test meal on serum 
gastrin is also studied in patients with various diseases with and 
without gastric surgery. 
12 
Finally, the ZE-syndrome may be accompanied by other endocrine 
disorders. The prevalence of endocrine abnormalities in ZE-
patients and in their families is studied in detail, as presented 
in chapter 9. Furthermore, some features of the MEA I-entity, of 
which ZE-syndrome can be a component, are analysed and are also 
presented in chapter 9. 
More details of the background of the different studies are 
presented in the introduction of each chapter. Each chapter is 
a more or less separate entity. This involves some overlap of 
data about patients and methods between the different chapters. 
Finally it has to be stressed that in the present investiga-
tions only total gastrin immunoreactivity is measured and that 
the possible implications of gastrin heterogeneity are therefore 
not taken into account. 
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Chapter 2 
THE ZOLLINGER-ELLISON SYNDROME. OBSERVATIONS ON 18 PATIENTS. 
2.1 Introduction 
In 1955 Zollinger and Ellison described the syndrome consis­
ting of recurrent peptic ulceration, hypersecretion of gastric 
acid, and ηοη-β-islet cell tumours of the pancreas (1). These 
tumours were shown to contain gastrin ( 2 ) , a polypeptide hormone, 
which under normal circumstances is mainly secreted by the gas­
trin (G-) cells in the antral and duodenal mucosa ( 3 ) . The demon­
stration of elevated gastrin levels in serum of Zol1 inger-El1 i son 
(ZE) patients was of great importance for the diagnosis of this 
syndrome ( 4 ) . Recent extensive monographs on the ZE-syndrome were 
presented by Isenberg et al (5) and Lamers et al (6). 
In this study experience is presented with diagnosis and 
treatment of 18 patients with the ZE-syndrome, examined at St. 
Radboud Hospital, Nijmegen, between 1963 and 1976. Diagnosis in 
12 out of the 18 patients studied was made after 1971. 
2.2 Definitions and methods 
In the present study the diagnosis of ZE-syndrome was made 
a. in patients, operated on for peptic ulcer disease, by non-ß-
islet cell tumours (9 cases), or by persistent hypergastrine-
mia after total gastrectomy without demonstrated tumours (3 
c a s e s ) ; 
b. in non-operated patients by the combination of basal gastric 
acid hypersecretion (more than 10 mmol H /h) and hypergastri-
nemia (more than 150 p g / m l ) , with an increase in serum gastrin 
of at least 50% of basal value after provocation with calcium 
or secretin, and a rise of less than 50% after ingestion of a 
standard test meal (chapter 8 . 3 ) . 
The gastric acid concentration was determined by titration of 
gastric juice with 0.1 M NaOH up to pH 7.0. Pentagastriη, б yg/kg 
17 
i.т., was used as stimulant of gastric acid secretion. 
Serum gastrin levels were measured by radioimmunoassay using 
a rabbit antibody (7,8; chapter 4 . 2 ) . This antibody, raised 
against synthetic human gastrin I containing residues 2 through 
17 conjugated to bovine albumin, binds gastrin components II 
and III with almost equal potency ( 9 ) . 
In the provocation tests release of gastrin was stimulated by 
infusion of 5 mg calcium/kg.h over 3 hours, administration of 
1 U secretin GIH/kg.30 sec, and ingestion of a standard test meal. 
Serum albumin concentration was measured by electrophoresis 
on cellulose acetate. Since hypoalbuminemia is often observed in 
gastrointestinal disorders ( 1 0 ) , serum albumin levels were deter­
mined in the ZE-patients studied. The methods of endocrine inves­
tigations and the defi nitions appiied to endocrine disorders are 
reported in chapter 9.2. 
2.3 Clinical manifestations 
Age at the time of diagnosis and sex distribution of the 18 
patients with the ZE-syndrome are recorded in table 2.1. The 
ages ranged from 17 to 64 years, with the majority of patients 
in the fourth and fifth decades. Eleven of the 18 patients were 
females and 7 were males. 
Ten patients had peptic ulcer disease without diarrhea, one 
patient had diarrhea without ulcers, 4 had both ulcers and dia­
rrhea and 3 had neither ulcers nor diarrhea (table 2 . 1 ) . Peptic 
ulcer disease was complicated by major gastrointestinal bleeding 
in 7 patients and by perforation in 7 cases. Weight loss of more 
than 5 kg was found in 11 cases. Five patients had marked com­
plaints of heartburn, one had serious dysphagia due to a severe 
distal oesophageal stricture and one had pancreatitis. The dura­
tion of complaints prior to the diagnosis of ZE-syndrome ranged 
from one up to 21 years. In 9 patients one to 5 laparotomies had 
been performed before the diagnosis was made. 
In table 2.2 results of endocrine studies in the 18 ZE-pa­
tients are shown. Four patients had evidence of pituitary gland 
tumours, 12 had a history or findings of hyperparathyroidism, 
two had hypoglycemia with pancreatic R-islet cell tumours, 3 had 
nodular adrenocortical hyperplasia and one had a bronchial car-
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Table 2.1 CLINICAL FEATURES OF 1Θ PATIENTS WITH THE ZOLLINGER-ELLISON SYNDROME. 
sex age ulcer diarrhea weight melaena perforation other 
(yrs) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
+ 
0 
f 
m 
m 
m 
f 
m 
present 
absent 
45 
40 
37 
48 
32 
27 
49 
41 
38 
39 
17 
64 
53 
35 
37 
40 
50 
43 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
0 
+ 
+ 
+ 
+ 
+ 
0 
0 
0 
loss 
(>5kg) 
+ 
О 
+ 
+ 
+ 
+ 
+ 
+ 
О 
+ 
+ 
о 
+ 
о 
+ 
о 
о 
о 
о 
+ 
+ 
о 
о 
+ 
+ 
+ 
о 
о 
+ 
о 
+ 
о 
о 
о 
о 
о 
symptoms 
heartburn 
heartburn 
oesophageal 
stricture 
heartburn 
pancreatitis 
heartburn 
heartburn 
duration of con-
pi aints prior to 
diagnosis 
(yrs) 
6 
12 
4 
21 
1 
3 
16 
1 
9 
10 
1 
15 
7 
5 
3 
15 
number of 
laparotomies 
prior to diagnosis 
5 
2 
2 
0 
1 
3 
4 
1 
0 
0 
0 
2 
3 
0 
0 
0 
0 
0 
Table 2.2 RESULTS OF ENDOCRINE STUDIES IN 18 PATIENTS WITH THE ZOLLINGER-
p1tuitary gland parathyroid glands 
18 
sella 
enlarge­
ment 
0 
0 
0 
« 
0 
0 
o'' 
0 
0 
0 
0 
+ 
0 
+ 
0 
+ 
0 
0 
growth 
hormone 
(i.U/nl) 
-
-
-
68 
-
'1 
*- 1 
<• 1 
< \ 
< \ 
< 1 
12 
< ι 
prolactin 
(ng/n 
-
-
-
106 
-
11 
39 
10 
9 
2 
5 
10 
4 
140 
10 
84 
4 
11. 
1) 
5 
5 
5 
tumour 
(tissue 
diagn. ) 
0 
-
-
+ 
-
-
-
0 
-
-
-
-
-
+ 
-
-
-
-
calcium 
(mmol/1) 
2.20 
2.84 
3.05 
2. 91'* 
2.10 
2.40 
2.85 
2.20 
2.30' 
2.80 
2.05 
2.82 
2.67 
2.51 
2.66 
2.69 
2.81' 
2.75 
ιnorganic 
phosphate 
(mmol/l ) 
0.80 
0.62 
0.60 
+
 0.93" 
0.76 
1.37 
0.78 
1.00 
0.881 
0.63 
1.24 
0.48 
0.68 
0.69 
0.65 
0.66 
0.74' 
0.62 
PTH 
(pg/ml 
-
-
-
4- + 
445 
-
60 
275 
85 
85" 
265 
25 
20 
330 
55 
290 
200 
3 9 b11 
220 
9 and 
e n l a r g e 
m e n t 
t-1-
0 
+ 
+ 
+ 
0 
-
-
0 
+ 
-
-
-
-
0 
-
-
+ 
. 
normal values <20 <30 2.20-2.60 0.85-1.30 <200 
+ present 
0 absent 
β equivocal 
not investigated 
* normal suppression after administration of dexamethasone 
urinary excretion of 17-hydroxycorticoids 12.6 ymol/mmol creatinine (normal 
'4 5) and 17-ketosteroids 10.4 i-mol/mmol creatinine (normal <3.2) 
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ELLISON SYNDROME. 
pancreatic islets 
glucose insulin- ß-islet 
glucose cel 1 
ratio tumour 
(mmol/1)(mU/mmol) 
adrenal cortex 
corti sol 
(umol/l ) 
nodular 
hyperplasia 
other 
m a m fes ta lions 
MEA I 
-
6 . 0 
6 .6 
4 . 9 
6 .8 
6 . 0 
5 . 9 
4 . 5 
4 V 
5 .4 
4 . 8 
5 .2 
4 . 5 
3 .7 
5 . 0 
5 .2 
5 . 0 
5 .3 
. 5 - 5 . 5 
-
-
-
2 .4 
-
3 . 4 
4 . 2 
5 .6 
4 . 5 f 
1.5 
4 . 5 
5 .5 
3 . 8 
8 . 8 
4 . 6 
6 . 2 
4 . 6 
3 .7 
< 7 . 3 5 5 
0 
0 
0 
0 
0 
0 
0 
0 
+ 
0 
0 
0 
0 
+ 
-
-
-
-
-
0 . 4 8 
0 . 5 0 * 
0 . 3 5 
1 .06" 
0 . 5 3 
0 .65 
0 . 4 3 
0 .35 
0 .48 
0 .50 
0 . 6 0 
0 .47 
·* 
0 . 0 2 
0 . 4 2 
0 .51 
0 . 4 2 
0 . 3 2 
0 . 3 5 - 0 . 8 0 
bronchial 
carcinoid 
§ low serum levels of FSH (1.4uIU/ml) and LH (13 ul U / m l ) ; secondary amenorrhea 
since age 26 
' after parathyroidectomy 
it after resection of 3 pancreatic ß-islet cell tumours 
** during treatment with cortisone 
tt value obtained during renal insufficiency 
§5 this figure has been calculated from the criterion of insulinoma, as des-
cribed by Grunt et al ( 1 1 ) . 
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cinoid tumour. Four patients (cases 1, 6, 8 and 11) were classi-
fied as isolated ZE-syndrome, 13 (cases 2-4, 7, 9, 10, 12-18) as 
ZE-syndrome as component of Multiple Endocrine Adenomatosis type 
I, and one (case 5) as ZE-syndrome with probably ectopic ACTH-
production by the pancreatic tumour. 
2 .4 Diagnosi s 
2.4.1 9.a.st.!l''£ £cjKl_secr.et.i£n 
In table 2.3 the basal gastric acid output, the basal gastric 
acid concentration, the ratio between basal and maximum acid out-
put and the ratio between basal and maximum acid concentration 
are presented. Moreover, the results of nocturnal gastric acid 
secretion over 12 hours are reported. The criterion of basal acid 
output, presented as characteristic for the ZE-syndrome in the 
literature (12), was met in 11 out of 15 studies, that of basal 
acid concentration (13) in 7 out of 18 tests, that of the ratio 
between basal and maximum acid output (14) in 7 out of 14 stu-
dies, that of the ratio between basal and maximum acid concen-
tration (15) in 11 out of 14 tests and that of 12 hours noctur-
nal acid secretion (16) in 9 out of 12 studies (table 2.3). 
Infusion of calcium, 5 mg/kg.h over 3 hours, resulted in 
a pronounced increase in gastric acid secretion, in acid con-
centration, and in serum gastrin in a patient with the ZE-syn-
drome (fig. 2.1). In 6 normal subjects the same calcium load 
caused only a moderate rise in gastric acid secretion and acid 
concentration and a minor increase in gastrin levels (fig. 2.2). 
Administration of secretin, 3 U/kg in one hour,resul ted in 
a definite increase in gastric acid output and acid concentration 
in a patient with the ZE-syndrome, but decreased gastric acid 
secretion in a duodenal ulcer patient (fig. 2.3). Serum gastrin 
levels increased in the ZE-patient, but were unchanged in the 
patient with duodenal ulcer after administration of secretin. 
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Table 2 .3 GASTRIC ACID STUDIES IN 18 PATIENTS WITH THE ZOLL INGER-ELLI SON 
SYNDROME. 
BAO* BAC t BAO ВАС nocturnal acid 
MAO5 MAC" secretion 
(mmol H +/h) (mmol H +/h) (mmol H +/1Z h) 
1 
2 9.7 48 0.34 0.41 58 
3 10.0 52 0.34 0.40 120 
4 40.3 124 0.71 0.85 159 
5 - 98 - - 140 
6 s.г11 ιοβ" 0.73 1.02 íes11 
7 6.4* ег* 0.75 0.73 сг11 
8 32.l f ÌZ9V 0.95 0.93 П9* 
9 12.5 66 0.55 0.70 90 
10 67.0 97 0.75 0.76 290 
11 57.5 140 0.81 1.00 353 
12 4.31' 
13 35.5 107 - - 427 
14 
15 23.4 96 0.38 0.86 3S2 
16 19.2 
17 15.4 
18 15.1 
normals 2.3+2.6 
(п-го) 
duodenal*· 6.9+5.8 
ulcer (n=30) 
criteria ZE-syndrome 
intact
 >
i5+ + 
stomach 
after 
part 
gast 
tomy 
78* 
4 
108* 
62' 
129' 
42' 
102 
86 
67 
67 
36+27 
60+21 
>10055 
>70§5 
-
34 
34 
71 
73 
75 
95 
55 
5 
1 
0.52 
-
8 
0.60 
0.57 
0.51 
0.10+0.10 
0.21+0.18 
>0.60 
>0.60" 
-
41 
40 
85 
02 
73 
93 
70 
6 
0 
0.47 
-
6 
0.67 
0.60 
0.62 
0 30+0.20 
0.52+0.18 
^.бО
1
" 
^.бО™ 
>100*** 
gastrêc- >5++ ^ 0 3' ^ . б О " ^.бО"" >100· 
not determined tt Aoyagi and Summerskill (12) 
* basal gastric acid output 55 Bader (13) 
t basal gastric acid concentration ll Marks et al (14) 
I maximum acid output HI Ruppert et al (15) 
ι maximum acid concentration *** Ellison and Wilson (16) 
и after partial gastrectomy 
** mean + 1 S.O. 
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h o u r s -1 V? О /2 1 І ^ ? ¿У? 3 
Acid output 
(mmomyiSmin) 
Acid cone 
( m m o l H * / l ) i 5 0 ' 
100 
50 
Gastrin 
( p g / m l ) 1O00 
750 
5 0 0 
250 
Calcium 
(mmol/l) з ь 
25 
20 
• m) 
25 
20 
15 
10 
5 
Zoll nger- E III son syndrome 
calcium 5mg/kg h 
г. : • -
-
^ 
- — 
^ 
— 
V Л' 
A 
f!g. 2.1 T h e e f f e c t of 3 h o u r s c a l c i u m i n f u s i o n 
(5 m g / k g . h ) on g a s t r i c acid o u t p u t , g a s t r i c 
acid c o n c e n t r a t i o n , s e r u m g a s t r i n and s e r u m 
c a l c i u m in a p a t i e n t w i t h the Z o l l i n g e r -
E l l i s o n s y n d r o m e 
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2V2 
Acid output 
(mrrralHVÌS min) 
Acid conc 
(ттоІНУІ) 
Gastrin (pg/ml) 
Calcium 
(mmol/l) 
6 0 
4 0 
20 
100 
80 
6 0 
4 0 
20 
4 0 
25-
20 
t 
un) 
I S 
30 
25 
2 0 
IS-
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05-
6 normal SU bjects 
calcium 5 mg/kg h 
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|—¡ 
_ 
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'f-i-f"f"+-[-H 
-K' 
y 
fig. 2.2 The e f f e c t of 3 hour s c a l c i u m i n f u s i o n 
(5 m g / k g . h ) on g a s t r i c acid o u t p u t , 
g a s t r i c acid c o n c e n t r a t i o n , serum g a s t r i n 
and serum c a l c i u m in 6 normal s u b j e c t s . 
V e r t i c a l bars r e p r e s e n t + 1 s t a n d a r d 
d e v i a t i o n 
25 
acid output acid cone gastrin 
(mmol H V (mmol н'/l) (pg/ml) 
Π ' 
'000-
in ) 
25-
20-
15-
10 
5-
0 
_ 
150-
100-
50-
0-
8 0 0 
6 0 0 
400 
200 
GIH secretin 
3U/kq 
Zollinger-Ellison 
syndrome 
male 39 yrs. 
\ 
"4 
tí 
Г 
\ 
20-
15-
10-
5-
0-
150-
100-
50-
0-
80 
60-
40-
20-
0-
GIH secretin 
iL/kg IV 
duodenal ulcer 
female 36 yrs 
60 -30 0 30 60 90 120(min) 
f i g . 2.3 The e f f e c t of i n f u s i o n of s e c r e t i n GIH (3 U / k g . h ) on 
g a s t r i c acid s e c r e t i o n , g a s t r i c acid c o n c e n t r a t i o n 
and serum g a s t r i n in a p a t i e n t w i t h the Z o l l i n g e r -
E l l i s o n s y n d r o m e and in a d u o d e n a l u l c e r p a t i e n t 
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2.4.2 ¿erum J!a£tMji lev^ej_s 
The results of basal and stimulated serum gastrin levels in 
the ZE-patients are summarized in table 2.4. The basal serum 
gastrin levels, reported in this table, are the highest and 
lowest values found during follow-up periods from I up to 31 
years. The wide ranges in fasting serum gastrin levels in some 
ZE-patients are the result of the effect of progressive tumour 
growth or surgical procedures, as total gastrectomy or parathy-
roidectomy, on serum gastrin. Eleven out of 12 patients had an 
increase in serum gastrin of more than 50% of basal level after 
stimulation with calcium or secretin. All 7 patients without 
previous gastric surgery showed a rise in serum gastrin of less 
than S0% of fasting value after ingestion of the standard test 
meal. More details of basal and stimulated serum gastrin levels 
are presented in chapters 4, 5, 6, 7 and 8. 
2 . 4 . 3 ¿erurn a jbumi j i 
Serum albumin concentrations in 15 ZE-patients ranged from 
33.9 to 53.5 g/1. In 10 out of these 15 patients the serum albu-
min level was below the lower limit of the normal range (44.5 
g / 1 ) . More detailed studies on albumin in ZE-patients are pre-
sented in chapter 3. 
2.4.4 2п1.е1.^Іп£^_аЬ.5°.г£^І0І1 І.еіЛ.£ 
Results of D-xylose, vitamin B ^ and fat absorption tests 
are shown in table 2.5. Absorption of D-xylose was found to be 
reduced in 6 out of 7 cases tested. In 2 out of 7 cases a 
pathologically low absorption of vitamin B 1 ? was measured. Af-
ter oral administration of NaHC0 3 vitamin B,- absorption im-
proved markedly in case 11 (table 2 . 5 ) . Fat absorption, measured 
by fat balance studies over 5 days, was reduced in 5 out of 6 
cases. 
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Table 2.4 FASTING AND STIMULATED SERUM GASTRIN LEVELS IN 18 
PATIENTS WITH THE ZOLL INGER-ELLISON SYNDROME 
serum gastrin* increase in serum gastrin after stimulation 
1 
2 
3 
4 
5 
б 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
pg/ml 
190-
945-
530-
620-
250-
400-
3100-
10800-
1540-
805-
350-
140-
142-
196-
1490 
10200 
750 
960000 
380 
1150 
21000 
27100 
3280 
2970 
470 
252 
196 
510 
H 
normal 66+18 
values 
calcium 
pg/ml 
305 
380 
500 
1120 
690 
7700 
80600 
6275 
620 
395 
404 
490 
95 
67 
11 
295 
138 
248 
340 
254 
177 
228 
258 
96 
secretin 
ng/ml % 
565 119 
440 
400 
19200 
13300 
57 
16 
660 264 
870 174 
480 
53 
4150 205 
550 125 
357 147 
298 211 
300 69 
meal 
pg/ml % 
220 
65 
2800 
42 
10 
48 
132 
110 
74 
180 
29 
44 
43 
47 
7+12 10+18 4+9 8+15 52+28 99+51 
(n=100) (n=15) (n=15) (n=34) (n=34) (n=12) (n=12) 
* lowest and highest fasting levels in periods from \ up to Ъ\ 
years 
t 5 mg calcium/kg.h over 3 hours 
§ 1 U secretin GIH/kg.30 sec 
I one slice of bread, 50 g of cheese, one boiled egg and 200 ml 
of milk 
H mean + 1 S.D. 
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Table 2.5 INTESTINAL ABSORPTION TESTS IN 7 PATIENTS WITH THE ZOLLINGER-ELLISON SYNDROME 
D-xylose 
g/5 h urine 
Schilling test 
;>öCo/48 h urine 
fat absorption5 
го 
IO 
4 
7 
8 
10 
11 
15 
16 
3.4 
4.9 
3.7 
3.3 
3.9 
6.4 
4.3 
17.0 
21.4 
6.0 
17.4 
4.4 
22.0* 
35.0 
24.6 
80 
94 
65 
80 
76 
97 
normal values >5.0 >17.0 >95 
*after ingestion of 2.5 g of NaHCO·, 15 min before and 15 min 
58 
after the intake of the Co Vit B , 2 " c a P s u l e 
Sfat balance study for 5 days 
2 . 4 . 5 jroenjtge^nol£gj_cal_f2nd^ir^g¿ 
Barium meal studies were performed in 12 non-operated patients 
and in 4 patients after partial gastrectomy. The findings of these 
studies are presented in table 2.6. One patient had a calcified 
pancreatic non-ß-islet cell tumour and another patient had a se-
vere distal oesophageal stricture ( 1 7 ) . 
2 . 4 . 6 а/і£ Іодга£ І іу 
Angiography of the celiac and superior mesenteric artery was 
performed in 6 patients. This procedure revealed evidence of pan­
creatic tumour in only one patient, but failed to show pancreatic 
tumour lesions in the other five cases. In 3 of the 5 patients 
with negative angiography pancreatic tumours were found at lapa­
rotomy . 
In 2 cases with histologically proven liver metastases metastatic 
lesions were also demonstrated angiographically. 
2 . 4 . 7 f indj_n£S_at^ l_a£arotoniy_ 
Pancreatic tumours were found in only 4 out of 12 patients, 
who underwent 1aparotomy.Lymph node metastases could be demon-
strated in 3, and liver metastases in 2 cases. At autopsy,how-
ever .pancreatic tumours were demonstrated in 6 out of 7 patients, 
whereas in the other patient non-3-islet cell tumour tissue was 
found in a peri pancreatic lymph node. The pancreatic tumours 
were multiple in 4 out of 6 cases and one of these patients also 
showed several tumours in the duodenal wall. Metastatic lesions 
in lymph nodes were found in 3 and liver metastases in 2 of the 7 
patients autopsied. 
2.5 Treatment 
The different types of therapy and the outcome of treatment 
are summarized in table 2.7. 
In the 16 symptomatic patients experience was obtained with the 
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Table 2.6 RESULTS OF BARIUM MEAL STUDIES IN 16 PATIENTS WITH 
THE ZOLLINGER-ELLISON SYNDROME 
intact stomach (n=12) 
ulcer stomach 
ulcer duodenal bulb 
ulcer descending duodenum 
ulcer jejunum 
giant gastric folds 
gastric hypersecretion 
nodular duodenum 
dilatation duodenum 
coarse duodenal folds 
dilatation jejunum 
coarse jejunal folds 
partial gastrectomy (n=4) 
stomal ulcer 
stomal stenosis 
giant gastric folds 
dilatation jejunum 
coarse jejunal folds 
mi seellaneous 
calcified pancreatic tumour 1 
severe oesophageal stricture 1 
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following types of treatment: partial gastrectomy, total gas­
trectomy, tumour excision, parathyroidectomy, antacids and anti­
cholinergics, histamine-2-receptor antagonists, calcitonin, 
streptozotociη and irradiation of the liver. 
2.5.1 £a r t i_a 1_ £a¿tr e£tomy 
Partial gastrectomy was performed in 7 patients, in whom 
the ZE-syndrome was not established at the moment of surgery. 
One of these patients died from postoperative complications. In 
2 other patients emergency total gastrectomy had to be performed 
because of postoperative complications. In none of the other 4 
patients was the ulcer disease cured. In 3 of them elective 
total gastrectomy was needed later on, whereas one patient was 
treated with antacids and anticholinergics for recurrent ulce-
ration. 
2.5.2 totaJ_ cjas^r^tom^ 
Total gastrectomy was performed in 8 cases. The 2 patients 
with total gastrectomy as emergency procedure died postoperati-
vely. All 6 patients with elective total gastrectomy had com-
plete disappearance of symptoms. All patients with total gas-
trectomy, without evidence of progressive tumour growth, could 
stabilize their body weight and none of them had major complaints 
of oesophagitis. 
2.5.3 t^mo£r_excj_s j_0£ 
Tumour excision was performed in 2 cases. In one patient 
(case 3) the distal part of the pancreas, containing 3 tumours, 
was resected. The immediate postoperative period was complicated 
by a major gastrointestinal bleeding and pancreatic necrosis. At 
autopsy multiple tumours were found in the remaining part of the 
pancreas. In case 4 total gastrectomy was combined with resec-
tion of a big pancreatic tumour and of metastatic lymph nodes. 
This patient died 4J years later from renal failure and at 
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Table 2.7 THE TYPE AND OUTCOME OF TREATMENT IN 18 PATIENTS WITH THE ZOLLINGER-ELLISON SYNDROME 
treatment outcome 
1 emergency total gastrectomy 
2 emergency total gastrectomy and total 
pancreatectomy 
3 partial pancreatic resection and 
partial gastrectomy 
4 elective total gastrectomy and 
excision of pancreatic tumour 
5 closure of duodenal perforation 
6 elective total gastrectomy 
7 elective total gastrectomy 
8 elective total gastrectomy 
9 histamine-2-receptor antagonists 
10 histamine-2-receptor antagonists 
11 elective total gastrectomy 
12 partial gastrectomy; antacids and 
anticholi nergics 
13 elective total gastrectomy 
14 no treatment 
15 hi stamine-2-receptor antagonists 
16 antacids and anticholinergics 
17 no treatment 
18 no treatment 
died postoperatively 
died postoperatively 
died postoperatively 
died after 4J years from renal failure: 
extensive liver metastases 
died postoperatively from septicemia 
excellent,4 years after surgery 
excellent,3J years after surgery 
died 13 months after surgery from 
tumour growth 
excel 1 ent 
sati sfactory 
extensive liver metastases 22 months 
after surgery 
recurrent ulceration 
e x c e l l e n t ^ years after surgery 
died from ulcer perforation 
excel 1 ent 
sati sfactory 
excel 1 ent 
excel 1 ent 
autopsy extensive liver metastases were found. In case 2 total 
gastrectomy was combined with total pancreatectomy. The patient 
died in the postoperative period. 
2.5.4 para thyrcn d^e£tom^ 
Parathyroidectomy, followed by normalization of serum cal-
cium levels, resulted in relief of complaints for periods ran-
ging from 7 months to 9 years in 3 patients with ZE-syndrome 
and coexisting hyperparathyroidism. 
2.5.5 £nta£i d^_and_ant ^choJjnA^gj-CS. 
Treatment with these drugs resulted in only moderate and 
temporary relief of symptoms. In most patients surgery was needed 
later on. One patient with recurrent stomal ulcers (case 12) had 
some symptomatic relief during treatment with these drugs for 
more than 10 years. Another patient (case 16) had slight improve-
ment of his complaints of heartburn. In some patients with 
diarrhea the oral dose of anticholinergics could be increased 
to very high amounts, up to 240 mg propantheline bromide (Proban-
D 
thine , Searle) daily, without complaints of dry mouth or 
sight impairment. Since a much lower intravenous dose, 120 mg 
propantheline bromide daily, was accompanied by these side-
effects, absorption of this drug might have been reduced. This 
is not astonishing, because impaired absorption is not rare in 
the ZE-syndrome (2.4.4). 
2.5.6 Jiistanri_n£ lH_]_-2^re£e£t£r_ajit¿gon2s_ts 
Two patients have been treated with Н-2-receptor antagonists 
for more than one year. One of these patients (case 10) received 
treatment with Metiamide and later Cimetidine (Smith, Kline and 
French Laboratories), in doses up to 2 g daily, for 17 months 
with marked symptomatic relief of his diarrhea. The other patient 
(case 9) was treated with a dose of 800 mg Metiamide or Cimetidine 
daily, for 13 months with complete disappearance of the complaints 
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of gastric pain and diarrhea. A third patient (case 12) discon­
tinued Metiamide treatment after 2 weeks, because of fever and 
general weakness. No granulocytopenia was found and it therefore 
seemed unlikely that these symptoms were related to the use of 
the drug. The fourth patient (case 1 5 ) , treated since only 2 
months, had marked relief of diarrhea and gastric pain. No un­
toward reactions, related to Н-2-receptor antagonists, were ob­
served at repeated physical and laboratory examinations of the 
patients under treatment. 
In table 2.8 the effect of Н-2-receptor antagonists on basal 
gastric acid output and on fasting serum gastrin level is recor­
ded. 
2.5.7 £a]_c Η£η_πι 
D 
Administration of calcitonin (Calcitare , Armour), in a 
dose of 80 U or 160 U b.i.d. subcutaneously, did not result in 
obvious symptomatic relief in a patient with ZE-syndrome and 
hyperparathyroidism (case 9) during 2 months of treatment. In 
this patient serum calcium was reduced from 2.69 to 2.42 mmol/1, 
serum gastrin from 1100 to 660 pg/ml and basal gastric acid 
output from 59.5 to 28.4 mmol H +/h two hours after a single dose 
of 160 U of calcitonin. 
2.5.8 ¿t£e£t£Zot0С2П 
Two patients with expansive growth of liver metastases were 
treated with Streptozotociη (National Cancer Institute, NIH, 
Bethesda, Maryland, U.S.A.) (18,19). In one patient (case 8) a 
weekly dose of 2 g of Streptozotocin was administered intrave­
nously for 9 weeks without any effect on liver size or symptoms 
(fig. 4 . 6 ) . In a later stage a weekly dose of 2 g Streptozotocin 
via the coeliac or hepatic artery for 5 weeks proved also to be 
ineffective. In another patient (case 11) Streptozotocin, once 
1 g and 5 times 2 g, was administered via the coeliac artery 
at intervals of 5 weeks. This treatment had no favourable effect, 
as assessed by progressive clinical deterioration, increase in 
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Table 2.8 EFFECT OF ADMINISTRATION OF HISTAMINE-2-RECEPTOR ANTAGONISTS ON BASAL GASTRIC 
ACID SECRETION AND SERUM GASTRIN LEVELS IN 4 PATIENTS WITH THE ZOLLINGER-
ELLISON SYNDROME 
case 
10 
12 
15 
treatment 
Metiamide 200 mg orally 
Cimetidine 200 mg orally 
Metiamide 200 mg orally 
Metiamide 400 mg orally 
Metiamide 250 mg i.ν. 
Cimetidine 200 mg orally 
Metiamide 200 mg orally 
Cimetidine 400 mg 
ßAO* 
mmol H+/h 
12. 
2, 
0 
67, 
15. 
10, 
12, 
11. 
,5 
.5 
.0 
.0 
.8 
.8 
.2 
4.3' 
1.21 
23.4 
2.5 
serum gastrin 
pg/ml 
540 
430 
460 
765 
495 
510 
580 
600 
31800 
28200 
585 
460 
* basal gastric acid output'was measured between one and two hours after the oral 
administration of the drug, or during intravenous infusion of Metiamide 
l· after partial gastrectomy 
§ serum gastrin was measured one hour after administration of the drug 
liver mass, deterioration of liver function, and rise in serum 
gastrin levels (fig. 4 . 6 ) . 
2.5.9 j / ü ^ i ^ t i o n £^_''І £г_п1£^£5І.а1.е1. 
In case 11 with wide-spread liver metastases the liver mass 
was irradiated by Cobalt teletherapy with 2500 rads over a period 
of 3| weeks. This treatment resulted in a marked reduction in 
liver mass and a fall in serum bilirubin from 115 to 42 ymol/l 
(normal value less than 10 pmol/l) and in gastrin from 14000 to 
5000 pg/ml (fig. 4 . 6 ) . Although these parameters were again de­
teriorating within some months, the patient is at this moment, 
12 months after irradiation, in a satisfactory condition. 
2.6 Discussion 
In addition to the studies of the Zoll inger-El1 i son Tumor 
Registry (16,20-24), several groups have published their expe­
riences with regard to diagnosis and treatment of ZE-patients 
from their centres (25-31). In the present study relevant fea­
tures of 18 patients with the ZE-syndrome, diagnosed or treated 
at St. Radboud Hospital, Nijmegen, between 1963 and 1976, are 
presented. In a previous report observations on 8 of these ZE-
patients have been published (32). 
2.6.1 £І j/ij^l _f e a tu£e¿ 
Serum gastrin measurements, especially in combination with 
stimulation tests, can detect ZE-patients in an early stage of 
the disease (5,33). Seven of the ZE-patients in the present study 
were diagnosed during family studies of patients with the ZE-
syndrome as component of Multiple Endocrine Adenomatosis type I 
(chapter 9 ) . Two of these 7 newly diagnosed patients were com-
pletely asymptomatic and one had mild complaints of heartburn. 
This selection of patients accounts for the relatively low inci-
dence of peptic ulcers (78%) and of diarrhea (28%) in the present 
study. In the literature peptic ulcer disease occurred in 90 to 
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95% (21) and diarrhea in up to 80% of the patients ( 2 6 ) . Five out 
of the 18 ZE-patients had complaints of heartburn and one of them 
had a severe distal oesophageal stricture, as a result of acid 
reflux oesophagitis. It has been stated that peptic oesophagitis 
is rare in patients with the ZE-syndrome ( 5 ) . An increased tonus 
of the gastro-esophageal sphincter, due to hypergastrinemia, 
is considered to be a protective factor against acid reflux into 
the oesophagus ( 3 4 ) . 
Weight loss was frequently observed in patients with symp-
tomatic ZE-syndrome. 
The present study confirms that major ulcer complications, 
e.g. bleeding or perforation, often occur in the ZE-syndrome 
( 2 6 ) . These complications were especially observed in the imme-
diate postoperative period after inadequate surgery. 
The selection of patients by family studies accounts for the 
high incidence (72%) of patients with ZE-syndrome as component of 
MEA I. In literature coexisting endocrine disease has been found 
in up to 48% ( 2 5 ) . One patient had Cushing's syndrome, probably 
caused by ectopic secretion of ACTH by the pancreatic tumour. The 
production of ACTH and gastrin by a pancreatic islet cell tumour 
has been described previously (35,36). 
2.6.2 ^i^gn.o¿i¿ 
The preoperative diagnosis of the ZE-syndrome is based on the 
combination of basal gastric acid hypersecretion and hypergastri-
nemia ( 5 ) . In equivocal cases stimulation tests with calcium, 
secretin and food are helpful to differentiate ZE-syndrome from 
other causes of hypergastrinemia and gastric acid hypersecretion 
(5,37). The prognosis of the patients in this study was markedly 
improved by early diagnosis of ZE-syndrome with gastrin radioim-
munoassay. In 5 out of 6 patients, studied before 1972 without a 
gastrin assay, the diagnosis was made not before repeated surge-
ry or at autopsy. Four of these 5 patients died in the immediate 
postoperative period. On the other hand only two of the 12 pa-
tients, diagnosed since 1972 with the aid of the gastrin radioim-
munoassay, have died. One of these 2 patients died from progres-
se 
sive tumour growth and the other patient refused adequate treat-
ment . 
As radioimmunoassay of gastrin is not available to all hos-
pitals, it is necessary to select patients with ulcer disease 
or unexplained diarrhea for serum gastrin determination. In ad-
dition to the clinical manifestations, measurement of basal and 
stimulated gastric acid secretion, determination of serum albu-
min concentration, intestinal absorption tests and barium meal 
studies may be helpful in the differential diagnosis. 
Measurement of basal gastric acid output for one hour is a 
relatively simple screening procedure. In 79% of the patients 
tested the results were compatible with the criteria proposed 
by Aoyagi and Summerskill (12). 
Stimulation with pentagastrin did not reveal more accurate re-
sults, as has been found earlier ( 3 2 ) . Furthermore, measurement 
of gastric acid output during infusion of secretin can be a very 
helpful provocation test (38), but alkaline reflux from the 
duodenum into the stomach may affect the results. 
Gastric acid output is markedly stimulated by infusion of cal-
cium in patients with the ZE-syndrome (fig. 2.1; 3 9 ) . However, 
this calcium load also results in a considerable rise in gastric 
acid secretion in both normal subjects and duodenal ulcer pa-
tients (fig. 2.2; 4 0 ) . 
A high ratio between gastric acid secretion after stimulation 
with calcium and betazole hydrochloride (Histalog , Lilly) is 
thought to be another helpful tool for the diagnosis of ZE-
syndrome (41 ) . 
In our hands determination of 12 hours nocturnal acid secretion 
did not reveal more information than accurate measurement of 
basal gastric acid output over one hour. Moreover, aspiration 
of gastric juice may depress serum gastrin levels and may con-
sequently affect gastric acid secretion in patients with the 
ZE-syndrome (42; chapters 4 and 6 ) . 
Serum albumin concentrations were depressed in 65% of the 
ZE-patients in comparison with the levels in normal subjects. 
Protein loss into the gastrointestinal tract, impaired absorp-
tion of amino acids, and neoplastic growth can contribute to 
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the hypoalbuminemia seen in these patients (chapter 3 ) . 
The intestinal absorption of D-xylose was moderately reduced in 
6 out of 7 patients tested. Only scanty data have been presen­
ted in the pastabout the absorption of D-xylose in patients with 
the ZE-syndrome. Vogel et al (43) reported low and normal results 
in a ZE-patient treated with anticholinergics, whereas Soergel 
(44) found a normal intestinal uptake of D-xylose in a patient 
with the ZE-syndrome and diarrhea. This reduced absorptive capa­
city for D-xylose is probably a result of structural mucosal 
changes of the proximal small bowel ( 5 , 4 5 ) , but may also be due 
to the rapid intestinal transit. Impaired vitamin B ^ absorption, 
found in 2 patients from this study, has been described previous­
ly (45,46). Ingestion of NaHCO,, before and shortly after the 
CO ^ 
intake of Co-vitamin B,«* normalized the absorption in one 
patient studied. From this result additional evidence is obtai­
ned that the reduced absorption of vitamin Β,ρ is not caused by 
a lack of intrinsic factor secretion, but is a result of the low 
ρΗ in the small intestine (4 5 , 4 6 ) . 
Absorption of fat was reduced in 5 out of 6 patients investigated. 
Steatorrhea is not unusual in the ZE-patients studied in the li­
terature ( 5 ) . It has been suggested that steatorrhea in ZE-pa­
tients results from mucosal damage of the small bowel, inactiva-
tion of lipase, and precipitation of bile acids by the low intra­
luminal pH ( 4 5 , 4 7 ) . 
Ulcers located in the jejunum were not often found on barium 
meal in this study. Dilatation of duodenum and jejunum with 
coarseness of the folds and a nodular pattern of the duodenum 
were more constant findings. Calcification of the pancreatic 
tumour (17) has also been described by Bozymski et al ( 4 8 ) , but 
this finding seems to be quite rare. 
Preoperative angiography is recommended, when tumour exci­
sion is planned at surgery. In the patients, examined by angio­
graphy in this study, this procedure did not prove to be very 
helpful in revealing tumour lesions. Both liver scintigraphy and 
angiography may be valuable techniques in evaluating the effect 
of total gastrectomy or cytostatic drugs on tumour growth (49, 
50) . 
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At laparotomy the tumours were often overlooked in this stu­
dy. It can therefore be concluded that negative findings at la­
parotomy do not exclude the ZE-syndrome. 
2.6.3 treatmen t 
Treatment should be directed to the hypersecretion of gastric 
acid with symptoms of ulcers and diarrhea, and to the tumours 
which may kill the patient in a later stage. Theoretically, exci­
sion of all tumour tissue is the procedure of choice. However, 
recent studies (30,31) showed that in most patients with apparent­
ly total tumour excision serum gastrin levels persisted to be 
elevated, indicating residual tumour lesions. In a patient from 
this study resection of the distal part of the pancreas, contai­
ning 3 tumours, was followed by a dramatic postoperative period, 
and at autopsy multiple tumours were found in the remaining part 
of the pancreas. As about half of the patients with duodenal wall 
tumours are reported to have a solitary lesion without evidence 
of additional tumour sites (23), tumour excision without total 
gastrectomy has been advocated in these patients (51-53). How­
ever, accurate analysis of case reports, collected at the 
Zol1 inger-El1 i son-Tumor Registry, indicates that local excision 
of duodenal wall tumours with less than total gastrectomy was 
successful in only 20 out of 103 patients (23). Since postopera­
tive normalization of serum gastrin level was documented in only 
3 cases (23), the results of local excision of duodenal wall 
tumours are probably even less favourable. In the patient with 
duodenal wall tumours in this study coexisting pancreatic tu­
mours were found at autopsy. It can therefore be concluded that 
excision of the duodenal wall tumours would not have cured this 
pati ent. 
In the treatment of gastric acid hypersecretion high doses 
of antacids and anticholinergics resulted in only a partial and 
temporary relief of symptoms, as has been found by others (54, 
5 5 ) . 
As Н-2-receptor antagonists have proved to be strong inhibitors 
of basal and stimulated gastric acid secretion, the favourable 
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results in ZE-patients were not unexpected. The effectiveness of 
these drugs in ZE-patients has also been demonstrated by others 
(56-58). A small decline in serum gastrin following ingestion of 
these drugs, as found in this study, has also been recorded by 
Blair et al (57). This fall in gastrin probably reflects a de­
crease in gastric acid secretion, since it is known that a reduc­
tion in gastric acid lowers gastrin release in ZE-patients (42; 
chapters 4 and 6 ) . Both the results of treatment with H-2-recep-
tor antagonists and the absence of adverse reactions have to be 
awaited in the long run. 
The effectiveness of calcitonin, in the dose used in the patient 
of this study, was less than that of Н-2-receptor antagonists. 
All gastric surgery short of total gastrectomy endangers 
the patient, as is shown in this study and has been found by 
others (20). The present study confirms that total gastrectomy 
is the only type of gastric surgery that is indicated in pa­
tients with the ZE-syndrome (20,22). The outcome of elective 
total gastrectomy in our patients was much better than the re­
sults of emergency total gastrectomy. It may therefore be wise 
to postpone surgery in severely ill patients and to start treat­
ment with oral or parenteral administration of Н-2-recepter anta­
gonists. The only justifiable acid reducing surgical procedure, 
besides total gastrectomy, is parathyroidectomy in patients with 
the ZE-syndrome and coexisting hyperparathyroidism (59). However, 
this type of surgery resulted only temporarily in relief of 
symptoms in the 3 patients studied and definitive surgery was 
needed later on. 
Recent studies from the Zol1inger-El1 i son Tumor Registry by Fox 
et al (24) showed that 17-25% of patients with metastatic ZE-
syndrome and total gastrectomy had died from progressive tumour 
growth. For this reason the authors recommend combining total 
gastrectomy with excision of as much tumour tissue as technically 
feasible (24). Moreover, the statement that total gastrectomy has 
to be performed even in the presence of wide-spread metastases 
(24), is confirmed in the present study. The prognosis of liver 
metastases in ZE-patients in this and other studies (24,30,60) 
is much better than the outlook for liver metastases of non-
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endocrine tumours (61). Furthermore, it has been claimed that 
total gastrectomy may inhibit tumour growth and may even result 
in regression of tumour lesions (49,62). Although well-documented 
regression of tumours was found in only 4 out of 137 cases stu­
died, some evidence was obtained that tumour growth was inhibited 
by total gastrectomy (24). As gastric acid itself might be the 
gastric factor, that stimulates tumour growth (42,63; chapters 
4 and 6 ) , early treatment of gastric acid hypersecretion by H-2-
receptor antagonists or total gastrectomy might improve the 
prognosis of ZE-patients. 
Although favourable effects of Streptozotociη on tumour growth 
have been described (50,64,65), this drug was not effective in 
inhibiting tumour growth in 2 patients with ZE-syndrome and ex­
tensive liver metastases in this study. In one of these patients 
palliative irradiation of the liver resulted in a definite re­
duction in liver mass and a considerable fall in serum concen­
trations of bilirubin and gastrin. Irradiation of the liver was 
also found to be effective in the symptomatic treatment of pa­
tients with liver metastases of other primary tumours (66). 
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Chapter 3 
SERUM ALBUMIN LEVELS IN PATIENTS WITH THE ZOLL INGER-ELLISON 
SYNDROME. 
3 .1 Introducti on 
The Zoll inger-El 1 i son (ZE) syndrome is characterized by 
symptoms of peptic ulcer disease, diarrhea, acid hypersecretion 
and gastrin producing tumours, usually originating in the pan-
creas (1,2) . 
Hypoalbuminemia is a well-known feature of gastrointestinal 
disease ( 3 ) . This hypoalbuminemia may be the result of both de-
creased albumin synthesis and increased loss or degradation of 
albumin. Increased plasma protein loss into the gastrointestinal 
tract is often a marker of gastrointestinal disease ( 3 ) . 
In this study serum albumin concentrations in ZE-patients 
were measured before and after total gastrectomy and compared 
to the levels found in normal controls and in patients with duode-
nal and stomal ulcer disease. 
Some characteristics of albumin metabolism were studied more 
extensively in 4 ZE-patients. The results were related to clini-
cal, laboratory, radiological and anatomical data of these pa-
tients, with special emphasis on intestinal absorption tests. 
3.2 Patients and methods 
Features of 20 patients with the ZE-syndrome are summarized 
in table 3.1. In all 12 patients without tissue diagnosis of 
gastrinoma the diagnosis of ZE-syndrome was confirmed by stimu-
lation tests. Increases in serum gastrin of at least 50% of 
basal value were found in these patients after provocation with 
calcium, 5 mg/kg.h over 3 hours (4,5; chapters 5 and 8) and 
secretin GIH, 1 U/kg.30 sec (6,7; chapters 6 and 8 ) . The rise 
in serum gastrin after ingestion of a standard test meal was 
in 8 out of 9 patients without previous gastric surgery less 
than 50% of basal level (chapters 7 and 8 ) . These results exclude 
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Table 3.1 CLINICAL, LABORATORY AND ANATOMICAL DATA OF 20 PATIENTS WITH THE ZOLLINGER-ELLI SON 
SYNDROME . 
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after partial gastrectomy 
basal gastric acid output 
mea η + 1 S.D. 
persiTtent hypergastrinemi a after total gastrectomy 
nodular pancreas; no tissue diagnosis 
no lapa rotomy 
+ present 
о absent or not demonstrated 
not determined or not investi 
gated 
antral G-cell hyperplasia (8,9,10). Serum gastrin levels persis­
ted to be elevated in all patients who underwent total gastrec­
tomy, indicating the extragastric origin of gastrin. 
The diagnosis of duodenal and stomal ulcer was made by barium 
meal or endoscopy. 
The group of duodenal ulcer patients consisted of 11 women and 
29 men, age 20-68 years. Two female and 18 male patients, age 
20-67 years, had a stomal ulcer. The group of normal subjects 
consisted of 8 women and 32 men, age 18-69 years. 
Serum albumin concentrations were measured by electrophoresis 
on cellulose acetate and amino acids as reported earlier (20). 
51 Gastrointestinal protein loss was studied by the C r C K - m e t h o d 
(11). Radioactivity was measured in gastric juice, collected 
during the first 12 hours after intravenous administration of 
51 
CrClg.and in the feces, produced over the next 5 days. Results 
of protein loss were expressed as ml plasma per 24 hours. 
14 The rate of albumin synthesis was measured by the C-carbonate 
method (12). 
Results are expressed as mean + 1 S.D. Student's t-test for 
unpaired results was used for statistical analysis. 
3.3 Results 
The serum albumin concentration in 20 ZE-patients (40.8 ± 
8.2 g/1) was significantly decreased in comparison with 40 nor­
mal controls (50.7 + 3.1 g / 1 ) , 40 duodenal ulcer patients (51.3 
+ 3.9) and 20 patients with stomal ulcer (50.6 + 3.4 g/1; ρ 
<0.001;fig. 3 . 1 ) . No differences in serum albumin concentration 
were found between normals and patients with duodenal and stomal 
ulcer (p > 0 . 4 0 ) . Six ZE-patients with histologically proven metas­
tatic gastrinoma had lower serum albumin levels (35.2 + 9.4) than 
14 ZE-patients without evidence of metastases, as assessed by 
findings at laparotomy, liver scan or liver function tests (43.2 
+_ 6.6; ρ < 0 . 0 5 ) . No significant difference in serum albumin con­
centration was observed between 7 ZE-patients with diarrhea 
(42.1 + 7.6) and 13 ZE-patients without diarrhea (40.1 + 8 . 8 ) . 
No correlation was found between serum albumin level and basal 
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gastric acid output (BAO) in 14 ZE-patients without previous 
gastric surgery (r= - 0 . 1 0 3 ) . 
Se^uT a DUT^I^ g 
normal controls duodendl j l c e r stomal Lieer Z E sydrome 
• =40 η = 4 0 η - 2 0 η = 2 0 
fig. 3.1 Serum albumin concentration in normal subjects 
and patients with duodenal ulcer, stomal ulcer 
and Zo1 1 inger- E 1 1 i son syndrome. Cross symbols 
indicate patients with metastatic gastrinoma 
Total gastrectomy induced a rise in serum albumin level in 
all 8 ZE-patients studied (fig. 3 . 2 ) . In one patient with metas­
tatic gastrinoma, however, serum albumin concentration persisted 
to be markedly reduced in comparison with the normal level. 
In 4 patients with ZE-syndrome albumin metabolism and absorp­
tion of fat, D-xylose and vitamin B,- were studied in detail 
(table 3 . 2 ) . These 4 patients had different clinical features: 
one had ulcers and diarrhea, one had ulcers without diarrhea, one 
had diarrhea without ulcers and one had neither ulcers nor 
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diarrhea (table 3 . 2 ) . In these 4 ZE-patients the serum albumin 
concentration was inversely correlated with gastrointestinal 
protein loss. 
Serum albumin q/t 
60 -
50 -
40 -
30 -
20 -
IO -
betöre after 
total gastrectomy 
Ζ E sydrome 
η=θ 
fig. 3.2 The eff e c t of total g a s t r e c t o m y on 
serum a l b u m i n level in 8 p a t i e n t s 
w i t h Zol1 inger-E1 1 i son s y n d r o m e . 
C r o s s s y m b o l s indicate p a t i e n t s w i t h 
m e t a s t a t i c g a s t r i n o m a 
In 3 out of 4 patients protein loss from the gastrointestinal 
tract was found to be increased. The intestine was in 2 cases 
the main site of protein loss. All 3 patients with increased 
gastrointestinal protein loss had impaired absorption of fat. 
The D-xylose test was slightly decreased in 3 patients and the 
Schilling test was markedly abnormal in one. In 2 out of 3 pa­
tients studied serum levels of several essential amino acids 
were moderately or markedly decreased. The rate of albumin 
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Table 3.2 CLINICAL, LABORATORY, RADIOLOGICAL AND ANATOMICAL DATA OF 4 PATIENTS WITH THE 
case 
ZOLLINGER-ELLISON SYNDROME, WITH SPECIAL EMPHASIS ON ALBUMIN METABOLISM AND 
ABSORPTION TESTS. 
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>17.0% 58co/48 h urine 
50.7 + 3.1 (n=40) 
6 + 3 ml plasma/24 h (n=6) 
<3ÏÏ ml plasma/24 h (n=25) 
22.3 +6.8 g/175cm.24 h (n=15) 
113 
227 
27 
84 
141 
74 
195 
45 
32 
42 
9 
21 
33 
15 
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14 
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synthesis was at the lower limit of the normal range in the pa­
tient studied (table 3 . 2 ) . 
Follow-up studies performed in 2 patients with total gastrec­
tomy and metastatic gastrinoma revealed that serum albumin concen­
tration fell in relation to progressive tumour growth (fig. 3 . 3 ) . 
Serum albumin g/l 
6 0 -
5 0 -
4 0 -
30-
so-
i o 
9 
1974 
1 
1975 
Serum albumin g/l 
60-1 
50-
40-
30-
20 
10-
У 
/ ' \ 
total gastrectomy 
1973 
1 
1974 
fig. 3.3 Serial serum a l b u m i n levels in 
2 p a t i e n t s w i t h p r o g r e s s i v e 
m e t a s t a t i c t u m o u r g r o w t h a f t e r 
total gas t ree tomy 
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3.4 Di scussi on 
The present study reveals significantly lower serum albumin 
levels in ZE-patients than in normal subjects and in patients 
with duodenal and stomal ulcer. These results are in contrast 
with the opinion of Brooks et al ( 1 3 ) , who believe that serum 
protein levels are normal in ZE-patients. Rambaud and 
Matuchansky (14),on the other hand,found serum albumin concen-
trations of less than 35 g/1 in 6 out of 19 ZE-patients with 
diarrhea, collected from the literature. In our group of 20 
ZE-patients decreased serum albumin levels were also found in 
patients without diarrhea. The mean serum albumin concentration 
in this study was not significantly different in ZE-patients 
with and without diarrhea. 
Malabsorption of proteins, as a result of irreversible inac-
tivation of pancreatic proteolytic enzymes by low duodenal pH 
(15) and defective mucosal uptake of basic and neutral amino 
acids ( 1 6 ) , has been suggested as a cause of hypoalbuminemia in 
ZE-patients ( 1 4 ) . 
Both studies of gastrointestinal protein loss and data on the 
influence of metastatic gastrinoma on serum albumin in patients 
with the ZE-syndrome, however, are lacking in the literature. 
In 2 out of 3 ZE-patients from this study moderately or 
markedly reduced serum concentrations of several essential amino 
acids were found. Low serum levels of amino acids may be the 
result of protein malabsorption due to intraluminal inactivation of 
proteolytic enzymes by low pH and/or morphologic changes of the 
jejunal mucosa (15,17,18). The 2 patients with low serum amino 
acid levels had decreased absorption of fat and one had an im-
paired D-xylose test together with an abnormal jejunal mucosa. 
The rate of albumin synthesis, measured in one patient, was at 
the lower limit of the normal range. This rather low albumin 
synthesis is somewhat remarkable, because this patient had in-
creased gastrointestinal protein loss. In patients with exuda-
tive gastroenteropathy, studied in the literatue, the albumin 
synthesis was usually found to be increased ( 1 9 ) . The lack of an 
increased albumin synthesis in our patient with gastrointestinal 
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protein loss may be due to the reduced serum levels of some 
amino acids, since it has recently been suggested that low serum 
concentrations of especially tryptophan and branched chain amino 
acids (valine, leucine and isoleucine) may impair albumin synthe-
sis (20). Except for the normal concentration of tryptophan 
moderately decreased serum levels of these amino acids were found 
in the patient studied. 
Increased loss of plasma proteins from the gastrointestinal 
tract was found in 3 out of 4 ZE-patients studied. Protein loss 
was increased both from the stomach and from the intestine. Pa-
thologically high protein loss from the stomach has been found 
in patients with hypertrophic gastropathy (13,21-25). Giant 
gastric folds are well-known features both in ZE-patients and 
in patients with hypertrophic gastropathy (chapter 2 . 4 . 5 ) , but 
in contrast to patients with ZE-syndrome patients with hyper-
trophic gastropathy tend to hypochlorhydria (22,23). On the 
other hand some patients with hypertrophic protein-losing 
gastropathy have normal or high gastric acid output without 
increased acid concentrations (13,24). Plasma protein loss from 
the stomach in our ZE-patients was only moderately increased in 
comparison with the values, reported with similar techniques in 
patients with hypertrophic gastropathy (13, 2 1 - 2 5 ) . Katzka et 
al (26) found that the protein concentration of the gastric 
juice in a patient with the ZE-syndrome was not different from 
normal. However, if gastric protein loss is estimated by extra-
polation from the enormous gastric juice output (4100 ml/12 h ) , 
then gastric protein loss obviously is increased in this patient. 
The huge amount of acid in the proximal small intestine in 
ZE-patients may cause mucosal lesions with abnormal villi toge-
ther with edema and infiltration with leucocytes of the lamina 
propria (17,18). It seems likely that damage to the jejunal 
mucosa by the low intraluminal pH is the major cause of the 
increased enteric protein loss in most ZE-patients with hypoalbu-
minemia. As has been pointed out by Cluysenaer et al (27), vil-
lous damage, as seen in coeliac sprue, is also often associated 
with increased plasma protein loss from the gastrointestinal 
tract. 
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Total gastrectomy in our ZE-patients induced an increase in 
serum albumin concentration , in general up to more or less nor-
mal levels. It may therefore be concluded that the gastrointes-
tinal protein loss was reduced and the absorption of proteins 
was improved after withdrawal of the giant acid load. Postopera-
tive normalization of the jejunal mucosa, as has been described 
in literature ( 1 7 , 1 8 ) , seems also to be related to the increase 
in jejunal pH. 
One other interesting point in this study was that serum 
albumin levels in patients with metastatic gastrinoma were sig-
nificantly lower than those observed in ZE-patients without evi-
dence of metastases. Low serum albumin levels are not uncommon 
in patients with neoplastic diseases ( 2 8 ) . In all 5 ZE-patients 
with metastatic gastrinoma serum albumin concentration rose after 
total gastrectomy, but in one of these patients the albumin level 
persisted to be markedly reduced. Although data are available in-
dicating inhibition or regression of tumour growth after total 
gastrectomy ( 2 9 , 3 0 ) , it seems highly unlikely that tumour reduc-
tion has led to the rise in serum albumin levels within a period 
of 1 to 2 months after total gastrectomy. Moreover, in none of 
the 5 ZE-patients with metastatic gastrinoma was clinical regres-
sion of tumour growth observed postoperatively. 
In 2 ZE-patients expansive tumour growth after total gastrec-
tomy was accompanied by decreasing serum albumin levels. 
In conclusion ,our data indicate that at least 3 mechanisms 
may be involved in the pathogenesis of hypoalbuminemia, often 
found in ZE-patients: 
- increased plasma protein loss from the stomach and especially 
from the small intestine, 
- impaired albumin synthesis as a result of decreased levels of 
essential amino acids in serum. These low concentrations of 
amino acids may be caused by protein malabsorption, 
- metastatic tumour growth. 
It is obvious from this study that serum albumin levels have 
to be measured in patients suspected of ZE-syndrome. Like gastric 
acid analysis, screening for endocrine disease and barium meal 
studies, determination of the serum albumin level may be a clue 
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to the diagnosis of the ZE-syndrome. It is recommended therefore 
to measure serum gastrin levels in peptic ulcer patients with 
unexplained hypoalbuminemia. 
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Chapter 4 
THE CLINICAL RELEVANCE OF GASTRIN RADIOIMMUNOASSAY. 
4.1 Introduction 
In 1905 Edkins found that extracts of antral mucosa stimulate 
gastric acid secretion after intravenous injection into cats ( 1 ) . 
The active substance was named gastrin. The existence of the acid-
stimulating hormone was definitely established in 1948 ( 2 ) . In 
1964 pure gastrin was isolated from hog antral mucosa ( 3 ) . Shortly 
thereafter the structure was determined (4) and the hormone was 
synthesized ( 5 ) . 
Knowledge about gastrin has considerably increased since 
physiological concentrations of gastrin in serum and tissue ex-
tracts could be measured by sensitive and reliable radioimmuno-
assay techniques ( 6 - 9 ) . The concentration of gastrin in serum is 
the resultant of release from antral, duodenal and possibly jejunal 
mucosa (10) and inactivation or extraction by a number of organs. 
The kidneys (11)» the small bowel (12), the gastric fundus (13) 
the liver (14) and the lungs (15) have been proposed as active sites 
of gastrin breakdown. The actions of gastrin are directed to many 
target organs and systems, but only the effects on gastric acid 
and pepsin secretion, on mucosal blood flow, and probably the 
trophic action on gastric mucosa, small bowel mucosa and pancreas, 
are considered to be of physiological significance ( 1 0 ) . 
By means of antibodies with different specificity (16,17) and 
chromatographic methods (18-20) several molecular forms of gastrin 
have been demonstrated in serum and tissue. The following gastrin 
components have been completely or partially characterized: gastrin-
13, gastrin-17, N-terminal gastrin -17, gastrin-34, component I 
gastrin and big big gastrin (21). Most components exist in a 
sulphated and a non-sulphated form (21). The various molecular 
components have not only different specificity to antibodies ( 2 2 ) , 
but also differ in degrees of biological activity (23,24). 
In the present study basal serum gastrin levels were measured 
in normal subjects and in patients with duodenal ulcer, gastric 
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ulcer, Zol1 inger-El1 i son (ZE) syndrome, achíorhydria , chronic 
renal failure, massive small bowel resection and in one patient 
with suspected antral G-cell hyperplasia. 
Moreover, data are presented about the variability of gastrin 
concentrations in normal subjects and in patients with achlorhydria 
and ZE-syndrome. 
Furthermore, the effect of aspiration of gastric juice, total 
gastrectomy and parathyroidectomy on serum gastrin was studied in 
ZE-patients. 
Finally the significance of gastrin measurements to evaluate 
the prognosis and the outcome of treatment in ZE-patients was 
examined in this study. 
4 . 2 Patients and methods 
Serum gastrin levels were measured in 100 normal subjects, 80 
patients with duodenal ulcer, 17 with gastric ulcer, 19 with ZE-
syndrome, 72 with achlorhydria, 44 with chronic renal failure, 4 
with massive small bowel resection and one with suspected antral 
G-cell hyperplasia. 
The diagnosis of duodenal and gastric ulcer was made by barium 
meal or endoscopy. 
The ZE-syndrome was characterized by: 
a. the combination of basal gastric acid hypersecretion (4.3 to 
32.1 mmol H /h in 3 patients with antrectomy and 40.3 to 57.5 
mmol H /h in 3 non-operated patients) and non-g-islet cell tumours 
in 6 patients, 
b. persistent hypergastrinemia after total gastrectomy without 
demonstrated tumours in 3 cases, 
c. in 9 non-operated patients by the combination of gastric acid 
hypersecretion (>10 mmol H /h) and hypergastrinemia (>150 pg/ml), 
with an increase in serum gastrin of at least 50% of basal value 
after stimulation with calcium and secretin respectively, and a 
rise in gastrin of less than 50% of fasting level after ingestion 
of a standard test meal. 
One non-operated patient with a fasting serum gastrin level of 
780 pg/ml had a marked postprandial rise in serum gastrin of 97% 
64 
of basal value, but the diagnosis of ZE-syndrome could be 
maintained in that patient because of a very high basal gastric 
acid output of 60 mmol H /h, an increase in serum gastrin of 75% 
after calcium infusion and a rise in gastrin of 140% after provo­
cation with secretin. 
Achlorhydria was defined as a gastric pH of more than 6.0 
after stimulation of gastric acid secretion with pentagastrin in 
a dose of 6 pg/kg i.m. 
All patients with chronic renal failure were on the hemodia­
lysis program. In these patients the blood sample was drawn before 
dialysis. 
Massive small bowel resection was performed in 4 patients 
because of volvulus or vascular lesions. The remaining parts of 
the small bowel measured 10 cm of duodenum in one patient, 40 
cm of jejunum in one case and about 50 cm of jejunum and 10 cm 
of terminal ileum in 2 patients. 
The patient with suspected antral G-cell hyperplasia had an 
elevated serum gastrin level together with a basal gastric acid 
output of 11 mmol H /h and a maximum acid output of 22 mmol H /h. 
After provocation with secretin serum gastrin decreased from 280 
to 183 pg/ml within 15 minutes, whereas ingestion of a standard 
test meal resulted in a steep and early rise in serum gastrin 
from 415 to 910 pg/ml (fig. 4 . 1 ) . 
Serum gastrin was measured by the radioimmunoassay technique 
as described by Stadil and Rehfeld ( 9 ) . 
The gastrin antibody, raised in a rabbit against synthetic 
human gastrin I containing residues 2 through 17 (SHG 2-17, 
Imperial Chemical Industries L t d ) , conjugated to bovine albumin 
( 2 5 ) , was a gift of Prof.Dr. J.F. Rehfeld and Dr. F. Stadil. 
Gastrin components I, II (gastrin-34), III (gastrin-17) and IV 
(gastrin-13) could be demonstrated using this antibody ( 2 0 ) . The 
antibody reacts with sulphated and non-sulphated forms of compo­
nents II and III with an almost equimolar potency (26). The ratio 
between the potencies of synthetic human gastrin I (SHG I, 
Imperial Chemical Industries L t d ) , pentagastrin (Imperial Chemical 
Industries Ltd) and purified porcine cholecystokini η (Gastro­
intestinal Hormone Research Unit, Karolinska Institute) to reduce 
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1 2 5I-SHG to 50Ï of initial value was 1.0 to 3.10" 
on a molar base respectively. No cross reactivity of 
the antibody was found with purified porcine secretin (Gastro-
intestinal Hormone Research Unit, Karolinska Institute). 
the binding of 
and 6.10"5 
gastrin 
( pg/ml ) 
4 0 0 -
200-
10 15 ( mm ) 
0 30 60 90 120 150(min) 
f i g . 't . 1 T h e e f f e c t of a d m i n i s t r a t i o n of s e c r e t i n 
GIH (1 U / k g . 3 0 sec ¡.v.) and i n g e s t i o n of 
a s t a n d a r d test meal on s e r u m g a s t r i n con-
c e n t r a t i o n in a p a t i e n t w i t h s u s p e c t e d 
a n t r a l G - c e l l h y p e r p l a s i a 
Synthetic human gastrin I (Imperial Chemical Industries Ltd) 
was iodinated with Na 1 2 5I (Behring werke AG) according to the 
method described by Stadil and Rehfeld (27). The mean specific 
activity of the labelled hormone was 382 + 104 yCi/ug gastrin with 
a range from 279 to 546 yCi/ug gastrin on 9 consecutive iodinations. 
Synthetic human gastrin I (Imperial Chemical Industries Ltd) 
was used as standard gastrin preparation. 
In a total volume of 2.5 ml 250 yl serum or standard solution 
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was incubated with 2 ml of gastrin antiserum (dilution 1:150000) 
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and 1 to 3 pg I-labelled SHG. All dilutions were made in 0.02 M 
veronal buffer pH 8.4, containing 30 pmol human albumin and 0.6 
mmol thiomersal per litre. All mixtures were incubated at 4 0C for 
4 days. Free and bound hormone was separated by adsorption of 
free gastrin to anionic exchange resin (Amberlite resin CG-B4, 
Rohm and H a a s ) , followed by décantation of the supernatant. Both 
the resin bound fraction and the supernatant were counted in a 
gammaspectrometer (Baird Atomic MS 5 8 8 ) . 
All determinations were performed in duplicate. Control mix-
tures containing no antiserum were set up for all samples to 
measure aspecific binding and to allow correction of the test 
results. Aspecific binding was 2.9 +_ 1.6% (n=10) for buffer 
solutions and 5.1 + 2.1%(п=10) for sera. Addition of heparin to 
the blood sample markedly increased aspecific binding, as demon­
strated by an aspecific binding of 2.6% for serum and 25.7% for 
plasma of the same patient. 
The intra-assay precision, determined by the coefficient of 
variation of tenfold measurements of three sera with a mean 
gastrin level of 42, 88 and 155 pg/ml , varied from 2.2 to 4.4%. 
The interassay variation ranged from 3.7 to 7.7% for 5 duplicate 
determinations of 4 sera with a mean gastrin level of 53, 78, 
129 and 162 pg/ml. The sensitivity of the assay, calculated from 
the 95% confidence limit at zero quantity of unlabelled hormone 
and the slope of the standard curve, was in 10 consecutive 
assays less than 1 pg/ml incubation mixture. Recovery, tested 
by adding 10 to 120 pg of synthetic human gastrin to 250 yl 
serum containing 10 pg of gastrin, was found to be 97 + 7%. 
Amounts of 5 to 20 pg of gastrin in 125 ul serum, added to 125yl 
serum containing 5 pg of gastrin, were recovered for 101 +_ 4%. 
Dilution curves of standard solution and sera of patients with 
hypergastrinemia (ZE-syndrome, achlorhydria and renal insuffi­
ciency) were superimposable (fig. 4 . 2 ) . 
In all subjects venous blood was drawn after an overnight 
fast. After centrifugation and décantation the serum was kept 
frozen at -20 oC up to the moment of determination. In table 4.1 
the effect of storing serum at different temperatures and for 
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Table 4.1 THE EFFECT OF STORING SERUM AT DIFFERENT TEMPERATURES 
AND FOR DIFFERENT PERIODS OF TIME ON THE SERUM GAS­
TRIN CONCENTRATION (PG/ML). 
time of 
storage 
•20oC 40C 250C 
serum A 1 day 
4 days 
27 days 
87 
89 
86 
79 
77 
62 
75 
71 
47 
serum В 1 day 
4 days 
27 days 
156 
165 
157 
149 
144 
142 
133 
109 
82 
serum С 1 day 
2 days 
1150 
1170 
1100 
1070 
850 
770 
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different periods of time on the gastrin concentration is recorded. 
If more than one serum sample of a subject was available, 
the result of the first sample obtained is presented in this study. 
Results are expressed as mean + 1 S.D., unless indicated 
otherwise in the text. 
Differences between the means of the patient groups studied are 
analysed by Student's t-test for unpaired results. 
"/о bound radioactivity 
60-
50-
40-
30-
20-
io 
5 10 5 0 100 500 1000 
gastrin ( p g / m l ) · · ^ 
standard 
1/IOÎ4 Ыг г м Иге К* Узг Vie Vfe 
serum dilution о 
f i g . ^ . 2 T h e p e r c e n t a g e of a n t i b o d y - b o u n d r a d i o ­
a c t i v i t y p l o t t e d a g a i n s t d i f f e r e n t d i l u ­
t i o n s of the s t a n d a r d g a s t r i n s o l u t i o n and 
of a s e r u m s a m p l e of a p a t i e n t w i t h the 
Zol I i n g e r - E 1 1 i son s y n d r o m e 
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4.3 Results 
4.3.1 .basa]_ 2 еІчш 3.as^t£Ì£ l eve2s_ 
Serum gastrin levels in 100 normal fasting subjects varied 
from 36 to 115 pg/ml with a mean of 66 pg/ml and a standard 
deviation of 18 pg/ml (fig. 4.3). 
serum 
gastrin 
(pg/mi) 
150 
125-
100-
75 
5 0 -
2 5 -
г 
т 
τ 
normal 
subjects 
η =100 
a i 
duodenal 
ulcer 
п= о 
f i g . 't . 3 F a s t i n g s e r u m g a s t r i n l e v e l s in 100 
no r m a l s u b j e c t s , 80 p a t i e n t s w i t h 
d u o d e n a l u l c e r and 17 p a t i e n t s w i t h 
g a s t r i c u l c e r 
In 80 patients with duodenal ulcer the serum gastrin level 
was 70 +_ 20 pg/ml with a range from 37 to 127 pg/ml (fig. 4.3). 
No statistically significant difference was found between the 
means of the serum gastrin levels in duodenal ulcer patients and 
normal subjects (p >0.10). In table 4.2 the mean serum gastrin 
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concentration in normal subjects and in duodenal ulcer patients 
is compared with the results as found in the literature. 
Table 4.2 SERUM GASTRIN LEVELS IN NORMAL SUBJECTS AND PATIENTS 
WITH DUODENAL ULCER. 
normal subjects duodenal ulcer 
η gastrin(pg/pil ) η gastri n( pg/ml ) 
(mean + SEM) (mean + SEM) 
Trudeau and McGuigan 
Ganguli and Hunter 
Hansky and Korman 
Stadil and Rehfeld 
Wesdorp and Fischer 
this study 
(28) 
(29) 
(30) 
(9) 
(31) 
10 
113 
252 
120 
30 
100 
71 
105 
36 
52 
54 
66 
+ 
+ 
+ 
+ 
+ 
+ 
9 
7 
4 
5 
9 
2 
22 
27 
206 
103 
101 
80 
76 
91 
13 
50 
61 
70 
+ 
+ 
+ 
+ 
+ 
+ 
7 
6 
8 
2 
7 
2 
The mean serum gastrin level in 17 patients with gastric 
ulcer, 92 + 28 pg/ml, was significantly elevated in comparison 
with the mean value found in the group of normal subjects 
(p <0.001). In these 17 patients basal serum gastrin levels varied 
from 53 to 160 pg/ml (fig. 4 . 3 ) . 
All 19 patients with the ZE-syndrome had elevated basal serum 
gastrin levels. In these patients the gastrin concentration ranged 
from 140 to 31000 pg/ml with a mean of 2716 pg/ml (fig. 4 . 4 ) . 
All 3 patients with serum gastrin values of more than 3000 pg/ml 
had evidence of metastatic gastrinoma at surgery. However, 2 other 
patients with metastatic lesions had gastrin levels of less than 
1500 pg/ml . 
Six out of 72 patients with achlorhydria had gastrin concen­
trations in the normal range. In the other 66 achlorhydric patients 
basal serum gastrin values were found to be elevated (fig. 4 . 4 ) . 
The mean serum gastrin level of the 72 patients with achlor­
hydria was 884 pg/ml with a range from 42 to 4200 pg/ml. 
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fig. h.k Serum gastrin levels in 19 patients 
with the Zo1 1 ingeг - E 1 1 i son s y n d r o m e , 72 
patients with a c h l o r h y d r i a and in k Ц 
patients with chronic renal f a i l u r e . The 
hatched area represents the normal range 
(mean + 2 S D ) . Cross symbols indicate 
patients with m e t a s t a t i c Z o l l i n g e r -
Ellison synd rome 
In table 4.3 the mean serum gastrin level in the achlorhydric 
patients from this study is compared with results from the lite­
rature . 
The mean serum gastrin concentration in 44 patients with 
chronic renal failure was 131 + 75 pg/ml with a range from 50 
to 460 pg/ml. Elevated serum gastrin values were found in 25 
out of 44 patients studied. 
The 4 patients with massive small bowel resection had gastrin 
levels in the low and normal range: 23, 47, 47 and 51 pg/ml. 
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Table 4.3 SERUM GASTRIN LEVELS IN PATIENTS WITH ACHLORHYDRIA. 
serum gastri η (pg/ml ) 
(mean + SEM) 
McGuigan and Trudeau (32) 
Hansky et al (33) 
Ganguli and Hunter (29) 
Stadil and Rehfeld (9) 
this study 
29 
21 
51 
36 
72 
997 + 
1036 + 
1167 + 
912 + 
884 + 
182 
215 
147 
163 
94 
The patient with suspected antral G-cell hyperplasia (fig. 
4.1) had an elevated serum gastrin concentration of 295 pg/ml. 
4.3.2 va r_i а Ь_П it^ o f _s er um_g a^ s t r2n_1 e ν el £ 
In table 4.4 the results are recorded of gastrin measurements 
in serum samples, obtained in normal controls and patients with 
ZE-syndrome and achlorhydria, on 5 consecutive days or weeks. 
The 5 samples of each subject were determined within one assay. 
4.3.3 eff.e£t_of 2.аіЛі,і£ £S£ira;tion_ojn serum £a£tri£ 
Aspiration of gastric juice for one hour resulted in a decrease 
in serum gastrin in all 9 ZE-patients studied (fig. 4 . 5 ) . This fall 
in gastrin did not seem to be the result of spontaneous diurnal 
variation, since serum gastrin levels did not change in 4 ZE-
patients during 3 hours saline infusion without gastric aspiration 
(chapter 5 . 3 ) . In 6 normal subjects a minor fall in serum gastrin 
from 53 + 9 to 49 + 8 pg/ml was observed during aspiration of 
gastric juice. 
4.3.4 £ff.e£t_o£ surg2ca^_and_m£dj_c£l_tre^tment_0£ serum ¿astriji 
In 3 out of 4 patients with the ZE-syndrome serum gastrin 
levels fell transiently after total gastrectomy (fig. 4 . 6 ) . In 
one of these patients with extensive liver metastases (fig. 4.6; 
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Table 4.4 VARIABILITY OF SERUM GASTRIN LEVELS (PG/ML) ON 5 CONSECUTIVE DAYS OR 5 CONSECUTIVE 
WEEKS IN 4 NORMAL SUBJECTS, 4 PATIENTS WITH ACHLORHYDRIA AND 4 PATIENTS WITH THE 
ZOLLINGER-ELLISON SYNDROME. 
5 consecutive days 
normal achlorhydria ZE-syndrome 
5 consecutive weeks 
normal achlorhydria ZE-syndrome 
64 67 700 3010 6900 420 
70 66 1230 2960 2800 370 
58 77 1520 3360 2500 450 
80 67 1310 3480 5000 450 
77 66 990 2720 2600 340 
53 79 1070 1390 530 570 
54 80 620 610 235 375 
54 94 850 855 380 580 
52 81 690 1030 255 545 
55 76 480 1210 270 590 
mean 70 69 1150 3106 3960 406 
S.D. 9 5 315 310 1940 49 
C.V.* 13 7 27 10 49 12 
S.E.M. 4 2 141 139 867 22 
54 82 
1 7 
2 8 
1 3 
742 
227 
31 
101 
1019 
303 
30 
136 
334 
123 
37 
55 
532 
89 
17 
40 
* coefficient of variation 
case A) total gastrectomy was followed by a marked decrease in 
serum gastrin from 4520 to 900 pg/ml. However, this fall in serum 
gastrin was not accompanied by a regression of tumour growth, as 
assessed by palpation of the liver and liver scan. 
serum gastrin 
(pg/ml) 
50 000-
10000· 
5 000-
1000-
5 0 0 -
100 J before after 
f gastric aspiration 
f i g . k . 5 T h e e f f e c t of g a s t r i c j u i c e 
a s p i r a t i o n over o n e hour on 
s e r u m g a s t r i n c o n c e n t r a t i o n 
in 9 p a t i e n t s w i t h the Z o l l i n g e r -
E 1 1 i son synd rome 
In one patient with ZE-syndrome and hyperparathyroidism norma-
lization of serum calcium concentration after parathyroidectomy 
was followed by a marked decrease in serum gastrin from 1300 to 
about 250 pg/ml (fig. 4 . 7 ) . After infusion of calcium, 5 mg/kg.h 
over 3 hours, the serum gastrin level rose to 1225 pg/ml, quite 
similar to the preoperative values in this patient. Five months 
after parathyroidectomy the patient died from renal failure and 
at autopsy extensive liver metastases were found in spite of only 
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moderately elevated serum gastrin concentrations shortly before 
death. 
Progressive tumour growth was accompanied by increasing serum 
gastrin levels in 2 patients with metastases to the liver (fig. 
4.6; cases A and B ) . The lack of effect of treatment with strep-
tozotocin was reflected in a continuous rise in serum gastrin in 
these 2 patients. A marked transient reduction in liver mass in 
one of these patients (fig. 4.6; case B ) , following palliative 
irradiation of the liver, was accompanied by a sharp, but brief 
fall in serum gastrin level. 
p a r a t h y r o i d ­
e c t o m y 
1 
1 3 5 7 9 1* 1 3 5 
1973 1974 
pdied 
-2 75 
2 5 0 
2 2 5 Я 
2 0 0 
9 11 
fig. k.7 T h e e f f e c t of p a r a t h y r o i d e c t o m y on 
se r u m c a l c i u m and serum g a s t r i n in 
a p a t i e n t w i t h Zo1 1 inger-E1 1 i son 
s y n d r o m e and h y p e r p a r a t h y r o i d i s m 
4.4 Discussion 
The present study confirms that the mean serum gastrin level 
in normal subjects is less than 100 pg/ml (9,34). Although in 
earlier studies in the literature (6,8) higher values were obtained, 
improvement of the assay technique depressed the levels to concen­
trations in the same range as in this study (28,35). 
No statistically significant difference was found between the 
mean serum gastrin level in duodenal ulcer patients and normal 
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controls. These results are in agreement with the findings of 
most groups in the literature (table 4.2). The elevated (36) and 
decreased (30) serum gastrin levels, reported in patients with 
duodenal ulcer, appear to be the result of different characteris-
tics of the antibody used (16). Since duodenal ulcer patients 
secrete on the average more gastric acid than normal subjects, 
decreased serum gastrin values would have been expected, because 
of the acid feedback mechanism of antral gastrin release (34). 
The lack of depressed serum gastrin levels in duodenal ulcer pa-
tients has been interpreted as a defect in acid feedback inhibi-
tion of gastrin release (37). 
Mildly elevated serum gastrin values in patients with gastric 
ulcer have been found by others (29,30,38,39). Since fasting serum 
gastrin levels are reported to be inversely related to basal and 
stimulated acid secretion (38), the low gastric acid output in 
some patients with gastric ulcer (40) may account for the slightly 
elevated gastrin values found in these patients (38). 
Serum gastrin levels were in all 19 patients with the ZE-
syndrome higher than the values obtained in normal controls and 
duodenal ulcer patients. All 3 patients with basal serum gastrin 
levels of more than 3000 pg/ml had metastatic gastrinoma. These 
results are in agreement with data of Hansky et al (41), who 
found very high gastrin levels of more than 6000 pg/ml exclusively 
in 3 patients with liver metastases. However, two patients with 
metastatic gastrinoma in the present study had serum gastrin levels 
of less than 1500 pg/ml. Autopsy in one of these patients (fig. 
4.7) revealed extensive liver metastases, in spite of only modera-
tely increased gastrin concentrations of about 400 pg/ml. This 
patient had a markedly elevated serum calcitonin level (1290 
pg/ml; normal value less than 400 pg/ml), and it has been found 
(42; chapter 2.5.7) that calcitonin is able to depress gastrin 
levels in ZE-patients. 
In the present study an overlap was found between serum gastrin 
values in the ZE-patients and patients with achlorhydria, chronic 
renal failure, gastric ulcer or suspected antral G-cell hyper-
plasia. Differentiation between ZE-patients and patients with 
achlorhydria or gastric ulcer can be made by gastric acid measure-
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ment. Patients with renal insufficiency can be readily detected 
by determination of serum creatinine concentration. Both ZE-
patients and patients with antral G-cell hyperplasia however 
have hypergastrinemia in combination with basal gastric acid 
hypersecretion (34,35,43-45). Provocation tests with secretin 
and food are able to distinguish between these entities. Intrave-
nous administration of secretin stimulates gastrin release in 
patients with the ZE-syndrome (46,47; chapters 6 and 8) but does 
not result in an increase in serum gastrin in patients with G-
cell hyperplasia (34,35; fig. 4 . 1 ) . Ingestion of food is followed 
by an early ard steep rise in serum gastrin in patients with 
antral G-cell hyperplasia (35,45; fig. 4 . 1 ) , but results in a 
slight and late increase in patients with the ZE-syndrome (48; 
chapters 7.3.2 and 8 . 3 ) . The differentiation between these 2 
entities is of great clinical importance, because total gastrec-
tomy is the only effective surgical treatment in patients with 
the ZE-syndrome (43,49; chapter 2 ) , whereas antrectomy should be 
performed in patients with antral G-cell hyperplasia ( 5 0 ) . 
In 66 out of 72 patients with achlorhydria serum gastrin 
levels were found to be elevated. On the other hand 6 achlorhydric 
patients had gastrin values in the normal range. These results 
are in agreement with data from the literature (9,29,32,33). The 
hypergastrinemia in achlorhydric patients is the result of antral 
G-cell hyperplasia, caused by the chronic lack of gastric acid 
inhibition of gastrin release (32,51). Yalow and Berson (8) demon-
strated that serum gastrin concentration fell markedly in these 
patients after intragastric instillation of hydrochloric acid. 
Stockbriigger (52) found that in normogastrinemic patients with 
achlorhydria the number of antral G-cells was not increased, 
probably as a result of coexisting antral gastritis. It has been 
suggested that normal serum gastrin values are especially found 
in achlorhydric patients with normal vitamin B,- absorption and 
absent parietal cell antibodies in circulation ( 5 3 ) . However, 
all 6 achlorhydric patients with normogastrinemia in this study 
had low vitamin B,- absorption (range 1.0 to 12.655/48h; normal 
value >17%/48h) and in 4 circulating antibodies to parietal cells 
were found. Two out of these 6 patients had adult onset hypogam-
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magiobulinemia, and both the lack of parietal cell antibodies 
and the absence of hypergastrinemia have been well documented 
in patients with the combination of achlorhydria and hypogamma-
globuli nemia (54 ,55) . 
Since the kidneys are active sites of inactivation of gastrin 
( 1 1 ) , hypergastrinemia may be found in patients with renal in-
sufficiency ( 5 6 ) . In the present study both elevated and normal 
serum gastrin levels were found in patients with chronic renal 
failure. The hypergastrinemia in the 25 patients with elevated 
serum gastrin concentrations could not be attributed to achlor-
hydria and was not accompanied by gastric acid hypersecretion. 
Korman et al (56) did not find a correlation between serum gastrin 
levels and basal gastric acid secretion in the patients with 
chronic renal failure studied. In their study gastrin values were 
well correlated with serum creatinine concentrations ( 5 6 ) . More-
over, a normalization of serum gastrin levels was observed after 
successful renal transplantation ( 5 7 ) . Since some patients with 
chronic renal failure in our study, even after bilateral nephrec-
tomy, had normal serum gastrin levels, a suppressed release of 
gastrin or enhanced removal by other organs might be present. The 
effect of gastrin on gastric acid secretion in these patients is 
hard to assess.since the molecular forms and the biological acti-
vity of gastrin in these patients may be different, the function 
of the parietal cells may be altered, and the levels of other 
humoral substances with influence on acid secretion may be in-
creased . 
None of 4 patients with massive small bowel resection from 
this study had increased basal serum gastrin levels. The low 
serum gastrin level of 23 pg/ml in one of the patients is probably 
the result of partial resection of the duodenum, since the duodenal 
mucosa is known to be one of the sites of gastrin release ( 1 0 ) . 
Both elevated (58) and normal fasting gastrin values (59) have been 
recorded in patients with small bowel resection in the literature. 
Our results indicate that the role of the small intestine in the 
inactivation of gastrin is inconsiderable or can readily be taken 
over by other sites of gastrin removal. 
Only minor variations in serum gastrin were found in 4 normal 
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subjects on 5 consecutive days or weeks (table 4 . 4 ) . In 4 patients 
with ZE-syndrome and 4 patients with achlorhydria the serum gas­
trin concentration varied considerably. However, no overlap in 
serum gastrin was found between the 4 normal subjects and the 8 
patients with ZE-syndrome or achlorhydria. 
Aspiration of gastric juice was accompanied by a fall in serum 
gastrin in all 9 ZE-patients tested. These results are in agree­
ment with the data of Stadi! et al (60), who found a decrease in 
serum gastrin during gastric acid aspiration in a ZE-patient, and 
afterwards a rise in gastrin following intragastric reinstillation 
of the gastric juice. The reason for the fall in gastrin during 
gastric aspiration is probably a reduced or absent influx of acid 
into the duodenum, resulting in a decrease in secretin release 
from the duodenal and small bowel mucosa. As secretin is known to 
raise serum gastrin levels in patients with the Zol1inger-Elli son 
syndrome (46; chapters б and 8 ) , a fall in secretin may be respon­
sible for the decrease in serum gastrin. However, this hypothesis 
has to be confirmed by radioimmunoassay of plasma secretin levels 
during gastric acid aspiration in ZE-patients. 
This gastric acid-secretin-gastriη relationship may also 
account for the fall in serum gastrin after total gastrectomy 
in 3 out of 4 ZE-patients (fig. 4 . 6 ) . In one patient (fig. 4.6; 
case A) with large liver metastases the marked postoperative 
decrease in serum gastrin was not accompanied by a regression of 
tumour growth, as assessed by progressive increase in metastatic 
liver mass on palpation and liver scan. 
In all 3 patients this fall in gastrin was only transient and a 
rise was observed later on. It can therefore be concluded that 
a postoperative fall in serum gastrin does not always reflect 
regression of tumour growth, as has been suggested by Friesen et 
al (61). Thompson et al (62) found a transient fall in serum 
gastrin after total gastrectomy in 4 out of 8 patients, and a 
lasting normalization of serum gastrin in one case. In some of 
these patients however total gastrectomy was combined with excision 
of primary or secondary tumours. Passare et al (63) found low serum 
gastrin levels in 5 ZE-patients 3 months to 4 years after total 
gastrectomy. The authors believed that these low concentrations 
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were the result of postoperative tumour regression. Accurate 
analysis of the data, collected at the Zol1 inqer-El1ison-Tumor 
Registry, revealed wel 1-documented tumour regression in only 4 
out of 137 patients with metastatic lesions and total gastrectomy 
(64). 
The marked fall in serum gastrin after parathyroidectomy in a 
patient with ZE-syndrome and hyperparathyroidism (fig. 4.7) was 
not accompanied by regression of tumour lesions. 
The progressive tumour growth in 2 patients with extensive 
liver metastases (fig. 4.6; cases A and B) was reflected in an 
increase in serum gastrin to very high levels. Streptozotociη 
did not inhibit tumour growth or depress gastrin concentration 
in these 2 patients (fig. 4.6; cases A and B; 65). Stadil et al 
(66) found that serum gastrin levels decreased markedly during 
treatment with streptozotocin in 2 patients with the ZE-syndrome. 
This fall in serum gastrin was accompanied by a well-documented 
reduction in liver size in one patient and a decrease in acid 
output in the other patient (66). Thompson et al (62) observed 
a fall in serum gastrin after hepatic artery infusion of 5-
fluorouracil in a patient with ZE-syndrome and large liver metas­
tases. However, these authors did not mention whether a regression 
of tumour lesions occurred in this patient. In one patient with 
extensive liver metastases in the present study (fig. 4.6; case 
B) palliative irradiation of the liver was accompanied by a sharp, 
but brief fall in serum gastrin and a reduction in liver size. 
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Chapter 5 
SERUM GASTRIN RESPONSE TO ACUTE AND CHRONIC HYPERCALCEMIA: 
STUDIES WITH EMPHASIS ON THE SIGNIFICANCE OF CALCIUM STIMULATED 
SERUM GASTRIN LEVELS TO THE DIAGNOSIS OF THE ZOLLINGER-ELLISON 
SYNDROME. 
5.1 Introduction 
In 1969 a close relationship was found between the serum 
levels of calcium and gastrin in a patient with Zollinger-
Ellison (ZE) syndrome and total gastrectomy ( 1 ) . This observa-
tion has evoked great interest in the study of the influence of 
hypercalcemia on serum gastrin. The results of the various 
studies.however 5are not compatible with each other. One group 
found a definite relation between calcium and gastrin in all 
ZE-patients, but not in patients with duodenal ulcer without 
gastrinoma ( 2 ) . These authors.therefore.proposed a calcium 
stimulation test to differentiate ZE-syndrome from "ordinary" 
duodenal ulcer in patients with slightly elevated serum gastrin 
levels ( 2 ) . In a number of reports the value of this test has 
been confirmed in patients with ZE-syndrome ( 3 - 8 ) . 
Another group.however .found significant increases in serum gas-
trin during calcium infusion in normal controls and duodenal 
ulcer patients ( 9 ) . In a later report of this group the porcen-
tual increase in serum gastrin after calcium stimulation was 
found to be even more pronounced in duodenal ulcer patients than 
in patients with ZE-syndrome (10). 
Calcium stimulated serum gastrin levels have been reported 
to be more accurate in identifying ZE-patients with residual 
tumour lesions after operation than basal serum gastrin values 
( 3 ) . Therefore this test has been advocated to evaluate the 
clinical course, the effect of treatment and the outlook in 
ZE-patients ( 3 ) . 
Apart from ZE-syndrome, it was found that serum gastrin 
levels did not increase after calcium infusion in 8 patients 
with antrectomy for "ordinary" peptic ulcer disease (11). One 
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patient with antrectomy in that study however showed a rise in 
serum gastrin after calcium stimulation. This patient was found 
to have retained antral tissue later on. 
Finally in patients with hyperparathyroidism both normal and 
increased basal serum gastrin values have been described ( 1 2 - 1 4 ) . 
In this study the effect of calcium administration on serum 
gastrin was determined in normal subjects and in patients with 
ZE-syndrome, achlorhydria, duodenal ulcer, stomal ulcer and total 
gastrectomy. Furthermore, basal serum gastrin values were measu-
red in patients with chronic hypercalcemia and compared with the 
levels in normal subjects. 
The aim of this study was to answer the following questions: 
1. is the increase in serum gastrin in response to calcium 
characteristic of the ZE-syndrome? 
2. is the calcium stimulation test helpful to diagnose metasta-
tic lesions in ZE-patients? 
3. is this calcium provocation test valuable in assessing the 
completeness of antrectomy? 
4. is chronic hypercalcemia accompanied by hypergastrinemia? 
5.2 Patients and methods 
The calcium infusion test was performed in 15 normal subjects, 
16 ZE-patients, 6 patients with achlorhydria, 10 duodenal ulcer 
patients, 9 stomal ulcer patients and 5 patients with total gas-
trectomy . 
Characteristics of the 16 patients with ZE-syndrome are summari-
zed in table 5.1. Two of the patients without tissue diagnosis 
had persistent hypergastrinemia after total gastrectomy, indica-
ting the extragastric origin of gastrin. Moreover, the diagnosis 
of ZE-syndrome was confirmed in all 11 patients without tissue 
diagnosis of gastrinoma by an increase in serum gastrin of at 
least 50% of basal level after administration of 1 U secretin 
GIH/kg.30 sec intravenously ( 1 5 ) . In all 9 patients without pre-
vious gastric surgery a meal stimulation test was performed to 
exclude antral G-cell hyperplasia ( 1 6 - 1 8 ) . In 8 out of the 9 pa-
tients the postprandial increase in serum gastrin was less than 
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Table 5.1 CHARACTERISTICS OF 16 PATIENTS WITH THE ZOLLINGER-ELLISON SYNDROME. 
sex 
CD 
U3 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
f 
m 
f 
f 
m 
m 
m 
m 
f 
m 
f 
f 
f 
f 
m 
f 
aqe 
(yrs) 
42 
39 
17 
49 
48 
61 
43 
42 
70 
26 
64 
38 
37 
50 
40 
43 
basal acid output 
(mmol H+/h) 
32.1* 
67.0 
57.5 
6.4* 
40.3 
35.5 
46.0 
13.4 
pH 1.2 
60.0 
4.3* 
12.5 
23.4 
15.4 
19.2 
15.1 
serum gastrin 
(pg/ml) 
620 
400 
3100 
530 
190 
1540 
215 
240 
400 
530 
10800 
250 
350 
142 
140 
196 
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
960000 
1150 
21000 
750 
1490 
3280 
320 
600 
1300 
850 
27100 
380 
470 
196 
252 
510 
pancreatic 
non-ß-tumour 
+ 
0§ 
+ 
о " 
+ 
о " 
-t 
_t 
0 
.t 
0 
-t 
-t 
-t 
-t 
-t 
metastatic 
lesions 
normal values (mean + 1 S.D.) 2.3+2.6 (n=20) 66+18 (n=100) 
+ present 
0 absent or not demonstrated 
not investigated 
* 
t 
after partial gastrectomy 
no laparotomy 
nodular pancreas;no tissue diagnosis 
0 
0 
+ 
0 + 
+ 
0 + 
persistent hyper-
gastrinemia after 
total gastrectomy 
50% of basal value (normal value 99 + 51%, mean + 1 S.D., n = 1 2 ) . 
The postprandial rise in serum gastrin in the other patient was 
97 % . The diagnosis of ZE-syndrome however could be maintained in 
that patient since secretin provoked an increase in serum gas-
trin of 140% of basal value and the basal gastric acid output 
of 60 mmol H /h is much higher than in patients with hypergastri-
nemia of antral origin (16,18). In non-operated ZE-patients me-
tastatic lesions were looked for by a thoracic X-ray and liver 
function tests in all, by liver scan in 6 and by angiography in 
3 patients. 
Achlorhydria was defined as a gastric pH greater than 6.0 after 
stimulation with pentagastrin in a dose of 6 wg/kg i.m. 
The diagnosis of duodenal and stomal ulcer was made by barium 
meal or endoscopy. 
Total gastrectomy had been performed in the 5 patients studied 
because of malignancy, exudative gastropathy and normogastrinemic 
peptic ulcer disease. 
Basal serum gastrin levels were measured in 44 patients with 
chronic hypercalcemia (serum calcium level of more than 2.65 
m m o l / 1 ) . In 31 of these patients primary hyperparathyroidism was 
proven or suspected. The other 13 patients had a variety of under-
lying diseases, such as metastatic bone lesions, sarcoidosis and 
myeloma. 
After an overnight fast calcium was infused as calcium glucon-
ate, in a dose of 5 mg per kg per hour, over 3 hours. In one ZE-
patient the same amount of calcium was also administered as cal-
cium chloride. Blood for the determination of calcium and gastrin 
was drawn before and 1, 2 and 3 hours after the start of the 
infusion. Gastric juice was not aspirated during the calcium 
infusion. The effect of a 3 hours saline infusion on serum gastrin 
was also determined in 6 normal subjects and 4 ZE-patients. 
Serum calcium concentrations were determined by atomic absorp-
tion spectrophotometry. 
Serum gastrin levels were measured by radioimmunoassay using a 
rabbit antibody (19,20; chapter 4 . 2 ) . This anti body,raised against 
synthetic human gastrin I 2 through 17, conjugated to bovine 
albumin, binds gastrin components II and III with an almost equi-
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Table 5.2 SERUM GASTRIN RESPONSE TO 3 HOURS CALCIUM INFUSION (5 MG/KG.H) IN NORMAL SUBJECTS 
AND PATIENTS WITH DUODENAL ULCER, STOMAL ULCER AND TOTAL GASTRECTOMY. 
basal 
serum gastrin (pg/ml)* 
1 h 2 h 3 h mean percentual 
increase 
normal subjects 15 63 + 1 5 65 + 16 67 + 1 8 69 + 22 10 
duodenal ulcer 10 70 + 1 3 71 + 16 73 + 1 7 73 + 18 
stomal ulcer 59 + 1 9 65 + 27 61 + 2 2 62 + 23 
total gastrectomy 5 5 2 + 1 9 54 + 25 60 + 3 0 61 + 30 17 
* mean + 1 S.D. 
Table 5.3 SERUM GASTRIN RESPONSE TO 3 HOURS CALCIUM INFUSION 
(5 MG/KG.H) IN 16 ZOLLINGER-ELLISON PATIENTS. 
serum gastrin (pg/ni1) 
basal I h 2 h 3 h % increase 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
4520 
620* 
36400* 
500 
3100 
5200Ф 
10600* 
700 
530* 
530* 
2470* 
320 
245 
1010* 
530 
27100 
380 
350 
156 
175 
510 
4650 
730 
36800 
580 
4300 
6500 
14300 
810 
660 
720 
3600 
570 
310 
1100 
610 
53600 
805 
480 
310 
355 
510 
4870 
790 
37600 
860 
5700 
9200 
20500 
960 
750 
840 
4975 
670 
385 
1020 
780 
71600 
1040 
720 
440 
475 
640 
5020 
840 
42400 
1190 
10800 
22500 
31000 
1080 
880 
1035 
8745 
790 
415 
1070 
930 
107700 
1500 
970 
560 
570 
1000 
11 
35 
18 
138 
248 
333 
193 
67 
66 
95 
254 
147 
69 
6 
75 
340 
295 
177 
258 
228 
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* after total gastrectomy 
t infusion of calcium chloride, 5 mg cal ci um/kg . h, over 3 hours 
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molar potency (21). Calcium concentrations of less than 
6.0 mmol/1 did not interfere with the determination of gastrin. 
Results are expressed as mean +_ 1 S.D. The significance of 
differences between means was analysed by Student's t-test for 
paired and unpaired results. 
5.3 Results 
Basal serum gastrin levels in patients with duodenal ulcer, 
stomal ulcer and total gastrectomy were not significantly dif­
ferent from the values in normal subjects (table 5.2; ρ >0.20). 
Fasting serum gastrin levels in all patients with ZE-syndrome 
and achlorhydria were higher than those in the other groups 
studied (tables 5.3 and 5.4). 
Table 5.4 SERUM GASTRIN RESPONSE TO 3 HOURS CALCIUM INFUSION 
(5 MG/KG.H) IN 6 PATIENTS WITH ACHLORHYDRIA. 
serum gastrin (pg/ml) 
basal 1 h 2 h 3 h % increase 
1 
2 
3 
4 
5 
б 
Serum gastrin levels of more than 5000 pg/ml were only found in 
patients with metastatic ZE-syndrome. However, two patients with 
extensive liver metastases (case 1 after total gastrectomy and 
case 5) had basal serum gastrin levels of less than 1000 pg/ml 
and one ZE-patient with metastases in lymph nodes and serosa 
(patient 9) had a fasting serum gastrin concentration of 1010 
pg/ml (table 5.3) . 
Preinfusion serum calcium concentrations in patients with 
610 
120 
460 
2960 
475 
1040 
670 
168 
705 
3670 
485 
1100 
1320 
162 
910 
4080 
500 
1190 
2090 
230 
1050 
4125 
530 
1530 
243 
92 
128 
39 
12 
47 
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duodenal ulcer (2.38 + 0.08 m m o l / 1 ) , stomal ulcer (2.41 + 0.06 
m m o l / 1 ) , total gastrectomy (2.43 + 0.14 m m o l / 1 ) , achlorhydria 
(2.33 + 0.13 mmol/1) and ZE-syndrome (2.38 + 0.27 mmol/1) were 
not significantly different (p >0.30) from normal (2.39 + 0.13 
m m o l / 1 ) . The increase in serum calcium after 3 hours calcium 
infusion was in the patients with duodenal ulcer 0.91 + 0.22 
mmol/1, with stomal ulcer 0.86 + 0.18 mmol/1, with total gas-
trectomy 0.86 + 0.23 mmol/1, with achlorhydria 0.96 + 0.17 
mmol/1 and with ZE-syndrome 0.88 + 0.22 mmol/1. These values 
were not significantly different (p >0.05) from the rise in 
serum calcium in normal subjects, 1.00 + 0.19 mmol/1. 
Calcium stimulation was followed by a non-significant 
(p >0.05) rise in serum gastrin in the patients with normal 
basal serum gastrin values (table 5 . 2 ) . In these groups both 
minor increases or decreases and unchanged serum gastrin levels 
were found in the individual subjects studied (fig. 5 . 1 ) . 
In all ZE-patients an increase in serum gastrin was found after 
calcium infusion (table 5 . 3 ) . 
All 6 patients with achlorhydria also showed a rise in serum 
gastrin after calcium administration (table 5 . 4 ) . An increase 
in gastrin of more than 50% of basal value was found in 14 out 
of 16 ZE-patients and in 3 out of 6 patients with achlorhydria 
(tables 5.3 and 5 . 4 ) . The 2 ZE-patients with a rise in serum 
gastrin of less than 50% of basal value (cases 1 and 9) had 
histologically proven ZE-syndrome. The increase in serum calcium 
after 3 hours calcium infusion in these 2 patients, 0.79 and 
0.91 mmol/1, was not different from the rise in serum calcium 
for the group of ZE-patients as a whole, 0.88 + 0.22 mmol/1. In 
none of the normal subjects and patients with duodenal ulcer, 
stomal ulcer and total gastrectomy was a more than 50% increase 
in serum gastrin observed (table 5 . 2 ) . 
Saline infusion over 3 hours was accompanied by a non-significant 
(p >0.10) decrease in serum gastrin from 52 + 13 to 47 + 8 pg/ml 
in the 6 normal subjects studied. No marked differences in serum 
gastrin were observed in 4 ZE-patients before and after 3 hours 
saline infusion. The mean serum gastrin level before infusion was 
1450 pg/ml with a range from 380 to 4250 pg/ml and 1415 pg/ml after 
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g a s t r i n ( p g / m l ) 
120 
100-
8 0 
6 0 
4 0 
2 0 
calcium 5mg/kg.h 
n = 15 
О 3 (hrs) 
normal subjects 
gastrin ( p g / m l ) 
120 
100-
8 0 
6 0 · 
4 0 -
20-
calcium 5mg/kg h 
ν///////////////Λ 
n = 10 
О 3 ( hrs) 
duodenal u l c e r 
gastrin ( p g / m l ) 
120-
1 0 0 
80-
60-
4 0 
2 0 -
calcium 5mg/kg.h 
/////////////Ш 
η * 9 
0 3 (hrs) 
stomal ulcer 
gastrin ( pg/ml ) 
120 
100-
8 0 
6 0 
4 0 
2 0 
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/////////////Ж 
η 5 
О 3 (hrs) 
t o t a l gastrectomy 
fig. 5·1 Serum gastrin response to 3 hours calcium infusion 
(5 m g / k g . h ) in 15 normal s u b j e c t s , 10 duodenal ulcer 
p a t i e n t s , 9 stomal ulcer patients and 5 patients with 
total ga s t ree tomy 
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the infusion with a range from 395 to 4000 pg/ml . 
Three ZE-patients (cases 1, 3 and 4) were tested by calcium 
infusion before and after total gastrectomy. No marked differen-
ces were found in the gastrin response to calcium before and 
after surgery (table 5 . 3 ) . 
The mean increase in serum gastrin in 5 patients with histo-
logically proven metastatic ZE-syndrome was 141% in comparison 
with 171% in 11 patients without evidence of metastases. In the 
2 patients with extensive liver metastases and relatively low 
serum gastrin levels (cases 1 and 5) the serum gastrin concen-
tration rose from 620 to 840 pg/ml and from 530 to 1035 pg/ml 
respectively after infusion of calcium. The calcium stimulated 
increase in serum gastrin in the patient with metastases in 
lymph nodes and serosa (case 9) was even weaker (table 5 . 3 ) . 
In the ZE-patient studied no marked difference was found 
between the rise in serum gastrin after infusion of equal amounts 
of calcium, as calcium gluconate or calcium chloride (table 5 . 3 ) . 
Basal serum gastrin levels in 44 patients with chronic hyper-
calcemia (72 + 24 pg/ml) were not significantly different 
(p >0.10) from the values found in 100 normal subjects (66 +_ 18 
p g / m l ) . The mean serum gastrin concentration in 31 patients with 
proven or suspected hyperparathyroidism (70 + 20 pg/ml) did also 
not differ significantly (p >0.50) from the levels in 13 patients 
with hypercalcemia of other origin (75 + 32 p g / m l ) . Four other 
hypercalcémie patients had hypergastrinemia (390, 855, 1380 and 
1950 p g / m l ) , because of achlorhydria. 
Normalization of chronic elevated serum calcium levels by para-
thyroidectomy was followed by a decrease in serum gastrin from 
1300 to 275 pg/ml in a patient with histologically proven ZE-
syndrome. In two patients with achlorhydria serum gastrin fell 
from 1380 to 620 pg/ml and from 230 to 76 pg/ml respectively 
following parathyroidectomy. 
5.4 Discussion 
The present study confirms that patients with ZE-syndrome and 
achlorhydria have elevated serum gastrin levels (20,22,23). 
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The calcium provocation test has been advocated in patients 
with equivocal ZE-syndrome with serum gastrin levels of less than 
1000 pg/ml (22) or less than ten times the normal median (23). 
This test however is of greatest diagnostic value in patients 
with serum gastrin levels in the high-normal or slightly elevated 
range, e.g. between 100 and 200 pg/ml. Two out of 16 ZE-patients 
(patients 14 and 15) in the present study had basal serum gastrin 
levels of less tan 200 pg/ml. Calcium infusion in these 2 patients 
induced a marked increase in serum gastrin up to levels of more 
than 500 pg/ml. Although no laparotomy has been performed in these 
two patients the diagnosis of ZE-syndrome was confirmed by the 
combination of basal gastric acid hypersecretion, slight hypergas-
trinemia with marked increase in serum gastrin after secretin 
administration (92 and 209%; 8 + 15% in 34 normal controls), a 
minor rise in gastrin after a protein-rich meal (44 and 4 2 % ; 
99 + 51% in 12 normals) and a family history of Multiple Endocrine 
Adenomatosis type I. In recent series basal serum gastrin levels 
of less than 200 pg/ml were found in one out of 8 (18), 2 out of 
12 (5) and none out of 9 patients (6) with ZE-syndrome. Thompson 
et al (4) reported a patient with normal to slightly elevated 
basal serum gastrin levels, which increased markedly after cal-
cium infusion. After careful and long-standing search at surgery 
a small pancreatic tumour was found in this patient. 
On the other hand patients with the combination of fasting 
hypergastrinemia and basal acid hypersecretion without tumours 
have been described (16,18). In these patients with "non-tumorous 
hypergastrinemic hyperchlorhydria" basal serum gastrin levels 
ranged from 100 to 1033 pg/ml (16,18). In contrast to patients 
with ZE-syndrome the serum gastrin level did not actually rise 
after calcium stimulation in these patients with hypergastrinemia 
of antral origin. 
In the present study of 16 ZE-patients two (cases 1 and 9) showed 
only a minor increase in serum gastrin after administration of 
calcium. In both patients however the diagnosis of ZE-syndrome 
was confirmed by the evidence of metastatic gastrinoma at lapa-
rotomy. 
If the criterion of 50% increase in serum gastrin after 
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calcium administration is used two false negative tests were 
found in the 16 patients with ZE-syndrome. In none of the pa-
tients without gastrinoma or achlorhydria was a more than 50% 
rise in gastrin observed. These results are in contrast with the 
data of Reeder et al (10), who found an even sharper percentual 
rise in gastrin in 12 patients with duodenal ulcer than in 5 
patients with ZE-syndrome and total gastrectomy. The mean 
increase in serum gastrin in 12 duodenal ulcer patients in that 
study was 90% of basal value compared to 4% in the present study 
of 10 duodenal ulcer patients. The procedure however were not 
actually comparable, since different amounts of calcium over 
different time periods were administered and gastric acid was 
aspirated continuously in the study of Reeder et al (10). Moreover, 
the significantly elevated basal serum gastrin level found in 
the duodenal ulcer patients in that study (10), in contrast to 
the normal levels in the present study and in the literature (22, 
2 3 ) , may indicate selection of patients or different characteris-
tics of the gastrin assay. 
In equivocal cases of ZE-syndrome other provocative agents 
besides calcium, e.g. secretin (15,24,25) or food (16,18),may 
give additional information. Recent studies from our laboratory 
have shown that the calcium infusion test can be substituted by 
the easier, faster and safer secretin stimulation test (26; 
chapter 8 ) . 
A marked increase in serum gastrin after calcium provocation 
is not unique for the ZE-syndrome. Three out of 6 patients with 
achlorhydria also showed a more than 50% increase in serum gas-
trin. In one achlorhydric patient, studied by Straus and Yalow 
(18), serum gastrin rose markedly after calcium infusion, 
but studies of larger groups are lacking (23). Differentiation 
between patients with ZE-syndrome and achlorhydria can be easily 
made by determining the pH of the gastric juice. 
No marked differences were found in the calcium stimulated 
rise in gastrin before and after total gastrectomy in 3 ZE-patients 
studied. It has been found that the gastrin response to calcium 
in ZE-patients is less after total gastrectomy compared to the 
results before surgery (5) . However, the results in that study 
98 
were apparantly influenced by an extremely pronounced increase 
in serum gastrin in one of the ZE-patients studied preoperatively 
(5). 
ZE-patients with metastatic gastrinoma had both major and 
minor gastrin responses to calcium.On an average the rise in serum 
gastrin was not different from patients without evidence of me-
tastatic lesions. Calcium stimulated serum gastrin levels were 
not more valuable to the diagnosis of metastases than basal 
serum gastrin concentrations. In 2 ZE-patients with extensive 
liver metastases calcium stimulated serum gastrin levels were 
still far below the basal values recorded in ZE-patients with 
liver metastases by Hansky et al (27). After tumour excision, 
however»cai cium infusion may be helpful to reveal retained tumour 
lesions in cases with normal or slightly elevated basal serum 
gastrin concentrations(3). 
In 8 patients with complete antrectomy, studied by Christiansen 
et al (11),no increase in serum gastrin was found after calcium 
infusion, whereas in one patient with retained antral tissue 
serum gastrin rose from 52 to 100 pg/ml . It was concluded in 
that study that extragastric gastrin was not released by calcium 
infusion. In the present study however both in some patients 
with stomal ulcer and in some patients with total gastrectomy a 
rise in serum gastrin during calcium administration was found. It 
is evident that gastrin, released by calcium infusion in the 
patients with total gastrectomy, is of extragastric origin (28). 
Therefore the calcium stimulation test does not seem to be of 
any value in assessing the completeness of antrectomy. 
In patients with primary hyperparathyroidism both normal and 
increased serum gastrin levels have been recorded in the litera-
ture (12-14). Serum gastrin concentrations in hypercalcémie 
patients without hyperparathyroidism have not been recorded 
previously. In this study no significant difference in gastrin 
level was found between patients with chronic hypercalcemia and 
normal controls. The origin of the hypercalcemia was also found 
to have no effect on serum gastrin level. 
It is concluded that serum gastrin concentrations are normal in 
hypercalcémie patients without ZE-syndrome or achlorhydria. 
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On the other hand, chronic hypercalcemia in patients with IE-
syndrome or achlorhydria is accompanied by higher serum gastrin 
levels in comparison with the values obtained during normocalcernia 
in the same patients. These results are in agreement with other 
studies (1,12,29). 
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Chapter б 
THE SIGNIFICANCE OF SECRETIN STIMULATED SERUM GASTRIN LEVELS IN 
PATIENTS WITH HYPERPARATHYROIDISM FROM FAMILIES WITH MULTIPLE 
ENDOCRINE ADENOMATOSIS TYPE I (MEA I) 
6.1 Introduction 
The MEA I-entity is characterized by an autosomal dominant 
inheritance with high penetrance and some variability in expres­
sivity ( 1 ) . Hyperparathyroidism, pancreatic islet cell tumours 
and pituitary tumours can be parts of this entity, but adrenocor­
tical hyperplasia, carcinoid tumours and thyroid nodules have 
also been described in this entity ( 1 ) . According to studies from 
the literature hyperparathyroidism was found in 87% and suspected 
or proven Zol1inger-El1ison (ZE) syndrome in 52 and 61% of the 
affected subjects (2,3). Patients with hyperparathyroidism from 
MEA I-families are prone to develop ZE-syndrome with increasing 
age ( 1 ) . 
Determination of serum gastrin levels by radioimmunoassay is 
the most valuable tool for the diagnosis of ZE-syndrome ( 4 , 5 ) . 
After administration of secretin most ZE-patients show a marked 
increase in serum gastrin (6,7). 
To detect ZE-syndrome, especially in an early stage of the 
disease, secretin stimulated serum gastrin levels were measured 
in patients with hyperparathyroidism from MEA I-families. The 
reliability of the secretin stimulation test was in positive 
cases evaluated by comparing the results with those of other 
tests, which have proved to be helpful in the diagnosis of ZE-
syndrome, such as basal gastric acid output ( 8 ) , calcium stimu­
lated gastrin levels (9) and meal stimulated gastrin values 
(10). 
6 . 2 Patients and methods 
Six families with the MEA I-entity were studied. Seven out 
of 23 deceased members of these MEA I-families had suffered from 
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proven hyperparathyroidism. In 5 out of these 7 patients 
pancreatic non-3-islet cell tumours were demonstrated. The 
other 2 patients with hyperparathyroidism had undergone neither 
laparotomy nor autopsy. 
Sixty-four out of 66 living members of these families with an 
age of at least 15 years could be investigated. Twenty-three 
out of these 64 subjects had a history or findings of hyper-
parathyroidism. In 7 out of these 23 patients enlarged parathy-
roid glands had been resected, but 5 had recurrent hyperparathy-
roidism later on. In the 16 non-operated patients the diagnosis 
of hyperparathyroidism was made on the combination of a serum 
calcium concentration of more than 2.65 mmol/1 (normal value 
2.20-2.60 mmol/1) and a serum inorganic phosphate level of less 
than 0.85 mmol/1 (normal value 0.85-1.30 mmol/1) on at least 
2 occasions. The group of patients with MEA I-hyperparathyroidism 
consisted of 12 women and 11 men, in age ranging from 17 to 64 
years with a mean age of 41 years. 
Secretin stimulation tests were performed in all 23 subjects 
with a history or findings of hyperparathyroidism from the 6 MEA 
I-families, in 34 normal subjects, in 23 unaffected members of 
these 6 MEA I-families, in 14 duodenal ulcer patients, in 10 
stomal ulcer patients, in 7 patients with hyperparathyroidism 
without MEA I-evidence, in 6 patients with ZE-syndrome without 
MEA I-evidence and in 11 patients with achlorhydria. 
The diagnosis of duodenal and stomal ulcer was made by barium 
meal or endoscopy. 
In all 7 patients with non-MEA I-hyperparathyroidism the diagnosis 
was confirmed at surgery. 
The diagnosis of ZE-syndrome was in 6 patients without MEA I-
evidence made on the combination of basal gastric acid hyperse-
cretion (basal acid output of more than 10 mmol H /h) and fasting 
hypergastrinemia (more than 150 pg/ml ) . 
Achlorhydria was defined as a gastric pH greater than 6.0 after 
stimulation with pentagastrin in a dose of 6 pg/kg body weight 
i .m. 
After an overnight fast venous blood was drawn twice with 
an interval of 5 minutes before pure natural porcine secretin 
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GIH (Karolinska Institute, Stockholm), in a dose of 1 U/kg, was 
injected intravenously within 30 seconds. At 5, 10 and 15 minutes 
after the secretin injection 3 more blood samples were drawn for 
measurement of serum gastrin levels. 
The calcium stimulation test was performed as proposed in 
literature ( 9 ) ; after an overnight fast 5 mg/kg.h calcium, as 
calcium gluconate, was infused over 3 hours. Blood samples for 
determination of calcium and gastrin were drawn before and 1,2 
and 3 hours after the start of the infusion. 
In the food stimulation test fasting subjects ingested a 
standard test meal within 15 minutes. This meal consisted of 
one slice of bread, 50 g of cheese, one boiled egg and 200 ml 
of milk, corresponding to 30 g of protein, 20 g of fat and 25 g 
of carbohydrate. Blood samples for determination of serum gastrin 
were drawn before and 15, 30, 45, 60, 90, 120 and 150 minutes 
after the start of the meal . 
Secretin, calcium and meal stimulation tests were considered 
positive, if serum gastrin concentration increased at least 50% 
of basal level (chapter 8 ) . This criterion has proved to be of 
value in the differentiation between patients with and without 
gastrinoma by calcium infusion (11; chapter 5 ) . 
Serum calcium levels were measured by atomic absorption 
spectrophotometry and serum gastrin levels by radioimmunoassay 
(12; chapter 4 . 2 ) . Secretin levels up to 10 pg/ml and calcium 
concentrations up to 6.0 mmol/1 did not influence the bound-free 
ratio at zero quantity of unlabelled gastrin in the gastrin assay. 
Serum gastrin levels were 66 + 18 pg/ml (mean + 1 S.D.) in 100 
fasting normal controls. 
6.3 Results 
Fasting serum gastrin levels ranged from 40 to 26100 pg/ml 
in the 23 patients with hyperparathyroidism from 6 MEA I-families. 
All 13 patients with normal fasting serum gastrin levels (less 
than 100 pg/ml) had negative secretin stimulation tests (fig. 
6 . 1 ) . In all 6 patients with marked basal hypergastrinemia of more 
than 250 pg/ml positive secretin stimulation tests were found. 
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i o J 
hyperparathy roid ism 
m MEA 1-families 
(p = 23) 
»10 І 5 чГПІГ J 
fig. 6.1 Basal and s e c r e t i n s t i m u l a t e d s e r u m 
g a s t r i n levels (1 U s e c r e t i n G I H / k g . 
30 sec ¡.v.) in 23 p a t i e n t s w i t h a 
h i s t o r y or f i n d i n g s of h y p e r p a r a t h y -
r o i d i s m from 6 MEA l - f a m i l i e s 
The other 4 patients had only slightly elevated serum gastrin 
levels, ranging from 119 to 250 pg/ml. In this group 3 patients 
showed a positive and one a negative secretin stimulation test 
(fig. 6 . 1 ) . One of the 9 patients with hyperparathyroidism and 
positive secretin stimulation test was normocalcemic after 
parathyroidectomy at the moment of study. 
Some features of patients with positive and negative secretin 
stimulation tests are compared in table 6.1. The 9 patients with 
positive secretin stimulation tests had both basal gastric acid 
hypersecretion and positive calcium stimulation tests (table 6.2), 
Moreover, the postprandial increase in serum gastrin was less 
than 50% of basal level in the 6 patients tested. In the group 
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Table 6.1 SOME FEATURES OF PATIENTS WITH HYPERPARATHYROIDISM, 
FROM 6 MEA I-FAMILIES, AND POSITIVE OR NEGATIVE 
SECRETIN STIMULATION TESTS. 
positive secretin negative secretin 
stimulation test stimulation test 
(n=9) (n=14) 
age (yrs) 47 (37-64)* 37 (17-64)* 
female:ma le 5:4 7:7 
ulcers and diarrhea 3/9 0/14 
ulcers without diarrhea 2/9 0/14 
diarrhea without ulcers 1/9 0/14 
slight gastric pain 0/9 2/14 
heartburn 1/9 2/14 
no gastric complaints 2/9 10/14 
BAO' >10 mmol H /h 8/9 0/4 
positive calcium test 9/9 
negative meal test 6/6 
other endocrinopathies 4/9 1/14 
serum calcium (mmol/1) 2.72 (2.32-2.98)* § 2.71 (2.40-2.93)** 
serum gastrin (pg/ml) 3405 (142-26100)* 64 (40-119)* 
not investigated 
* mean and range 
t basal acid output 
§ in this group one patient with normocalcernia after 
parathyroidectomy 
I patients with slight gastric complaints or heartburn 
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Table 6.2 CHARACTERISTICS OF 9 PATIENTS WITH HVPERPARATHYROIDISM ANO A POSITIVE SECRETIN STIMULATION TEST. 
о 
CD 
sex age serum complaints 
calcium ulcer diarrhea 
B.A.O.' non-g- serum increase in serum gastrin after 
ι si et cel 1 gastrin* secretin calcium meal 
tumour 
m 
f 
f 
m 
f 
39 
64 
38 
61 
37 
2.71 
2.88 
2.32* 
2.67 
2.68 
0 
+ 
+ 
+ 
+ 
normal § § 2.20-2.60 
values 
67.0 
4.3* 
12.5 
35.5 
23.4 
2.3+2.6 
(n-20) 
0 400- 1150 
+ 10800-27100 
other 
endocrine 
di sorders 
m 
f 
f 
m 
(yrs) 
40 
50 
43 
48 
(mmol/1 ) 
2.71 
2.98 
2.75 
2.82 
0 
0 
0 
+ 
0 
0 
0 
0 
(mmol H 
19.2 
15.4 
15.1 
40.3 
'/h) 
_ § 
_§ 
.§ 
+ 
(рд/л 
140-
142-
196-
190-
Ί) 
252 
196 
510 
1490 
(*) 
147 
211 
69 
119 
(%) 
228 
258 
96 
95 
(S) 
44 
43 
47 
-
pi tu ιtary 
tumour 
adrenocortical 
hyperplasía 
pi tu ι ta ry 
tumour 
174 
53 
264 
205 
125 
8 + 15 
(n=34) 
138 
340 
295 
254 
177 
10+18 
(n=15) 
10 
-
42 
-
29 
99 + 51 
(n=12) 
pi tuitary 
tumour 
ιnsulι noma 
+ present 
0 absent or not demonstrated 
not investigated 
* lowest and highest basal value, found in 
periods ranging from i up to 3J years 
+
 after partial gastrectomy 
•
§
 250- 380 
1540- 3280 
•
§
 350- 470 
66 + 18 
(n=100) 
i no laparotomy 
I basal gastric acid output 
f after parathyroidectomy 
** nodular pancreas; no tissue diagnosis 
tt persistent hypergastrinemia after total gastrectomy 
i! mean + 1 S.D. 
of 9 patients with a positive secretin stimulation test 3 had 
ulcers and diarrhea, 2 had ulcers without diarrhea, one had 
diarrhea without ulcers and 3 had neither ulcers nor diarrhea 
(table 6 . 2 ) . Four out of these 9 patients underwent laparotomy 
and in 2 metastatic gastrinoma was detected, in one a nodular 
pancreas without tissue diagnosis and in one no tumours could be 
found, but persistent elevated serum gastrin levels after total 
gastrectomy confirmed the diagnosis. In 4 out of these 9 patients 
coexisting endocrine disorders were demonstrated. 
In the group of 14 patients with hyperparathyroidism and 
negative secretin stimulation tests 2 had complaints of heartburn 
and 2 of minor gastric pain, including the patient with a slightly 
elevated basal gastrin level. The 4 patients with slight complaints, 
however,had both negative barium meal studies and normal basal 
gastric acid output (less than 5 mmol H + / h ) . 
The patients with positive secretin stimulation tests were at 
least 37 years of age, whereas 8 out of 14 patients with a nega-
tive secretin stimulation test were younger than 35 years. 
Serum calcium levels were not different in both groups. 
Positive secretin stimulation tests were not found in 34 
normal subjects, 23 non-affected members of the MEA I-families, 
14 duodenal ulcer patients, 10 patients with stomal ulcer and 7 
patients with hyperparathyroidism without MEA I-evidence (fig. 
ß . 2 ) . 
All 11 patients with fasting hypergastrinemia due to achlor-
hydria showed a decrease in serum gastrin level after secretin 
administration (fig. 6 . 3 ) . 
Four out of 6 patients with ZE-syndrome without MEA I-evidence 
showed a positive secretin stimulation test, whereas the other 2 
patients with histologically proven gastrinoma had only a minor 
increase in serum gastrin (fig. 6 . 4 ) . 
The peak in serum gastrin was always found approximately 5 
minutes after secretin injection, as is shown in fig. 6.1, 6.4 
and 6.5. 
One clinical unit of pure natural porcine secretin (secretin 
6IH, Karolinska Institue, Stockholm) was much more potent in 
increasing serum gastrin levels than 1 Crick-Harper-Raper Unit 
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80 
60 
¿о 
20 
r i n Í DC/m' ) • 
secret η ЗІН 
I J ng ιν 
non-affected m e m b e r s of 
MEA I - famil ies 
- 5 * ISimin) 
gastrin (pg/ml ) • 
100 
4 0 
secrete GIH 
l U / k g iv 
duodenal ulcer 
(n - 14) 
g a s t r i n { pg/ml ) -
0 
secretin GIH 
1U 'kg iv 
g a s t r i n ( og/ml ) 
4 0 
20 
secretin GIH 
'u/kg iv 
stomal ulcer 
i n - 1 0 ) 
hyperparathyroidism without 
MEAI-evidence ( n - 7 ) 
.10 
Ί 
•15 (min) 
f i g . 6.2 Ser u m g a s t r i n l e v e l s b e f o r e and a f t e r sec r e t . η admι η ιs-
t r a t i o n (1 U s e c r e t i n G I H / k g . 3 0 sec ¡.v.) in З1» normal 
c o n t r o l s , 23 n o n - a f f e c t e d m e m b e r s of MEA I - f a m i l i e s , 
U d u o d e n a l u l c e r p a t i e n t s , 10 stomal ulcer p a t i e n t s 
and 7 p a t i e n t s w i t h h y p e r p a r a t h y r o i d i s m w i t h o u t MEA I-
e v i d e n c e . V e r t i c a l bars i n d i c a t e m e a n + 1 S.E.M. 
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of partially purified secretin (Boots Pure Drug Company Ltd., 
Nottingham), as presented in fig. 6.6. 
gastrin ( pg/ml ) 
10000- a c h l o r h y d n a 
(n = 11) 
1000-
1 0 0 , 
• 5 'Ю •15 ( m m ) 
f i g . 6.3 Serum g a s t r i n levels b e f o r e and a f t e r 
s e c r e t i n i n j e c t i o n (1 U s e c r e t i n G IH/ 
kg. 3 0 sec i.v.) in 11 p a t i e n t s w i t h 
a c h l o r h y d r i a 
Intraduodenal administration of hydrochloric acid in a 
patient with hyperparathyroidism and ZE-syndrome was followed 
by an increase in serum gastrin, which was similar to the gastrin 
response to secretin infusion in the same patient (fig. 6 . 7 ) . 
No adverse reactions to secretin were observed in the pa­
tients studied. 
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gastr in ( Dg/m I ) 
100 OOO 
1 0 0 0 0 
1000 
100 
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• 10 •15 ( m m ) 
f i g . 6.'t F a s t i n g and s e c r e t i n s t i m u l a t e d s e r u m 
g a s t r i n l e v e l s (1 U s e c r e t i n G I H / k g . 
30 sec i.v.) in 6 p a t i e n t s w i t h the 
Z o l l i n g e r - E l l i s o n s y n d r o m e w i t h o u t 
MEA I -ev i d e n c e 
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gastrin (pg/ml) 
8000 
60OO 
4000-
2000-
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fig. 6.5 Serial serum g a s t r i n levels b e f o r e and 
a f t e r s e c r e t i n i n j e c t i o n (l U s e c r e t i n 
G I H / k g . 3 0 sec i.v.) in a p a t i e n t w i t h 
the Zo1 1 i n g e r - E 1 1 i son s y n d r o m e 
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fig. 6.6 Serum gastrin levels after injection of various 
amounts of secretin Boots and secretin GIH in a 
patient with the Zo1 1 inger- E 1 1 i son syndrome 
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fig. 6.7 The effect of ! ηtraduodena1 instillation of 
hydrochloric acid and infusion of secretin 
GIH (3 U/kg.h) on serum gastrin in a patient 
with Zo1 1 inger-E 1 1 i son syndrome and hyperpara­
thyroidism. Note the initial fall in serum 
gastrin during aspiration of gastric juice 
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6.4 Discussion 
Both in this study and in the literature (1,2,3) hyperpara-
thyroidism is the most frequent endocrine disorder in the MEA 
I-entity. In most of the patients from this series hypercalcemia 
was mild, as has been found in patients with hyperparathyroidism 
from MEA I-families by Marx et al ( 1 3 ) . In the absence of ZE-
syndrome or achlorhydria patients with hyperparathyroidism have 
normal fasting serum gastrin levels (11,13; chapter 5 ) . With 
increasing age hyperparathyroidism may become accompanied by 
other endocrine abnormalities in members of MEA I-families ( 1 ) . 
In this study the patients with hyperparathyroidism and positive 
secretin stimulation testswere older and had more often other 
endocrinopathies, such as pituitary tumour, insulinoma or adre-
nocortical hyperplasia, than patients with hyperparathyroidism 
and negative secretin provocation tests(table 6 . 1 ) . 
Because every patient with hyperparathyroidism from MEA I-
families may develop ZE-syndrome in the future, secretin stimula-
ted serum gastrin levels were measured to reveal both asymptoma-
tic and symptomatic ZE-syndrome. 
The secretin stimulation test has been advocated in cases with 
equivocal ZE-syndrome ( 7 ) . Positive secretin stimulation tests 
were found in 9 out of 23 patients with hyperparathyroidism from 
these families. Basal serum gastrin levels were markedly elevated 
in 6, but only slightly increased in 3 of them. Although only 6 
of these patients had peptic ulcer disease or diarrhea and gas-
trinoma was histologically proven in only 2 cases, the combination 
of basal gastric acid hypersecretion ( 8 ) , positive calcium stimu-
lation test (9,11) and negative meal stimulation test (10,14) 
provided the diagnosis of ZE-syndrome. 
A positive secretin stimulation test was also found in a patient 
with normocalcernia after parathyroidectomy. From this result and 
the absence of hypercalcemia in the ZE-patients without MEA I-
evidence it can be concluded that elevated serum calcium levels 
are not necessary for an increase in serum gastrin after secretin 
i njecti on. 
If the 7 deceased patients with hyperparathyroidism are in-
cluded, 14 out of 30 patients (47%) with hyperparathyroidism from 
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the 6 MEA I-families in this study had ZE-syndrome. Snyder et 
al (15) found hypergastrinemia in 12 out of 18 patients with a 
history or findings of hyperparathyroidism from 5 MEA I-families. 
However, lacking gastric acid measurements, stimulation tests or 
tissue diagnosis in 5 patients with slight hypergastrinemia, 
the diagnosis of ZE-syndrome seems to be uncertain in 5 of these 
12 patients. 
It may be assumed that the 14 patients with hyperparathyroi-
dism and negative secretin stimulation tests from this study 
do not harbour gastrin producing tumours. It is valuable to 
repeat secretin testing in these patients at regular intervals 
in the future to reveal the development of gastrinoma with in-
creasing age. Two patients , aged 63 and 64 years, have 
isolated hyperparathyroidism and it is still questionable whether 
other endocrinopathies will ever develop in them. 
The secretin stimulation test is all the more valuable, since 
no false positive results were obtained in normal subjects, non-
affected members of MEA I-families, duodenal and stomal ulcer 
patients, patients with non-MEA I-hyperparathyroidism and patients 
with achlorhydria. 
The secretin test was false negative in 2 patients with 
histologically proven ZE-syndrome without MEA I-evidence. Diffe-
rentiation from hypergastrinemia of antral origin however is 
possible, because a slight increase in serum gastrin after secre-
tin administration was observed in these 2 patients, whereas a 
decrease in gastrin levels is usually found in patients with 
hypergastrinemia of antral origin, e.g. in achlorhydria (16; fig. 
6 . 3 ) , non-tumorous hypergastrinemic hyperchlorhydria (14), ex-
cluded gastric antrum (17) and postprandial normal subjects and 
duodenal ulcer patients ( 7 ) . False negative secretin stimulation 
tests in ZE-patients were also found by other groups (6,16,18-21). 
The negative secretin stimulation test in ZE-patients may be 
partly understood when the less potent Boots secretin was used 
or the first post-secretin blood sample was drawn after the 
gastrin peak (fig. 6 . 5 ) . Different hypotheses have been put 
forward to elucidate the cause of negative secretin stimulation 
tests in some ZE-patients. Creutzfeldt et al (21) supposedthat 
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the negative secretin stimulation test in one of their 9 ZE-
patients was the result of coexisting hyperglucagonism. According 
to Walsh and Grossman (5) a weak gastrin response to secretin may 
especially be found in ZE-patients with large metastatic tumours 
with relatively low gastrin content. The 2 ZE-patients with nega-
tive secretin tests in our study had metastatic gastrinoma. 
Bonfils et al (20) found positive secretin tests in all 4 ZE-
patients without previous gastric surgery, but only in one out 
of 3 ZE-patients with total gastrectomy. The possibility that 
total gastrectomy abolishes the gastrin response to secretin is 
unlikely, because in another study (19) no difference in secretin 
stimulated serum gastrin levels was found in ZE-patients before 
and after total gastrectomy. 
The exact reason for the negative secretin test in some ZE-pa-
tients .however ,i s up to now obscure. It is of considerable inte-
rest to test these patients with higher doses of secretin, because 
the gastrin response to secretin is dose-related (6,22; fig. 6 . 6 ) . 
Whether negative secretin stimulation tests are only present in 
ZE-patients without MEA I-evidence, as suggested in this study, 
has to be studied more extensively. 
Release of endogenous secretin was provoked by intraduodenal 
administration of hydrochloric acid in a patient with ZE-syndrome 
and hyperparathyroidism ( 2 3 ) . The increase in serum gastrin during 
instillation of acid into theduodenum was similar to the rise in 
serum gastrin during secretin infusion (fig. 6 . 7 ) . From these 
data it may be concluded that a substance released from duodenum 
by acidification, probably endogenous secretin, is able to increase 
serum gastrin levels in ZE-patients. The decrease in serum gastrin 
during gastric aspiration (24; fig. 6.7) may be caused by a depres-
sed secretin release from the duodenal mucosa, resulting from a 
reduced acid influx into the duodenum. 
The secretin stimulation test is indicated in patients with 
hyperparathyroidism from MEA I-families for the following reasons: 
1. to diagnose early ZE-syndrome in subjects with slight hypergas-
tri nemia ; 
2. to differentiate ZE-syndrome with tumorous gastrin form hyper-
gastrinemia of antral origin in patients with marked hypergastrin-
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ernia ; 
3. to study the development and early manifestations of ZE-syndrome 
in subjects with still normal fasting serum gastrin levels. 
The secretin stimulation test is easy, fast and without com-
plications. It is helpful in selecting patients for more 
extensive investigations, such as gastric acid aspiration, calcium 
and meal stimulation tests. 
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Chapter 7 
FASTING AND POSTPRANDIAL SERUM GASTRIN LEVELS IN SUBJECTS WITH 
AND WITHOUT PREVIOUS GASTRIC SURGERY. 
7.1 Introduction 
Ingestion of food is a physiological stimulus to gastrin 
release from antral and duodenal mucosa ( 1 , 2 ) . Cephalic, chemical, 
mechanical and neutralizing factors are probably involved 
in the postprandial increase in serum gastrin ( 3 ) . Gastrin is 
known to play a crucial role in the regulation of gastric acid 
secretion in man. 
For this reason the gastrin release after ingestion of a 
standard test meal was measured in normal subjects and in non-
operated patients with duodenal ulcer, achlorhydria and Zollinger-
Ellison (ZE) syndrome. Moreover, patients with antrectomy and 
gastroduodenostomy (Billroth I ) , antrectomy and gastrojejunostomy 
(Billroth I I ) , total gastrectomy and one patient with ZE-syndrome 
and total gastrectomy were studied. 
The aim of this study is to investigate the effect of a phy-
siological stimulus to gastrin release in normal subjects, in 
non-operated patients with various diseases and in patients with 
partial or total gastrectomy. 
7.2 Patients and methods 
The following subjects were studied: 8 male and 4 female 
normals, mean age 34 years; 12 male and 4 female duodenal ulcer 
patients, mean age 41 years; one male and 8 female patients with 
achlorhydria, mean age 61 years; 4 male and 5 female patients 
with ZE-syndrome without previous gastric surgery, mean age 38 
years; 8 male patients and one female with Billroth I antrectomy, 
mean age 41 years; 7 male patients with Billroth II antrectomy, 
mean age 43 years; 7 male patients with total gastrectomy without 
gastrinoma, mean age 58 years and 1 male patient with ZE-syndrome 
and total gastrectomy, age 61 years. 
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The diagnosis of duodenal ulcer was made by barium meal or 
endoscopy within 2 weeks before the study. Achlorhydria was defi­
ned as a gastric pH of more than 6.0 after stimulation with pen-
tagastrin in a dose of 6 ug/kg i.m. The ZE-syndrome was diagnosed 
on the combination of a. hypergastrinemia of more than 150 pg/ml 
(normal value 66 + 18 pg/ml, mean +1SD, n=100), b. basal gastric 
acid hypersecretion of at least 10.0 mmol H /h (normal value 2.3 
+ 2.6 mmol H /h, mean +1SD, n=20), с. an increase in serum gastrin 
of more than 50% of basal value after administration of 1 U/kg. 
30 sec secretin GIH intravenously (4; chapters 6 and 8) and d. a 
rise in serum gastrin of at least SO?' of basal value after infusion 
of 15 mg calcium/kg over 3 hours (5; chapter 5 ) . In all patients 
with previous gastric surgery the gastric remnant and the stoma 
were investigated by barium meal or endoscopy to exclude large 
gastric remnants and narrow anastomoses. The reasonfor antrectomy 
was peptic ulcer disease in all patients. Total gastrectomy was 
performed because of normogastrinemic peptic ulcer disease, 
gastric malignancy and hypertrophic exudative gastropathy. One 
patient had total gastrectomy because of ZE-syndrome. 
After an overnight fast the subjects ingested a standard test 
meal within 15 minutes. This meal consisted of one slice of bread, 
50 g of cheese, one boiled egg and 200 ml of milk, corresponding 
to 30 g of protein, 20 g of fat and 25 g of carbohydrate. Before 
and 15, 30, 45, 60, 90, 120 and 150 minutes after the start of the 
meal blood was drawn for measurement of gastrin. The reasons for 
the above-mentioned composition of the meal were: 1. moderate 
volume, which was also acceptable to patients with partial or 
total gastrectomy, 2. the kind of meal is not unusual as breakfast 
in this country and 3. high protein content, which is a strong 
stimulus to gastrin release (6). 
Serum gastrin levels were measured by radioimmunoassay using a 
rabbit antibody (7,8; chapter 4.2). The antibody, raised against 
synthetic human gastrin I 2 through 17 conjugated to bovine albumin, 
has an almost equimolar potency to bind gastrin components II and 
III (9). Serum gastrin levels in 100 normal controls were 66 + 18 
pg/ml (mean + 1 SD, n=100). 
The significance of differences between means of different 
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groups was analysed using Student's t-test for unpaired results. 
Comparing the results of the same group Student's t-test for 
paired data was used for normogastrinemic patients and Wilcoxon's 
signed rank test for the patients with basal hypergastrinemia. 
Integrated gastrin response to feeding was calculated from the 
summation of the products of the mean serum gastrin concentration 
during each time period times the number of minutes in that time 
period minus the product of the basal gastrin value times the 
total number of minutes after the start of the meal. The results 
of the integrated gastrin response to the standard test meal were 
analysed by Wilcoxon's two-sample test. A p-value of less than 
0.05 was considered significant. 
7.3 Results 
7.3.1 ba¿a^ s^rum £a¿tMji J_e^.els 
No difference in fasting serum gastrin levels was found 
between normal subjects and patients with duodenal ulcer, Billroth 
I and Billroth II antrectomy and total gastrectomy (table 7.1, fig. 
7.1). The mean basal serum gastrin level in patients with Billroth 
II antrectomy however was significantly lower than in duodenal 
ulcer patients, whereas no difference was found between the means 
of patients with Billroth I antrectomy and duodenal ulcer. Fasting 
serum gastrin levels in all patients with achlorhydria and ZE-
syndrome were higher than in the other groups studied (table 7.1, 
fig. 7.2). No significant difference was observed between basal 
serum gastrin levels in patients with achlorhydria and those with 
ZE-syndrome. 
7.3.2 me£l_sjn'mul_atec[ ¿erum ga^triji l_e^ el_s 
A: subjects without previous gastric surgery 
In all 12 normal subjects ingestion of food was followed by 
an increase in serum gastrin (table 7.1, fig. 7.1). The postpran-
dial serum gastrin level at 150 minutes was still significantly 
higher than basal value. 
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Table 7.1 SERUM GASTRIN LEVELS IN 7 GROUPS OF SUBJECTS, WITH AND WITHOUT PREVIOUS GASTRIC SURGERY, MEASURED 
BEFORE AND AT INTERVALS AFTER THE INGESTION OF A STANDARD TEST MEAL. 
norma 1 
subjects (n=12) 
serum gastrin pg/ml' 
45 60 0 15 30 90 120 150 m m 
52 + 12 77 + 18 89 + 25 92 + 29 97 + 33 96 + 34 91 + 34 81 + 36 
duodenal 
ulcer (n=16) 
59 + 11 104 + 37 123 + 30 129 + 25 130 + 28 122 + 26 117 + 36 108 + 36 
ZE-syndrome 1033 1063 1166 1248 1293 1271 1476 1436 
(n=9) (170-5800) (202-5900) (232-6200) (224-6900) (214-7200) (224-7000) (220-8600) (244-8200) 
l-· 
Ю 
σι 
a c h í o r h y d r i a 
(n = 9) 
8 6 3 1275 1 2 9 2 1294 1250 1289 1344 1438 
( 1 3 8 - 3 3 2 0 ) ( 1 9 3 - 4 3 0 0 ) ( 2 1 5 - 3 9 9 0 ) ( 2 1 0 - 3 8 4 0 ) ( 2 3 0 - 3 5 3 0 ) ( 2 9 0 - 3 5 7 0 ) ( 3 1 5 - 3 5 7 0 ) ( 3 1 1 - 4 0 9 0 ) 
B I - a n t r e c t o m y 
(n = 9) 
54 + 1 4 67 + 14 77 + 1 9 78 + 18 86 + 2 3 84 + 18 83 + 2 6 72 + 21 
B I I - a n t r e c t o n y 4 8 + 7 4 8 + 9 4 9 + 9 5 0 + 8 4 9 + 4 4 7 + 8 5 1 + 1 1 4 8 + 1 1 
(n = 7) - _ _ - - - - -
total 
gastrectomy (n=7) 
55 + 1 4 59 + 11 61 + 1 2 62 + 12 59 + 1 3 58 + 12 54 + 1 3 54 + 12 
* mean + 1 S.D. 
mean and range 
gastrin (pg/ml) 
150 
100 
120 150 
time (mm) 
fig. 7.1 F a s t i n g and p o s t p r a n d i a l serum g a s t r i n 
levels in 12 normal s u b j e c t s (· · ) , 16 
du o d e n a l u l c e r p a t i e n t s (x *) , 9 p a t i e n t s 
w i t h B i l l r o t h I a n t r e c t o m y (Δ Δ ) , 7 pa­
tie n t s w i t h B i l l r o t h II a n t r e c t o m y (· ·) 
and 7 p a t i e n t s w i t h total g a s t r e c t o m y (x- x) 
V a l u e s that are s i g n i f i c a n t l y d i f f e r e n t 
(p < 0 . 0 5 ) from the levels in normal s u b ­
j e c t s a r e d e n o t e d by a s t e r i s k s 
Meal stimulated serum gastrin levels in 16 patients with 
duodenal ulcer were significantly higher than the levels in 
normal controls at 15, 30, 45, 60 and 90 minutes after feeding 
(table 7.1, fig. 7 . 1 ) . At 150 minutes serum gastrin level had 
not returned to basal value. 
Ingestion of food was followed by an early, steep and long­
standing increase in serum gastrin in the 9 patients with achlor-
hydria (table 7.1, fig. 7 . 2 ) . All postprandial levels were sig­
nificantly higher than basal value in these patients. At 150 
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minutes no tendency of decline in serum gastrin was observed. 
gastrin(pg/ml ) • 
test meal 
1500 
1250 
1000-
7 5 0 
3 0 6 0 9 0 120 ISO 
time (mm) 
fig. 7.2 Fasting and postprandial serum gastrin 
levels in 9 patients with a c h l o r h y d r i a (·—·) 
and 9 patients with Zo1 1 i η ge г - E 1 1 i son 
syndrome without previous gastric surgery 
(x----x) . A s t e r i s k s indicate values that are 
s i g n i f i c a n t l y higher ( p < 0 . 0 5 ) than basal 
levels 
The 9 ZE-patients had a gradual and long-standing increase 
in serum gastrin after ingestion of food (table 7.1, fig. 7 . 2 ) . 
Postprandial levels at 90, 120 and 150 minutes were significantly 
higher than basal value. No clear fall in serum gastrin was found 
in the non-operated patients with Zol1 inger-Ellison syndrome at 
the end of the test. 
B: patients with previous gastric surgery. 
In patients with Billroth I antrectomy ingestion of food was 
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followed by a marked increase in serum gastrin (table 7.1, fig. 
7 . 1 ) . No significant difference was observed between the post-
prandial serum gastrin levels in patients with Billroth I antrec-
tomy and normal controls. Meal stimulated serum gastrin levels in 
patients with Billroth I antrectomy however were significantly 
lower than the values in duodenal ulcer patients. 
Patients with Billroth II antrectomy did not show a significant 
rise in serum gastrin after ingestion of the test meal (table 7.1, 
fig. 7 . 1 ) . All postprandial gastrin levels were lower than those 
found in normal controls, in duodenal ulcer patients and in patients 
with Billroth I antrectomy. 
Patients with total gastrectomy showed a slight but significant 
increase in serum gastrin at 30 and 45 minutes after the start of 
the meal (table 7.1, fig. 7 . 1 ) . The postprandial levels at 15, 30, 
45, 60, 90 and 120 minutes were significantly lower than in normal 
control s. 
A pronounced postprandial increase in serum gastrin, peaking 
at 30 minutes, was observed in the patient with ZE-syndrome and 
total gastrectomy (fig. 7 . 3 ) . 
7.3.3 j_nte£ra^£d_ga^tH_n_res£Ojis£ І0_^£еа''І19_ 
The integrated gastrin response to feeding was in patients 
with duodenal ulcer, achlorhydria and ZE-syndrome significantly 
greater and in patients with Billroth II antrectomy and total 
gastrectomy smaller than in normal subjects (fig. 7 . 4 ) . Patients 
with Billroth II antrectomy had a smaller response to the meal 
than patients with duodenal ulcer and Billroth I antrectomy. The 
integrated gastrin response to feeding in patients with Billroth 
I antrectomy however was significantly less than in duodenal 
ulcer patients. 
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gastrin (pg/ml)— 
Lest meal 
8000 
6000 
4O0O-
20OO-
30 60 90 120 150 
time (mm) 
f i g . 7.3 F a s t i n g and p o s t p r a n d i a l s e r u m 
g a s t r i n l e v e l s in a p a t i e n t 
w i t h Zo1 1 inger - E 1 1 i son s y n d r o m e 
and total g a s t r e c t o m y 
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integrated gastrin response 
(ng /ml χ 150mm) 
Θ0-
70-
60-
50-
40-
30-
20-
10-
-H*-
normal duodenal billroth I biDrothlI total achlor. Ζ E 
subjects ulcer antrec- antrec- gastrec- h y d n a syndrome 
tomy tomy tomy 
η · 12 n - 1 6 n-9 n>7 η · 7 n > 9 n>9 
f!g. 7.'* Integrated g a s t r i n r e s p o n s e to ingestion 
of a s t a n d a r d test meal (mean +_ 1 S. E . M . ) 
in normal s u b j e c t s and p a t i e n t s with 
d u o d e n a l u l c e r , B i l l r o t h I and B i l l r o t h II 
a n t r e c t o m y , total g a s t r e c t o m y , a c h l o r h y d r i a 
and Zo1 1 inger-E 11 i son s y n d r o m e 
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7 .4 Di scussion 
Gastrin containing cells (G-cells) have been demonstrated in 
the mucosa of antrum and proximal duodenum (3). These cells can 
be identified by immunohistochemical methods (10) or by electron 
microscopy (11). Ingestion of food is a physiological stimulus 
to gastrin release from antral and duodenal mucosa (2). In the 
present study serum gastrin levels were measured before and after 
a standard test meal in normal subjects, in patients with various 
diseases without previous gastric surgery and in patients with 
partial or total gastrectomy. 
7.4.1 f.a¿tj^n£ ¿ej^um £a¿triji 2_ev^ el_s 
It is now Generally accepted that mean basal serum gastrin 
levels do not differ significantly in patients with duodenal 
ulcer and normal subjects (18).This finding is confirmed in the 
present study. As gastric secretion on the average is increased 
in duodenal ulcer patients lower serum gastrin levels would have 
been expected because of the acid feedback mechanism by which 
low antral pH inhibits gastrin release. The absence of decreased 
serum gastrin levels has been interpreted as a defect in acid 
feedback inhibition of gastrin release (12). During hourly serum 
gastrin measurements over ?.& hours Feurle et al (13) reported 
significantly higher serum gastrin concentrations during the late 
night in patients with duodenal ulcer than in normal controls. 
Moreover, Stadil et al (14) found relatively higher serum concen-
trations of gastrin-17 (little gastrin, component III gastrin) in 
duodenal ulcer patients. In equimolar concentration gastrin-17 is 
found to be more potent than gastrin -34 (big gastrin, component 
II gastrin) in stimulating gastric acid secretion (15). 
Basal serum gastrin levels in patients with Billroth II antrec-
tomy were significantly lower than in duodenal ulcer patients, 
whereas patients with Billroth I antrectomy had serum gastrin 
values that were not significantly different from the levels in 
duodenal ulcer patients. These results are in agreement with the 
data of Stern and Walsh (16), but these authors studied patients 
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with antrectomy in combination with vagotomy. The reason for the 
difference between the effects of both types of antrectomy on 
serum gastrin is not clear. The lack of decreased fasting serum 
gastrin levels in patients with Billroth I antrectomy may be 
either a result of incomplete antrectomy or caused by the fact 
that the duodenum is still connected to the gastric remnant. 
Moreover, the results in this study .obtained in patients with 
partial gastrectomy without vagotomy, have to be confirmed in 
studies of larger groups of patients. 
Patients with total gastrectomy had a basal serum gastrin 
level that was not significantly different from duodenal ulcer 
patients and normal subjects. This may be explained by the fact 
that total gastrectomy always entails vagotomy. Vagotomy is known 
to increase serum gastrin levels not only from gastric but also 
from extra-gastric origins (17). Studies of larger groups of 
patients with total gastrectomy however are needed. 
The elevated serum gastrin level in the patients with 
Zol1inger-El1 i son syndrome is a result of gastrin producing 
tumours, usually originating in the pancreas (18). 
The chronic lack of acid feedback in achlorhydric patients 
results in antral G-cell hyperplasia with increased serum gastrin 
levels (7,19-21). 
7.4.2 f0£d_st^muJ_a^ec[ ¿erum £a^trij! lev.e]_s_ 
Both normal subjects and duodenal ulcer patients showed a 
marked increase in serum gastrin after ingestion of the test 
eal. However, the gastrin response to food was more pronounced 
in patients with duodenal ulcer than in normal subjects. This 
difference in rate of postprandial gastrin release has also 
been found by others (14,22). By extraction and immunohistochemical 
studies of antral and duodenal mucosa both normal and higher 
tissue gastrin contents have been demonstrated in duodenal ulcer 
patients (19,21,23). Recently Stadil et al (14) demonstrated 
that not only in the fasting state but also after feeding the 
biologically more potent gastrin-17 component was released in 
relatively larger amounts in patients with duodenal ulcer than 
m 
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in normals. Moreover, results of Walsh et al (24) suggest a 
defect in the autoregulation of postprandial gastrin release 
and gastric acid secretion at low pH in duodenal ulcer patients. 
These authors found that the ingestion of a test meal at constant 
intragastric pH of 2.5 was followed by a significantly greater 
increase in serum gastrin and in gastric acid in these patients 
than in normal controls. 
Although the exact part of gastrin in the pathogenesis of acid 
hypersecretion in duodenal ulcer disease is still uncertain accum­
ulated data indicate that this role may be of considerable value. 
Moreover, the usually increased parietal cell mass in these 
patients (25) was found to be more sensitive to administration of 
pentagastri η ( 2 6 ) . 
The food stimulated gastrin release in patients with Billroth 
I antrectomy is not significantly different from normal subjects. 
However, patients with Billroth I antrectomy had significantly 
lower postprandial serum gastrin levels than patients with 
duodenal ulcer disease. Gastrin, released into the blood after 
the standard test meal in these patients, is probably of duodenal 
origin ( 1 6 ) . How far incomplete antrectomy may also be implicated 
in the food stimulated gastrin release in these patients is hard 
to determine, but the gastric remnants in the present study and 
in that of Stern and Walsh (16) were not large, as assessed by 
radiological or endoscopic examination. Stern and Walsh (16) 
suggest that the postprandial release of duodenal gastrin in 
patients with antrectomy and gastroduodenostomy (Billroth I) may 
account for the higher incidence of recurrent ulceration in these 
patients than in those with antrectomy and gastrojejunostomy 
(Billroth I I ) . 
In patients with total gastrectomy ingestion of food was 
followed by a slight, but significant increase in serum gastrin 
at 30 and 45 minutes after the start of the meal. Because total 
gastrectomy is always combined with vagotomy this rise in serum 
gastrin probably reflects post-vagotomy release of gastrin of 
extragastric origin ( 1 7 ) . However, all postprandial serum gastrin 
levels, except at 150 minutes after the start of the meal, were 
significantly lower than the levels in normal subjects. 
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In patients with hypergastrinemia because of achlorhydria 
an early, steep and long-standing increase in serum gastrin was 
found. These results are in agreement with those of Korman et 
al (20). Antral G-cell hyperplasia has been found by immunohis-
tochemical studies in achlorhydric patients (19,21). No fall 
in serum gastrin level was found in the present study up to 150 
minutes after the meal. This may be explained by insufficient 
secretin release from the duodenal mucosa. It has been suggested 
by Rayford et al (27) that small amounts of secretin are released 
after the ingestion of food. However, at pH levels of more than 
4.5, as in achlorhydric patients, secretin is not released in 
amounts sufficient for physiological action (28). As secretin 
is known to decrease serum gastrin levels both in achlorhydric 
patients (4,29) and in subjects after feeding (30), the lack of 
sufficient secretin release may be responsible for the absence 
of a fall in serum gastrin level in these patients during the 
time of study. In patients with hypergastrinemia of antral 
origin and high gastric acid secretion on the other hand serum 
gastrin levels are reported to decrease within one to 2 hours 
after the meal (31,32; chapter 4 . 2 ) . This fall in serum gastrin 
may be a result of postprandial secretin release in the presence 
of a low duodenal pH. 
In patients with ZE-syndrome a gradual and long-standing 
increase in serum gastrin after ingestion of the test meal was 
observed. Only late postprandial serum gastrin levels at 90, 
120 and 150 minutes after the meal were significantly greater 
than basal value. The reason for this late increase in serum 
gastrin is probably postprandial secretin release from duodenal 
and jejunal mucosa. In contrast to patients with hypergastrinemia 
of antral origin secretin is known to raise serum gastrin levels 
in patients with gastrin producing tumours (4,30,32-35; chapters 
6 and 8 ) . Postprandial serum gastrin levels in ZE-patients are 
difficult to compare with results in the literature, since in 
most studies of relatively larger groups of ZE-patients cases 
with previous gastric surgery have been included (33,35). 
The patient with Zol1inger-El1ison syndrome and total gas-
trectomy showed a marked and early rise in serum gastrin. This 
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result is in agreement with data of Thompson et al (3 0 , 3 5 ) , 
who suggest that release of intestinal secretin may be responsible 
for the pronounced increase in serum gastrin. However, no post-
prandial plasma secretin levels have been reported in these pa-
tients up to now. Other mechanisms therefore cannot be excluded. 
The results of the integrated gastrin response to feeding 
in patients with duodenal ulcer and achlorhydria indicate an 
increased antral or duodenal reactivity to food. This hyper-
responsiveness may be due to either an increased G-cell mass 
or an elevated mucosal gastrin content or an increased sensitivity 
to the test meal or a combination of factors. So far as achlorhy-
dria is concerned the number of G-cells and the antral gastrin 
content seem to be increased ( 1 9 ) . In duodenal ulcer patients, 
however,the results of determination of antral gastrin content 
are reported to vary (19,21,23). 
The integrated postprandial gastrin output in non-operated 
ZE-patients was significantly higher than in normal subjects. 
The reason for this increased postprandial gastrin output may 
be antral or duodenal hyperresponsiveness to food or a direct 
or humoral interaction of the meal with the gastrin producing 
tumour. Creutzfeldt et al (33) found that the antral gastrin 
content of 5 ZE-patients was not increased in comparison with 
normal. In one ZE-patient in that study (33) a marked postprandial 
rise in serum gastrin was accompanied by a gastrinoma originating 
in the duodenum. A direct interaction between food entering the 
duodenum and the duodenal wall tumour cannot be excluded in that 
patient. However, a humoral factor, released from the proximal 
small intestine in reaction to food, is most likely responsible 
for the postprandial increase in gastrin in ZE-patients. This 
humoral substance may be secretin, since this hormone raises 
serum gastrin levels in ZE-patients (4,30,32-35). The late post-
prandial increase in gastrin in non-operated patients and the 
early rise in Zoll inger-El1ison patients with total gastrectomy 
(fig. 7.3; 35) are in accordance with this hypothesis. 
In patients with Billroth I antrectomy gastrin release from 
duodenal mucosa seems to be responsible for the gastrin output, 
that was not significantly different from the response in normal 
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subjects. Antrectomy is followed by a significantly lower inte-
grated gastrin output in patients with Billroth II antrectomy 
and total gastrectomy, probably because food products bypass the 
duodenum in these patients. 
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Chapter 8 
A COMPARATIVE STUDY OF THE VALUE OF THE CALCIUM, SECRETIN AND 
MEAL STIMULATED INCREASE IN SERUM GASTRIN TO THE DIAGNOSIS OF 
THE ZOLLINGER-ELLISON SYNDROME. 
8.1 Introduction 
The preoperative diagnosis of Zol1inger-El1 i son (ZE) syndrome 
is based on the combination of basal gastric acid hypersecretion 
and hypergastrinemia ( 1 ) . The criteria applied to acid secretion 
in the ZE-syndrome, however, give both false positive and false 
negative results ( 2 , 3 , 4 ) . The serum gastrin level, measured by 
radioimmunoassay, is a valuable tool for the diagnosis of ZE-
syndrome (1, 5 , 6 ) . In some ZE-patients.however, the serum gastrin 
level may at times be only slightly elevated and an overlap with 
non-ZE-patients may be present (1, 5 , 6 ) . On the other hand hyper-
gastrinemia in the absence of achlorhydria or gastrinoma has been 
found in patients with excluded gastric antrum ( 7 ) , antral G-cell 
hyperplasia (8,9; chapter 4 . 2 ) , non-tumorous hypergastrinemic 
hyperchlorhydria ( 1 0 ) , chronic renal failure ( 1 1 ) , postvagotomy 
( 1 2 ) , pyloric obstruction (13) and postprandial conditions (14). 
Stimulation tests have been advocated in patients suspected of 
ZE-syndrome with fasting serum gastrin levels of less than 
1000 pg/ml (1) or less than 10 times the normal median ( 6 ) . The 
aim of stimulation tests is to differentiate tumorous from antral 
gastrin in patients with slight or moderate hypergastrinemia. 
Different provocation tests have been proposed, such as intra-
venous administration of calcium ( 1 5 ) , secretin (16,17) and 
glucagon (18,19) and ingestion of a protein rich meal ( 1 4 ) . The 
value of these tests has been studied in small series (14-22) 
and recently in relatively larger groups of ZE-patients (23,24). 
However, comparison of the value of different stimulation tests 
in the same patient has not been recorded previously. 
In this study the significance of calcium and secretin sti-
mulation tests was determined in 15 patients with the ZE-syndrome. 
Moreover, the increase in serum gastrin after stimulation with 
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calcium was compared with the rise in gastrin after administra-
tion of secretin in the same patient. The effect of ingestion of 
a standard test meal on serum gastrin was studied in 9 ZE-patients 
without previous gastric surgery. The incidence of false test 
results in patients without gastrinoma was evaluated by studying 
these tests in normal subjects, duodenal ulcer patients, patients 
with antrectomy and gastroduodenostomy (Billroth I) or gastro-
jejunostomy (Billroth I I ) , total gastrectomy and achlorhydria. 
8.2 Patients and methods 
The characteristics of 15 patients with the ZE-syndrome are 
summarized in table 8.1. 
The diagnosis of duodenal ulcer and stomal ulcer was made by 
barium meal or endoscopy. 
The definition of achlorhydria was a gastric pH of more than 
6.0 after stimulation with pentagastrin in a dose of 6 yg/kg i.m. 
The calcium stimulation test was performed as described by 
Passaro et al ( 1 5 ) . After an overnight fast 5 mg/kg.h calcium, 
as calcium gluconate, was infused over 3 hours. The serum gastrin 
levels before and at the end of the calcium infusion were used 
for calculation. 
After drawing two fasting blood samples pure natural porcine 
secretin GIH (Karolinska Institute, Stockholm) in a dose of 
1 U/kg was injected intravenously within 30 seconds. Five, 10 and 
15 minutes after secretin injection 3 more blood samples were 
taken for measurement of serum gastrin levels. Because the gas-
trin peak was always found 5 minutes after secretin injection, 
the fasting and the 5 minutes post-secretin gastrin level were 
used for calculation of the result. 
In the meal stimulation test fasting subjects ingested a 
standard test meal within 15 minutes. This meal consisted of one 
slice of bread, 50 g of cheese, one boiled egg and 200 ml of 
milk, corresponding to 30 g of protein, 20 g of fat and 25 g of 
carbohydrate. Blood samples were drawn before and 15, 30, 45, 60, 
90, 120 and 150 minutes after the start of the meal for determin-
ation of serum gastrin. The fasting and the highest postprandial 
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Table 8.1 FEATURES OF 15 PATIENTS WITH THE ZOLLINGER-ELLISON SYNDROME. 
sex age basal acid output serum gastrin η 
с 
(years) (mmol ti+/h) (pg/ml) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
f 
m 
f 
f 
m 
m 
m 
f 
m 
f 
f 
f 
f 
m 
f 
42 
39 
17 
49 
48 
61 
43 
70 
26 
64 
38 
37 
50 
40 
43 
32.1* 
67.0 
57.5 
6.4* 
40.3 
35.5 
46.0 
PH 1.2 
60.0 
4.3* 
12.5 
23.4 
15.4 
19.2 
15.1 
620 -
400 -
3100 -
530 -
190 -
1540 -
215 -
400 -
530 -
10800 -
250 -
350 -
142 -
140 -
196 -
960000 
1150 
21000 
750 
1490 
3280 
320 
1300 
850 
27100 
380 
470 
196 
252 
510 
normal values 2.3+2.6 (n=20) 66+18 (n=100) 
* after partial gastrectomy H no laparotomy 
t nodular pancreas; no tissue diagnosis + present 
§ persistent hypergastrinemia after total gastrectomy 0 not demonstrated 
I mean + 1 S.D. - not investigated 
serum gastrin concentrations were used for calculation. 
In one ZE-patient a secretin stimulation test was performed 
immediately after 3 hours calcium infusion. The result of this 
test was compared with that of secretin administration under 
basal conditions in the same patient. 
Serum gastrin levels were measured by radioimmunoassay using 
a rabbit antibody (25,26; chapter 4 . 2 ) . This antibody, raised 
against synthetic human gastrin I 2 through 17, conjugated to 
bovine albumin, binds gastrin components II and III with an almost 
equimolar potency ( 2 7 ) . In 100 normal subjects the serum gastrin 
level was 66 + 18 pg/ml (mean + 1 S . D . ) . 
Calcium, secretin and meal stimulation tests were considered 
positive, if serum gastrin level increased at least 50% of basal 
value. This criterion has proved to be of value in the differen-
tiation between patients with and without ZE-syndrome by calcium 
infusion (28; chapter 5 . 3 ) . 
Regression analysis was done by the method of least squares with 
calculation of slope, regression coefficient and intercept. 
8.3 Results 
Calcium infusion was followed by an increase in serum gastrin 
in all 15 ZE-patients studied (table 8.2; fig. 8 . 1 ) . In 2 patients 
however this test had to be considered negative, because only a 
slight rise in gastrin was observed. 
Intravenous administration of secretin induced a rise in serum 
gastrin in all 15 ZE-patients (table 8.2; fig. 8 . 2 ) . In the 2 
patients with a negative calcium provocation test the secretin 
stimulated increase in serum gastrin was also less than 50% of 
basal value. 
The combination of a positive calcium test and negative secre-
tin test or a negative calcium test and a positive secretin test 
was not found in the ZE-patients studied. 
The percentual increase in serum gastrin after calcium infu-
sion was compared with the secretin stimulated rise in gastrin in 
11 ZE-patients with basal serum gastrin levels of less than 1000 
pg/ml, as shown in fig. 8.3. In these patients a good correlation 
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Table 8.2 INCREASE IN SERUM GASTRIN AFTER STIMULATION WITH 
CALCIUM, SECRETIN AND A STANDARD TEST MEAL IN 15 
PATIENTS WITH THE ZOLLINGER-ELLISDN SYNDROME. 
increase in serum gastrin after stimulation 
calcium secretin meal 
Pg/ml % pg/ml % pg/ml % 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
500 
690 
7700 
330 
505 
6275 
470 
60 
400 
80600 
1120 
620 
404 
395 
490 
11 
138 
248 
66 
95 
254 
147 
6 
75 
340 
295 
177 
258 
228 
96 
400 
870 
19200 
440 
565 
4150 
170 
110 
1190 
13300 
660 
550 
298 
357 
300 
16 
174 
480 
57 
119 
205 
61 
12 
140 
53 
264 
125 
211 
147 
69 
-
65 
2800 
-
-
-
66 
-
760 
-
220 
132 
74 
110 
180 
-
10 
48 
-
-
-
21 
-
97 
-
42 
29 
43 
44 
47 
normal* 7+12 10+18 
values
 (n=15) (n=15) 
4+9 8+15 
(n=34) (n=34) 
52+28 99+51 
(n=12) (n=12) 
not determined 
* mean + 1 S.D. 
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was found between the rise in gastrin after both provocation 
tests (r = 0.841; ρ <0.01) . 
gastrin ( p g / m l ) 
100000-
10 000 
1000 
1 0 0 
I « · Zo l l inger-El l ison syndrome (n =15) 
" Ό " ' 1 · 1 1 ' 
0 1 2 3 ( h r s ) 
f i g . 8.1 Basal and c a l c i u m s t i m u l a t e d s e r u m 
g a s t r i n l e v e l s in 15 p a t i e n t s w i t h 
the Z o l l i n g e r - E l l i s o n s y n d r o m e and 
15 no rma1 s u b j e c t s 
Comparing the increase in serum gastrin after calcium and secre­
tin stimulation in 4 ZE-patients with basal gastrin levels of 
more than 1000 pg/ml, the gastrin response to calcium was found 
to be more pronounced in one, almost equal in 2, and more marked 
after secretin in one (cases 10,1,6 and 3; tables 8.1 and 8 . 2 ) . 
One (case 1) of the 2 patients with negative calcium and 
secretin tests had a basal serum gastrin level of more than 1000 
pg/ml, whereas the other patient (case 8) had a fasting serum 
calcium D mg/kg η 
г " ^ · ^ ^ ^ ^ · ' •••-• "i 
i i i i 
-o n n r m n l t n h i í i f - t t i í n =1^1 i m o n n ^ l Я E M 
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gastrin concentration of less than 1000 pg/ml at the time of 
study. 
gastrin (pg/ml) , 
100000 
10000-
1000-
Ю0-
-5 О 5 10 15 (mm) 
f i g . 8.2 Basal and s e c r e t i n s t i m u l a t e d s e r u m 
g a s t r i n levels in 15 p a t i e n t s w i t h 
the Zo1 1 inger - E 1 1 i son s y n d r o m e and 
3Ί no rma1 s u b j e c t s 
The diagnosis of ZE-syndrome was histologically proven in these 
two patients with negative provocation tests. 
In one ZE-patient the gastrin response to secretin under 
basal conditions was compared with the increase in serum gastrin 
after secretin administration at the end of a 3 hours calcium 
infusion test. Calcium infusion induced a rise in serum calcium 
from 2.40 to 3.50 mmol/1 and in serum gastrin from 350 to 970 
pg/ml in that patient. This calcium test was immediately followed 
by intravenous administration of 1 U/kg.30 sec secretin GIH. The 
serum gastrin level rose from 970 up to 2500 pg/ml within 5 
-5 t 
. -o normal subject s (n = 34) meani 1 S Ε M 
— · Zollinger - Ellison syndrome (n = 15) 
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minutes after secretin injection (fig. 8 . 4 ) . 
gabtr 
300 
200-
100 
π a'te- calci 
• 
• > 
• 
,m 
/ 
• 
• У 
• 
• 
/ 
• 
• 
/ 
/ 
y = 101x * 'ν 
Г-0 41 
3<001 
n=11 
100 200 300 
°/c ncrease in serum gaslnn a'ter secretin 
f i g . 8.3 C o m p a r i s o n b e t w e e n the p e r c e n t u a l 
i n c r e a s e in s e r u m g a s t r i n a f t e r 
stiirulation w i t h c a l c i u m and s e c r e t i n 
in 11 Zo1 1 i n g e r - E 1 1 i son p a t i e n t s w i t h 
basal s e r u m g a s t r i n l e v e l s of less 
than 1 0 0 0 pg/ml 
When the patient had a secretin stimulation test under basal 
conditions the serum gastrin level increased from 440 to 990 
pg/ml (fig. 8 . 4 ) . 
Only one out of 9 ZE-patients without previous gastric sur­
gery had a positive meal stimulation test, whereas the increase 
in gastrin in the other 8 patients was less than 50% of basal 
level (table 8.2; fig. 8.5) . 
The incidence of false positive calcium and secretin tests 
and false negative meal tests in patients without ZE-syndrome was 
studied in normal subjects, duodenal ulcer patients, patients with 
Billroth I and Billroth II antrectomy, total gastrectomy and 
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achlorhydria (table 8 . 3 ) . 
gastrin (pg/mD-
2500-
2 0 0 0 
1500 
Ю00 
5 0 0 - \ 
secretin G.I.H. 
1 U/kg l.v. 
3 0 
calcium 5 mg/kg.h ¡.v. 
secretin G.I.H. 
1 U/kg i.v. 
60 - ι — 
о 
"б5 120 180 240 
time (mm) 
f ig. 8 Л C o m p a r i s o n b e t w e e n the s e c r e t i n s t i m u l a t e d i n c r e a s e 
in s e r u m g a s t r i n u n d e r b a s a l c o n d i t i o n s and a f t e r 
3 h o u r s c a l c i u m i n f u s i o n in a p a t i e n t w i t h the 
Zo1 1 i n g e r - E 1 1 i son s y n d r o m e . N o t e the i n i t i a l fall in 
s e r u m g a s t r i n d u r i n g g a s t r i c a s p i r a t i o n b e f o r e t h e 
s t a r t of the c a l c i u m i n f u s i o n 
A more than 50% increase in serum gastrin after calcium infusion 
was found in 3 out of 6 patients with achlorhydria, but not in 
the other groups studied. None of the non-ZE-patients had a posi­
tive secretin provocation test. An increase in serum gastrin of 
less than 50% of basal value after ingestion of the test meal 
was found in 3 out of 12 normal controls and in 2 out of 9 
achlorhydric patients. In patients with antrectomy or total 
gastrectomy negative meal tests were frequently found: in 2 out 
of 9 patients with Billroth I antrectomy, in all 7 patients with 
Billroth II antrectomy and in all 7 patients with total gastrec­
tomy. All 16 duodenal ulcer patients had a postprandial increase 
in serum gastrin of more than 50% of basal value (table 8 . 3 ) . 
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Table 8.3 THE INCIDENCE OF POSITIVE STIMULATION TESTS, DEFINED AS AN INCREASE IN SERUM GASTRIN 
OF AT LEAST 50% OF BASAL LEVEL, IN PATIENTS WITH THE ZOLL INGER-ELLI SON SYNDROME, IN 
NORMAL SUBJECTS AND IN PATIENTS WITH DUODENAL ULCER, ACHLORHYDRΙΑ, BILLROTH I AND 
BILLROTH II ANTRECTOMY AND TOTAL GASTRECTOMY. 
positive calcium 
stimulation test 
positive secretin 
stimulati on test 
positive meal 
stimulation test 
ZE-syndrome 
normal subjects 
duodenal ulcer 
achlorhydria 
Billroth I antrectomy 
Billroth II antrectomy 
total gastrectomy 
13/15 (87%) 
0/15 (0%) 
0/10 (0%) 
3/6 (50%) 
0/2 (0%) 
0/7 (0%) 
0/5 (0%) 
13/15 (87%; 
0/34 (0%) 
0/14 (0%) 
0/11 (0%) 
0/4 (0%) 
0/6 (0%) 
1/9 (11%) 
9/12 (75%) 
16/16 (100%) 
7/9 (78%) 
7/9 (78%) 
0/7 (0%) 
0/7 (0%) 
g a s t r i n ( p g / m l ) 
10000-
1000-
100-
10 
test m eoi 
CU 
л-
_ } — { — § } } _ _ 
о о normal subjects (η = 12) mean i 1S Ε M 
• · Zollinger -Ellison syndrome (η«9) 
0,5 1.5 2,5(hrs) 
f i g . 8.5 F a s t i n g and meal s t i m u l a t e d s e r u m g a s t r i n 
l e v e l s in 9 p a t i e n t s w i t h the Z o l l i n g e r -
E l l i s o n s y n d r o m e w i t h o u t p r e v i o u s g a s t r i c 
s u r g e r y and in 12 n o r m a l c o n t r o l s 
Calcium infusion was accompanied by gastric pain, heartburn. 
nausea and vomiting in a small number of subjects and phlebitis 
of a forearm vein in one patient. No adverse reactions were 
observed after administration of secretin or ingestion of the 
test meal. 
8.4 Discussion 
In this study the value of different stimulation tests to 
distinguish ZE-patients from patients without gastrinoma has 
been evaluated. 
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A stimulation test is valuable to the diagnosis of ZE-syndrome 
if: 
1. the number of false test results in ZE-patients is small 
2. the number of false test results in non-ZE-patients is small 
3. the test is easy and fast to perform 
4. the test has no or only minor adverse reactions. 
1. False negative calcium stimulation tests were found in 2 out 
of 15 ZE-patients. The secretin stimulation test was also found 
to be negative in the same 2 patients with histologically proven 
gastri noma. 
Different hypotheses have been put forward in the literature to 
understand these negative stimulation tests in ZE-patients, e.g. 
low gastrin content of tumour and metastases ( 6 ) , the influence 
of gastrectomy (22) and, as far as negative secretin tests are 
concerned, coexisting hyperglucagonism ( 2 3 ) . However, the exact 
reason for the negative stimulation tests in some ZE-patients is 
up to now obscure. Moreover, the frequency of negative stimula-
tion tests in ZE-patients in the literature is difficult to eva-
luate, because different amounts of provocative agents of diffe-
rent potency over different periods of time have been adminis-
tered (29; chapter 6 . 4 ) . 
Stimulation tests are considered to be of clinical signifi-
cance in patients with basal serum gastrin levels of less than 
1000 pg/ml ( 1 ) . If the percentual increase in serum gastrin 
after calcium infusion is compared with the secretin stimulated 
rise in gastrin in 11 ZE-patients with basal serum gastrin levels 
of less than 1000 pg/ml, the correlation between the results is 
found to be rather good (fig. 8 . 3 ) . The slope of 1.01 in fig. 
8.3 indicates an almost equal potency of calcium and secretin, 
in the amounts used, to increase serum gastrin levels. 
In ZE-patients with markedly elevated basal gastrin levels of 
more than 1000 pg/ml the correlation between the rise in serum 
gastrin after both provocative agents was poor. The reason for 
this different sensitivity of the tumour to the two provocative 
agents is unclear. 
In one ZE-patient the rise in serum gastrin after secretin 
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administration was more pronounced, when this test was performed 
during hypercalcemia after calcium infusion (fig. 8 . 4 ) . From 
these data it may be concluded that the provocative agents are 
capable to potentiate each other mutually. 
Moreover, it is evident that calcium infusion does not result in 
exhaustion of the tumorous gastrin content. Both in acute hyper-
calcemia after calcium infusion (fig. 8.4) and in chronic hyper-
calcemia, as found in ZE-syndrome with coexisting hyperparathy-
roidism, secretin is effective in increasing serum gastrin levels 
(29; chapter 6 . 3 ) . How far administration of calcium or secretin 
stimulates not only the release but also the synthesis of gastrin 
by the tumour has still to be investigated. 
It has been found by Berson and Yalow (14), that patients 
with ZE-syndrome show no or only minor increases in serum gas-
trin after ingestion of a protein-rich meal. These results are 
interpreted by the suggestion that extragastric tumorous gastrin, 
which forms the bulk of serum gastrin in the ZE-syndrome, is not 
stimulated by ingestion of food (1,14). Only one (case 9) out of 
9 ZE-patients without previous gastric surgery from this study 
had an increase in serum gastrin of more than 50% of basal value. 
Although this patient has not been operated on, the diagnosis of 
ZE-syndrome is confirmed by the combination of a very high basal 
gastric acid output, a positive calcium and a positive secretin 
stimulation test. Patients with non-tumorous hypergastrinemia of 
antral origin have in general a lower basal acid output, negative 
calcium and secretin stimulation tests and a more pronounced 
postprandial increase in serum gastrin in comparison with the 
results in this patient (10,14). 
Thompson et al (24) described a postprandial increase in serum 
gastrin of less than 50% in both ZE-patients without previous 
gastric surgery studied, whereas Creutzfeldt et al (23) found a 
more than 50% increase in gastrin in the 2 non-operated ZE-
patients from that series. The reason for the marked increase 
in serum gastrin after a test meal in some ZE-patients is not 
clear. Several mechanisms may be put forward to understand the 
pronounced meal stimulated increase in serum gastrin in these 
patients, such as direct interaction between food entering the 
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duodenum and a tumour originating in the duodenal wall, the re-
lease of a gastrin stimulating agent from the small intestine, 
e.g. secretin, and pancreatic tumours coexisting with antral G-
cell hyperplasia ( 8 ) . One of the ZE-patients with marked post-
prandial increase in serum gastrin, described by Creutzfeldt et 
al ( 2 3 ) , underwent laparotomy and a duodenal wall tumour was 
found. 
A better understanding of the factors, responsible for the food 
stimulated rise in serum gastrin in some ZE-patients, is of con-
siderable pathophysiological interest. 
2. Positive calcium stimulation tests were found in 3 out of 6 
patients with achlorhydria, but in none of the other non-ZE-
patients. 
Positive secretin tests were not observed in patients without 
gastri noma. 
The secretin test is more valuable than the calcium test, because 
this test differentiates between hypergastrinemia from antral and 
tumorous origin. In patients with hypergastrinemia of antral 
origin administration of secretin is usually followed by a fall 
in serum gastrin, such for instance as in achlorhydria (21,29), 
excluded gastric antrum ( 7 ) , non-tumorous hypergastrinemic hyper-
chlorhydria (10) and postprandial conditions ( 1 7 ) . On the other 
hand marked increases in serum gastrin after calcium infusion 
have been described in patients with achlorhydria or excluded 
gastric antrum (1 0 , 2 8 ) . 
Postprandial increases in serum gastrin of less than 50% of 
basal value were found in several patients without gastrinoma 
studied, especially in those with previous gastric surgery. 
Because the meal stimulated rise in serum gastrin in ZE-patients 
with partial or total gastrectomy is often more than 50% of basal 
value (17,23,24; chapter 7.3.2) and the increase in operated 
patients without gastrinoma is often less than 50% of basal gas-
trin level, it can be concluded that meal stimulation tests are 
only helpful to differentiate ZE-patients from non-ZE-patients 
in cases without previous gastric surgery. 
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3. The secretin stimulation test takes only 5 to 20 minutes, 
whereas the calcium stimulation test takes 3 hours and the meal 
stimulation test 2| hours. The secretin test is easy to perform, 
because only one intravenous injection and no infusion is needed. 
4. The calcium stimulation test was accompanied by moderate 
complaints in a small group of patients, whereas no untoward 
reactions to the administration of secretin or to the ingestion 
of the standard test meal were observed. Because of the risk 
of complications, as a result of long-standing calcium stimu-
lated gastric acid secretion, gastric aspiration may be needed 
in ZE-patients during and after the calcium infusion. Moreover, 
the calcium load may be dangerous in elderly patients and in 
patients with preexisting hypercalcemia. 
It can be concluded from this study that the secretin stimu-
lation test is preferable to calcium and food provocation 
in equivocal cases of ZE-syndrome. 
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Chapter 9 
PREVALENCE OF ENDOCRINE ABNORMALITIES IN PATIENTS WITH THE 
ZOLLINGER-ELLISON SYNDROME AND IN THEIR FAMILIES. 
9.1 Introduction 
The Zol1inger-El1 i son (ZE) syndrome is characterized by 
ulcers, diarrhea, gastric acid hypersecretion and gastrin producing 
tumours, usually originating in the pancreas (1 , 2 ) . Tumours or 
hyperplasia of extrapancreatic endocrine glands are found in up 
to 48% of ZE-patients ( 3 ) . This association has been named 
Multiple Endocrine Adenomatosis or Neoplasia type I (MEA I; 4 , 5 ) . 
Hyperparathyroidism, pituitary tumours and pancreatic islet cell 
tumours are the most frequent manifestations of this entity 
( 5 - 7 ) . Apart from the MEA I-entity pancreatic tumours may secrete 
other hormones besides gastrin (8-12). 
In families of some patients with the ZE-syndrome, especially 
if this syndrome is a component of MEA I, an increased incidence 
of endocrine abnormalities has been found (5,13). A number of 
observations on families with MEA I has been recorded (4,6,13-20). 
The results of these studies,however,are often incomplete since 
not all family members have been investigated. Moreover, selection 
of probands or family members is often made by a history or symp-
toms suspected of endocrine disease. Since endocrinopathies are 
often asymptomatic in the MEA I-entity (17) the incidence of 
endocrine involvement may be underestimated. 
In this report the results of endocrine studies in 10 ZE-
patients and in at least all their first degree relatives, aged 
15 years or more, are recorded. The only criterion of selection 
was the willingness of the patient and all his first degree rela-
tives to participate in this study. 
9 .2 Patients and methods 
In table 9.1 relevant features of the 10 patients with the 
ZE-syndrome are summarized. 
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Table 9.1 FEATURES OF 10 PATIENTS WITH THE ZOLLINGER-ELLISON SYNDROME. 
sex age 
<n 
о 
1 
г 
3 
4 
5 
f 
f 
f 
f 
m 
45 
17 
42 
32 
40 
10 m 
37 
61 
76 
48 
compia m t s non-r-1 slet В. A. 0.* serum increase τη serum gastrin after comments 
ulcer diarrhea cell tumour 
+ 0 t 
+ 0 + 
+ 0 + 
<· 0 + 
norma 1 values 
(mmol H + 
pH 1.2S 
57.5 
32.1s 
23.2 
9 7 
67.0 
10.0 
35.5 
pi! 1.2S 
40.3 
2 3+2.6 
(п=го) 
gastrin ca 
/h) (pg/ml) 
-
3100-21000 
620-960000 
-
" 
400-1300 
" 
1540-3280 
" 
190-1490 
66 + 18 
(n=100) 
Icium 
(Ï) 
-
248 
11 
-
" 
138 
254 
95 
10+18 
(n=15) 
secretin 
(*) 
-
480 
16 
-
" 
174 
205 
119 
8 + 15 
(n=34) 
meal 
(«) 
-
48 
-
-
" 
10 
99 + 51 
(n=12) 
died after 
gastric surgery 
alive, extensive 
metastases 
died from tumour 
growth 
died after 
gastric surgery 
died after 
gastric surgery 
(A II 7, fig 9 1) 
alive, no 
metastases 
(B II 1, tig 9 1, 
died after 
gastric suraery 
(C II 6, fig 9 :) 
h y p e r g a s t n пепла 
after total 
gastrectomy 
(0 11 6, fig 9 1) 
died from tumour 
growth 
(E II 3, fig.9 I) 
died from renal 
failure, exten­
sive metastases 
(F II 1, Fig.9.1) 
+ present 
0 absent or not demonstrated 
not determined 
* basal gastric acid output 
+ lowest and highest basal serum gastrin level 
S after partial gastrectomy 
ι nodular pancreas; no tissue diagnosis 
и mean + 1 S.D. 
A total of 76 first degree relatives of these 10 ZE- patients, 
including all living subjects with a minimum age of 15 years, were 
studied (table 9 . 2 ) . If endocrine disease was detected in first 
degree relatives, the study was extended to all family members 
older than 15 years. Two non-first degree relatives could not 
be investigated. Seven children younger than 15 years were 
examined at their parents 'request. In case the family member had 
died the medical history and the autopsy report were reviewed. 
A total ofl09 family members was studied (table 9 . 2 ) . These sub-
jects were mainly investigated in the out-patient department. 
The investigation consisted of the history, an X-ray of the 
sella turcica and measurement in plasma or serum of growth hormone, 
prolactin, thyroxine, calcium, inorganic phosphate, parathyroid 
hormone, gastrin, glucose, insulin and Cortisol. Blood samples 
were drawn after an overnight fast. In all subjects with elevated 
serum gastrin levels gastric acid secretion was measured. In 
hypergastrinemic subjects without tissue diagnosis of gastrinoma 
provocation tests with calcium, secretin and food were performed 
to confirm the ZE-syndrome and to exclude antral G-cell hyperplasia 
(21-28; chapter 8 ) . 
Serum calcium levels were measured by atomic absorption spec-
trophotometry, inorganic phosphate by a modification of the 
Fiske-Subbarow technique ( 2 9 ) , Cortisol by a fluorimetrie assay 
(30) and glucose by the ferricyanide method ( 3 1 ) . The plasma or 
serum levels of growth hormone, prolactin, thyroxine, parathyroid 
hormone, gastrin and insulin were measured by radioimmunoassay. 
Normal values are recorded in the tables 9.1, 9.3, 9.5 and 9.6. 
In the gastrin assay a rabbit antibody was used with almost equal 
potency to gastrin components II and III ( 3 2 ) . 
In the calcium stimulation test 15 mg calcium/kg was infused 
over 3 hours and in the secretin provocation test 1 U secretin 
GIH (Karolinska Institute, Stockholm)/kg was administered intra-
venously within 30 seconds. The standard test meal consisted of 
one slice of bread, 50 g of cheese, one boiled egg and 200 ml of 
milk. For calculation of the results the basal serum gastrin level 
was compared with the gastrin concentration after 3 hours calcium 
infusion, the value obtained 5 minutes after secretin injection 
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Table 9.2 NUMBER OF RELATIVES OF 10 PATIENTS WITH THE ZOLL INGER-ELLISON SYNDROME STUDIED 
AND FOUND AFFECTED BY ENDOCRINE DISEASE. 
proband 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
MEA I* number of relatives studied number of relatives affected 
0 
0 
0 
0 
+ 
+ 
+ 
+ 
+ 
+ 
al i ve 
>15yrs 
9 
3 
10 
9 
16 
3 
7 
22 
7 
6 
al i ve 
<15yrs 
-
-
-
-
1 
2 
1 
3 
-
_ 
died 
-
-
-
-
2 
-
4 
2 
2 
_ 
alive 
>15yrs 
0 
0 
0 
0 
8 
1 
1 
5 
4 
1 
alive di ed 
<15 yrs proven suspected 
0 
0 
0 
0 
_ 
2 
-
3 
2 
0 
0 
-
1 
0 
2 
*+ present 
0 absent 
and the highest postprandial gastrin level. 
The diagnosis of pituitary tumour was based on a markedly en-
larged sella turcica on X-ray or histological findings. The 
diagnosis of hyperparathyroidism was made on the combination of 
an elevated serum calcium concentration of at least 2.65 mmol/1 
and a decreased inorganic phosphate level of less than 0,85 
mmol/1, found on at least 2 occasions. The diagnosis of ZE-
syndrome was confirmed in operated cases by the finding of non-
ß-islet cell tumours or persistent elevated serum gastrin levels 
after total gastrectomy. In non-operated patients the diagnosis 
of ZE-syndrome was made by the combination of the following re-
sults: a. basal gastric acid output of at least 10 mmol H /h 
(normal value 2.3 + 2.6; mean +_ 1 SD; n = 2 0 ) , b. hypergastri nemia 
of at least 150 pg/ml (normal value 66 + 18, mean + 1 SD, n=100), 
c. a more than 50% increase in serum gastrin after calcium in-
fusion (21,22), d. a rise in serum gastrin of at least 50% of 
basal value after secretin administration (23-25) and e. a maxi-
mum rise in serum gastrin of less than 50% of fasting level 
after ingestion of the standard test meal (26-28). The definition 
of suspected ZE-syndrome was the presence of characteristic 
clinical and radiological features of the syndrome in deceased 
subjects, in whom non-ß-islet cell tumour tissue had not been 
found and serum gastrin levels were not available. The diagnosis 
of insulinoma and nodular adrenocortical hyperplasia was proven 
histologically. 
9.3 Results 
9.3.1 епсІО£гіде studjes^ .in_P£t_i_ent£ wit^_the_Z£-syndrome 
Endocrine studies in 10 patients with the ZE-syndrome revealed 
endocrine disorders in 7 (table 9 . 3 ) . One of these 7 patients 
(case 4) had clinical Cushing's syndrome with elevated plasma 
Cortisol concentrations and increased urinary excretion of 17-
hydroxycorticoids and 17-ketosteroids (table 9 . 3 ) . Enlargement 
of the sella turcica was not observed and at autopsy bilateral 
adrenocortical hyperplasia and a pancreatic tumour were 
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Table 9.3 RESULTS OF ENDOCRINE STUDIES IN 10 PATIENTS WITH THE 
pi tui tary gland parathyroid 
sella growth prolactin tumour calcium inorganic PTH 
enlarge- hormone (tissue phosphate 
ment di agn . ) 
(uU/tnl) (ng/ml) (mmol/1) (mmol/1) (pg/ml) 
1 0 0 2.20 0.80 
2 0 2.05 1 .24 25 
3 0 10 2.20 1 .00 85 
4 0 2.10 0.76 
5 0 2.84 0.62 
6 0 2.80 0.63 265 
7 0 3.05 0.60 
8 0 
9 0 
0 β 
normal 
v a l u e s 
7 
-
68 
<20 
4 
-
106. 
<30 
,5 
2.67 
2.80 
0.68 330 
0.70 
li 
2.91 0.93 445 
2.20-2.60 0.85-1 .30 <200 
+ present 
0 absent 
β equivocal 
not determined 
H serum thyroxine levels are not recorded, since all results 
were normal 
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ZOLLINGER-ELLISON SYNDROME? 
glands pancreatic islets adrenal cortex 
gland glucose insulin $-islet Cortisol nodular 
enlarge- glucose cell hyperplasia 
ment ratio tumour 
(mmol/1) (mU/mmol) (ymol/l) 
MEA I 
4.8 4.5 0.50 
0 
4.5 
6.8 
6.0 
5.4 
6.6 
4.5 
5.0 
4.9 
5.6 
1.5 
3.8 
2.4 
4.5-5.5 <7.3-
0 
0 
0 
0 
0 
0 
0 
0 
0.43 
1.06* 
0.48 
0.48 
0 .50+ 
0.47 
0.47 
0.35 
0 . 3 5 - 0 . 8 0 
* urinary excretion of 17-hydroxycorticoids 12.6 pmol/mmol 
creatinine (normal value <4.5) and 17-ketosteroids 10.4 
pmol/mmol creatinine (normal value <3.2) 
t normal suppression after administration of dexamethasone 
§ this figure has been calculated from the criterion of insu-
linoma, as described by Grunt et al (37) 
" value obtained during renal insufficiency 
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found. It might be assumed that the pancreatic tumour was res-
ponsible for ectopic secretion of ACTH or an ACTH-like substance. 
No evidence of MEA I was found in this patient. 
The other 6 ZE-patients with coexisting endocrinopathies had 
signs of the MEA I-entity. In table 9.4 the total number of 
endocrine abnormalities in these 6 patients and the number of 
endocrinopathies, diagnosed for the first time during this study, 
are summarized. 
Table 9.4 TOTAL NUMBER AND NUMBER OF NEWLY DIAGNOSED ENDOCRINO-
PATHIES IN 6 PATIENTS WITH THE ZOLL INGER-ELLISON 
SYNDROME AS COMPONENT OF MEA I. 
total newly diagnosed 
pituitary tumour 1 1 
hyperparathyroidism 6 2 
i nsuli noma 0 0 
nodular adrenocortical hyperplasia 2 0 
hyper- or hypothyroidism 0 0 
9.3.2 en¿0£ri_n£ !tiidie¿ І П _ Г Ё . ^ £ І ^ 5 _ 0 £ .iE.lpa-t.ien.ts. 
In none of 31 first degree relatives of 4 patients with 
the ZE-syndrome without MEA I-involvement was endocrine disease 
diagnosed (table 9.2). Overt diabetes mellitus was the only 
abnormal finding in one of these family members. 
All 6 patients with ZE-syndrome as component of MEA I had 
relatives with endocrine disease. Abnormalities of endocrine 
glands were demonstrated in 27 out of 78 family members and 
suspected in 3 (table 9.5 and 9.6). None of 7 subjects 
younger than 15 years had endocrine disease (table 9.2). The 
total number of endocrine abnormalities and the number of newly 
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diagnosed endocrinopathies in the 30 relatives with MEA I-
involvement are recorded in table 9.7. 
Table 9.7 TOTAL NUMBER AND NUMBER OF NEWLY DIAGNOSED ENDOCRINO-
PATHIES IN 30 AFFECTED RELATIVES OF 6 PATIENTS WITH 
THE ZOLLINGER-ELLISON SYNDROME AS COMPONENT OF MEA I. 
total newly diagnosed 
pituitary tumour 7 
hyperparathyroidism 24 
ZE-syndrome 9 
suspected ZE-syndrome 5 
insulinoma 3 
nodular adrenocortical hyperplasia 2 
hyper- or hypothyroidism 0 
3 
15 
7 
0 
1 
0 
0 
In fig. 9.1 the pedigrees of the б MEA I-families are pre­
sented . 
9.3.3 !e^tures_o£ £ndO£ri_ne aj)normaj_i_tj_es. Ι π ^ ί Λ Ε . 0 ! 6 ! member^ 
о f _6_M£A_ I ^ f a m j_l _i_e£ 
The endocrine abnormalities in the affected members of the 
MEA I-families were often asymptomatic, as is shown in table 9.8. 
More than 65% of the newly diagnosed endocrinopathies had not 
resulted in complaints at the moment of diagnosis (table 9.8). 
Out of a total of 8 patients with pituitary tumour one had 
amenorrhea, one had amenorrhea and loss of sight and one had 
retardation of growth, whereas the other 5 patients had no com-
plaints. The 4 newly diagnosed patients with pituitary tumour 
were all asymptomatic, but a temporal defect in visual field was 
found in the 3 patients investigated. In the fourth patient 2 
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Table S.5CLINICAL, LABORATORY, HISTOLOGICAL AND RADIOLOGICAL DATA, RELATED TO THE DIAGNOSIS OF THE ZOLLINGER-
ELLISON SYNDROME, IN 30 AFFECTED RELATIVES OF 6 PATIENTS WITH THE ZOLL INGER-ELLI SON SYNDROME AS 
COMPONENT OF MEA I. 
sex age non-P-islet 
eel 1 tumour 
(yrs) 
B.A .0. serum* increase τη serum gastrin after ZE- comments 
gastri π calcium secretin meal syndrome 
(mmol H + /h) ipg/ml ) (Ϊ) (%) {%) 
CTi 
CO 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
В 
С 
С 
с 
с 
с 
II 
II 
II 
II 
III 
III 
III 
III 
III 
III 
I 
I 
II 
II 
II 
II 
1 
2 
3 
5 
1 
3 
4 
5 
6 
θ 
2 
1 
1 
7 
8 
9 
m 
m 
m 
f 
f 
63 
54 
58 
32 
40 
25 
25 
29 
26 
19 
65 
45 
24 
27 
38 
36 
67 
82 
19.2 140-252 228 
51 
50 
55 
53 
69 
4 . 3 S 10800-27100 340 
pH 1.0 
pH 1.1 
12.5 250-380 295 
pH 1.2 850-2800 
15 
15 
147 
28 
28 
-2 
20 
24 
53 
44 
died from myocardial 
infarcii on 
suicide 
heartburn 
264 42 
stomal ulcer 
4 gastric resections; 
died postoperatively 
recurrent ulcer; died 
after GI-bleeding 
ulcers and diarrhea ; 2 
gastric resections, 
died postoperatively 
ulcers and diarrhea 
duodenal ulcer 
Ο Π 1 f 59 + pH 1.2 
en 
<J3 
D 
D 
D 
D 
D 
D 
E 
I 5 
I 2 
I 3 
[I 4 
[I 6 
Il 13 
[I 2 
f 
f 
f 
f 
m 
m 
m 
E I 
I 5 f 40 
I 2 f 52 
I 3 
I 4 
I 6 
I 1 
normal values 
50 
47 
43 
17 
1 
-
1.8 
pH 1.0 
23.4 
pH 1.7 
-
62 
68 
-
350-470 
79 
40 
1.8 119 
15.4 
0.9 
15.1 
-
2.3+2.6 
(n=20) 
142-196 
94 
196-510 
47 
66 + 18 
(n=100) 
+ present 
0 absent or not denonstrated 
• equivocal 
not determined or not investigated 
117 
258 
96 
-2 
48 
125 
29 
17 
-15 
10 + 18 
(n=15) 
211 
20 
69 
19 
8 + 15 
(n=34) 
29 
43 
47 
99+51 
(n=12) 
died from renal 
fai lure ; siight 
gastric pain 
heartburn 
ulcers and diarrhea; 
died after perforation 
ulcers and diarrhea 
heartburn 
4 gastric resections, 
died postoperatively 
4 gastric resections, 
died postoperatively 
slight gastric com­
plaints 
no complaints 
no complaints 
basal gastric acid output 
lowest and highest basal serum gastrin levels, found in periods 
ranging from J up to 2J years 
after partial gastrectomy 
referring to pedigrees in figure 9 1 
mean + 1 S.D. 
Table β 6 ENDOCRINE STUDIES IN 30 AFFECTED RELATIVES OF 6 PATIENTS 
pituitary gland parathyrotd 
sella grow t h 
en large- hormone 
ment 
iuU/ml) 
prolactin tumour calcium inorganic 
(tissue phospha te 
d a gn ) 
(ng/ml) (mmol/l) (mmot/l) 
A 1 
A 1 
A 1 
A 1 
A 1 1 
A 1 1 
A 1 1 
A 1 1 
A 1 1 
A 1 1 
В 
С 
С I 
с I 
с I 
с I 
0 I 
D 1 
0 1 1 
D 1 1 
0 1 1 
0 1 1 
0 1 1 
ε ι ι 
Ε I 1 
Ε I 1 
Ε I 1 
F I 1 
1 1 Ί1 
ι 13 
0 
0 
0 
-
+ 
0 
0 
0 
0 
0 
+ 
+ 
-
α 
+ 
+ 
0 
0 
+ 
D 
+ 
0 
-
-
0 
0 
D 
0 
0 
6 
< I 
-
-
<1 
<1 
<1 
10 
' 1 
-4 
1 
. 
-
< 1 
<-\ 
-
7 
1 5 
-
<1 
<1 
8 5 
-
-
Π 
12 
Ί 
< 1 
< 1 
6 
5 
-
84 5 
6 6 
4 5 
9 
3 
5 5 
10 
_ 
_ 
9 
ΜΊΟ 
-
36 5 
15 5 
10 
3 5 
3 5 
-
-
Ί 
Ιέ 
H 
3 5 
2 77 
2 78 
2 85 
2 69 
2 71 
2 98 
2 68 
2 81 
2 75 
2 82 
0 69 
0 50 
0 71 
0 66 
0 6l< 
0 66 
0 73 
0 81 
0 81 
0 Ίβ 
2 30* 
2 51 
2 77* 
2 72 
2 58* 
2 66 
2 76 
0 88 
0 69 
0 60 
0 82 
0 51 
0 65 
0 56 
3 oo 
о 80 
normal values <20 <30 
2 8li* 
2 81* 
3 02 
2 75 
2 86 
0-2 60 
0 8i| 
0 7'· 
0 56 
0 62 
0 68 
0 85-
+ present 
0 absent or not demonstrated 
not determined or not investigated 
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WITH THE ZOLLINGER-ELLISON SYNDROME AS COMPONENT OF MEA I*· 
glands pancreatic islets adrenal cortex 
pa гаthyroιd gland 
hormone enlarge­
ment 
(pg/ml) 
70 
20 
200 
210 
ΙΊΟ 
180 
260 
205 
20 
es* 
55 
20. 
20 
290 
330 
НЮ 
3 7 » : 
395 
325 
220 
310 
g 1ucose 
(mmol/I) 
6 1 
6 2 
5 4 
5 2 
5 0 
5 7 
5 6 
5 1 
5 0 
5 2 
-
ιns u 1 in 
g 1ucose 
ratio 
(mU/miro 
2 1 
2 3 
-
6 1 
<< 9 
3 2 
5 5 
2 5 
l· 9 
5 5 
-
-
1) 
ce 
1 s 
• ] 1 
let 
tumou rs 
_ 
-
-
-
-
-
-
-
-
0 
0 
Cortisol 
(-mcl/l) 
0 56 
0 Ίΐ 
0 52 
0 51 
0 62 
0 50 
0 52 
0 ΊΙ 
0 ΊΟ 
0 60 
-
nod 
hyp 
ular 
er ρ 1 a s a 
_ 
-
-
-
-
-
-
-
-
-
0 
Ί 6 
Ί 't 
3 7 
Ί 5' 
•ι 6 
0 6 
5 4 
0 355 
0 02 
0 60 
0 50 
0 42 
0 45 
0 57 
45 
53 
66 
53 
62 
<200 4 5-5 5 <7 3 0 35-0 30 
* after parathyroidectomy 
t after resection of pancreatic 6-islet cell tumours 
§ during cortisone treatment 
II this figure has been calculated from the criterion of insulinoma, 
as described by Grunt et al (37) 
H referring to pedigrees in figure 3 1 
** serum thyroxine levels are not recorded since all results were normal 
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adenomas of the pituitary gland were found at autopsy. Growth 
hormone levels were found elevated in one out of 5 patients 
with pituitary tumour studied and prolactin levels were increased 
in 3 out of these 5 patients. 
A history or findings of hyperparathyroidism were present in 
30 members of the 6 MEA I-families. In all 14 patients, who came 
to operation, enlarged parathyroid glands were found. Parathyroid 
hormone levels were found elevated in 13 out of 21 hypercalcémie 
patients studied (tables 9.3 and 9 . 6 ) . 
Table 9.8 OCCURRENCE OF ASYMPTOMATIC ENDOCRINOPATHIES IN RELATION 
TO THE TOTAL NUMBER OF ENDOCRINE ABNORMALITIES AND TO 
THE NUMBER OF NEWLY DIAGNOSED ENDOCRINOPATHI ES IN 36 
AFFECTED MEMBERS OF 6 MEA I-FAMILIES. 
total newly diagnosed 
pituitary tumour 
hyperparathyroidism 
ZE-syndrome 
suspected ZE-syndrome 
i nsuli noma 
nodular adrenocortical hyperplasia 4/4 
5/8 
14/30 
3/15 
0/5 
1/3 
4/4 
4/4 
12/17 
3/7 
0/0 
1/1 
0/0 
Increased parathyroid hormone levels were not found in normocal-
cemic subjects. Two patients had died as a result of renal 
failure due to hypercalcémie nephrocalcinosis. Sixteen out of 
the 30 patients with hyperparathyroidism had a history or findings 
of renal stones and one had severe osteitis fibrosa cystica. In 
only 5 out of 17 newly diagnosed cases of hyperparathyroidism 
the disease had resulted in clinical symptoms. 
The ZE-syndrome was diagnosed in 15 subjects. Non-ß-islet cell 
tumours were detected in 8 cases. One patient had persistent 
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hypergastrinemia after total gastrectomy, indicating the extra-
gastric origin of gastrin. In the 7 patients without tissue 
diagnosis the ZE-syndrome was confirmed by the combination of 
elevated serum gastrin levels, basal gastric acid hypersecretion, 
a more than S0% increase in serum gastrin after stimulation with 
calcium and secretin and a rise of less than 50% of fasting value 
after ingestion of the standard test meal (tables 9.1 and 9 . 5 ) . 
All 12 cases with serum gastrin levels of more than 150 pg/ml 
were found to have ZE-syndrome. 
Moreover, 5 deceased subjects, in whom no tumours were found and 
serum gastrin levels were not available, had suffered from fulmi-
nant peptic ulcer disease. 
Ulcers or diarrhea were found in only 4 out of the 7 newly diag-
nosed ZE-patients. The complaints were rather mild and had neces-
sitated gastric surgery in only one of the 4 patients with symp-
tomatic ZE-syndrome. One of 3 ZE-patients without ulcers had mild 
complaints of heartburn and 2 patients had no complaints at all. 
However, in 10 out of 12 patients from these 6 families, who died 
as a result of endocrine disease,was proven or suspected ZE-
syndrome the cause of death. 
In one patient an increased insulin-glucose ratio was found 
and insulinoma was histologically proven later on. This patient 
had no major complaints of hypoglycemia. The other 2 patients 
with insulinoma had been operated on because of severe hypoglyc-
emic attacks, which disappeared after resection of pancreatic 
ES-islet cell tumours. 
Nodular adrenocortical hyperplasia was found at autopsy in 
4 members of the MEA I-families. In all 4 cases this endocrinopathy 
was asymptomatic. 
Serum thyroxine levels were normal in all subjects studied. 
Thyroid nodules were palpable in 4 cases. 
9.4 Discussion 
The present study revealed coexisting endocrine disease in 
7 out of 10 patients with the ZE-syndrome. One of these 7 patients 
had Cushing's syndrome, probably caused by the ectopic production 
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of ACTH or an ACTH-like substance by the pancreatic tumour. 
Ectopic secretion of ACTH by the pancreatic tumour has been 
described in the ZE-syndrome previously ( 9 , 1 0 ) . The other 6 
patients had evidence of MEA I. Coexisting endocrine disease 
occurs in 15 to 485» of ZE-patients studied in the literature 
( 3 , 3 3 , 3 4 ) . The high incidence of endocrinopathies in this study 
is probably the result of performing endocrine investigations 
not only in patients with a history or findings suspected of 
endocrine disease, but also in patients without clinical evidence 
of endocrine abnormalities. Two of the ZE-patients had asymptomatic 
hyperparathyroidism and one a pituitary tumour without complaints. 
All 6 ZE-patients with evidence of MEA I had affected rela-
tives. These results differ from the studies of Stocks (18) and 
Croisier et al ( 7 ) , who mainly collected their data from the 
literature and found that the MEA I-entity was in only 21 and 45% 
of the cases a hereditary disorder. The main reason for this 
difference is probably insufficient study of asymptomatic family 
members. 
It has been stressed that endocrinopathies are often asymptomatic 
in affected members of MEA I-families ( 1 7 ) . The family history 
was in only 3 out of 6 MEA I-families in the present study sus-
pected of MEA I-involvement. 
In the families of 4 ZE-patients without MEA I-evidence no 
endocrine abnormalities were found in first degree relatives. 
The results of the family study give additional support 
to Wermer's hypothesis that the ZE-syndrome exists in 2 forms: 
1. the ZE-syndrome as component of MEA I, a hereditary disease, 
for which the name ZE-syndrome has to be maintained and 
2. the ZE-syndrome without MEA I-evidence, a non-hereditary 
disorder, for which the name ZE-disease is proposed ( 5 ) . 
To verify this hypothesis however, more families of ZE-patients 
have to be studied thoroughly. 
Radiological examination of the sella turcica as well as 
measurements of growth hormone and prolactin levels are helpful 
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to reveal pituitary involvement. In one patient (F II 1) with 
equivocal sella enlargement high circulating levels of growth 
hormone and prolactin were found. At autopsy two pituitary 
adenomas were demonstrated in this patient. 
The combination of hypercalcemia and hypophosphatemia was 
a good marker of hyperparathyroidism. However, serum calcium 
levels have to be interpreted with care because steatorrhea 
and hypoalbuminemia, often present in the ZE-syndrome ( 3 5 ) , may 
depress serum calcium levels in patients with the combination of 
hyperparathyroidism and ZE-syndrome. Moreover, the present study 
confirms the finding of Marx et al ( 3 6 ) , that hypercalcemia in 
patients with hyperparathyroidism as component of MEA I is often 
mild. Measurement of parathyroid hormone levels in peripheral 
blood has only limited value. An elevated concentration supports 
the diagnosis of hyperparathyroidism, but a normal level does 
not exclude this disorder. In the present study normal peripheral 
parathyroid hormone levels were found in about 40% of the patients 
with hyperparathyroidism as a component of MEA I. This value is 
slightly higher than the incidence of 30% normal peripheral 
parathyroid hormone levels found in unselected patients with 
primary hyperparathyroidism by the assay used (Hackeng, personal 
communication). Marx et al (36) found elevated peripheral 
parathyroid hormone levels in only one out of 7 patients with 
hyperparathyroidism from the MEA I-family studied. The value of 
measurement of parathyroid hormone concentrations can be increased 
by selective sampling from thyroid veins ( 3 6 ) , but this 
procedure obviously is not a simple screening test to be performed 
in an out-patient department. 
The ratio of insulin to glucose after an overnight fast may 
be helpful in diagnosing insulinoma ( 3 7 ) . In the only patient 
with an increased insulin-glucose ratio in this study (C II 9) 
was the diagnosis of insulinoma histologically proven later on. 
It is questionable whether more sophisticated provocation tests 
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may reveal other cases with asymptomatic insulinoma. 
The present study confirms that serum gastrin determinations 
are very helpful to the diagnosis of ZE-syndrome ( 2 , 3 8 ) . In 
subjects with hypergastrinemia gastric acid secretion has to be 
measured to exclude achlorhydria ( 3 9 ) . If hypergastrinemia is 
less than 1000 pg/ml stimulation tests have been advocated to 
verify the diagnosis of ZE-syndrome ( 2 ) . In all patients with 
hypergastrinemia without histologically proven gastrinoma the 
diagnosis of ZE-syndrome was confirmed by calcium (21,22) and 
secretin stimulation tests (23-25). In hypergastrinemic patients 
without previous gastric surgery meal stimulation tests were also 
performed. The lack of major increases in postprandial serum 
gastrin in these patients excluded antral G-cell hyperplasia 
(2 6 - 2 8 ) . Although Friesen et al (13) believe that antral G-cell 
hyperplasia may be found in members of MEA I-fami 1ies, no case 
of antral G-cell hyperplasia was detected in the present study. 
Nodular adrenocortical hyperplasia was an autopsy finding in 
all cases. This disorder was not accompanied by clinical symptoms 
or laboratory abnormalities in the MEA I-patients involved. 
Thyroid disease did not seem to be a component of MEA I 
in the families studied. The thyroid lesions, found in the 
literature, are diverse, e.g. goitre, thryoiditis, thyrotoxicosis 
and simple adenoma ( 7 ) . Since thyroid diseases are relatively 
common in the general population, it is questionable whether 
thyroid lesions should be considered an integral feature of the 
MEA I-entity ( 4 0 ) . 
MEA I is inherited as an autosomal dominant disorder with 
high penetrance and some variability in expressivity, as pointed 
out earlier by Wermer ( 4 ) . The MEA I-entity also tends to show 
some interfamilial variability. All 3 patients with insulinoma, 
for example, were members of family C, whereas in the other 5 
families no cases of insulinoma were found. In family F (fig. 9.1) 
a new dominant mutation probably occurred, as indicated by 
the lack of endocrine diseases in the parents, brother and sister 
of patient F i l l and the presence of hyperparathyroidism in his 
son. Although endocrinopathies have been described in children 
(5 , 1 6 , 4 1 ) , the incidence is very low ( 1 7 ) . In this study none of 
178 
7 children younger than 15 years was affected. 
From the present study it can be concluded that detailed 
endocrine studies have to be done in all ZE-patients and in their 
families. The endocrinopathies are frequently asymptomatic and 
laboratory and radiological investigations have to be performed. 
The investigation should at least be directed to the pituitary 
gland, the parathyroid glands and the pancreatic islets. These 
studies have to be repeated with intervals, because endocrine 
disease may develop with increasing age ( 5 ) . 
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SUMMARY 
Chapter 1 Introduction and problem statement 
In addition to some historical and introductory notes the 
outline of investigations and objectives in this thesis was 
presented . 
Chapter 2 The Zol1inger-E11ison. Observations on 18 patients 
Relevant features of 18 patients with the ZE-syndrome, examined 
at St. Radboud Hospital, Nijmegen, between 1963 and 1976, were 
analysed. Peptic ulcer disease, often complicated by bleeding or 
perforation, diarrhea, weight loss and heartburn were the most 
prominent clinical symptoms. The introduction of the radioimmuno-
assay of gastrin, facilitating the diagnosis of the ZE-syndrome, 
resulted in more adequate treatment and better prognosis of the 
patients. Other factors, such as coexisting endocrine disease, 
hypersecretion of gastric acid, hypoalbuminemia, impaired intesti-
nal absorption tests and findings at barium meal studies were 
useful in selecting patients for gastrin assay. Treatment with 
total gastrectomy or hi stamine-2-receptor antagonists resulted in 
marked symptomatic improvement. The effect of streptozotocin on 
tumour growth was not favourable in 2 patients with extensive 
liver metastases. Palliative irradiation of the liver was followed 
by a marked reduction in liver mass and a fall in serum bilirubin 
and gastrin levels in one of these patients. 
Chapter 3 Serum albumin levels in patients with the Zollinger-
El1 i son syndrome 
Serum albumin concentrations in 20 patients with the ZE-
syndrome (40.8 +_ 8.2 g/1 ; mean + S.D.) were significantly 
(p <0.001) lower than the levels observed in 40 normal controls 
(50.7 + 3.1 g / 1 ) , 40 duodenal ulcer patients (51.3 + 3.9 g/1) and 
20 stomal ulcer patients (50.6 + 3.4 g / 1 ) . Six ZE-patients with 
metastatic gastrinoma had significantly (p <0.05) lower serum 
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albumin concentrations (35.2 + 9.4 g/1) than 14 ZE-patients 
without evidence of metastatic lesions (43.2 + 6.6 g / 1 ) . 
In 2 out of 3 ZE-patients investigated serum concentrations of 
several essential amino acids were moderately or markedly decrea-
sed.In one of them albumin synthesis was measured and found to be 
at the lower limit of the normal range. Gastrointestinal protein 
loss was increased in 3 out of 4 ZE-patients studied. In 2 the 
intestine and not the stomach was the major site of protein loss. 
Total gastrectomy induced a rise in serum albumin concentration 
in all 8 patients studied, although in one patient with metastatic 
gastrinoma the albumin level persisted to be markedly decreased. 
In 2 ZE-patients, treated with total gastrectomy and suffering 
from extensive liver metastases, serum albumin concentration fell 
concomitant with progressive tumour growth. 
It is concluded that determination of serum albumin is 
helpful in selecting peptic ulcer patients for gastrin radioimmuno-
assay. At least 3 mechanisms may be involved in the pathogenesis of 
hypoalbuminemia as observed in some ZE-patients: 
- increased gastrointestinal protein loss, especially from the 
smal 1 i ntesti ne, 
- impaired albumin synthesis as a result of decreased serum levels 
of amino acids, probably in relation with malabsorption, 
- (metastatic) tumour growth. 
Chapter 4 The clinical relevance of gastrin radioimmunoassay 
Serum gastrin levels varied in 100 normal fasting subjects 
from 36 to 115 pg/ml . The mean serum gastrin concentration in 80 
patients with duodenal ulcer (70 + 20 pg/ml; mean + SO) did not 
differ significantly from the mean value in normal subjects (66 
+ 18 p g / m l ) . Serum gastrin values in 17 patients with gastric 
ulcer (92 + 28 pg/ml) were significantly increased compared with 
normal (p < 0 . 0 0 1 ) . All 19 patients with the ZE-syndrome had ele-
vated serum gastrin levels. Three ZE-patients with values of more 
than 3000 pg/ml had evidence of metastatic lesions. However, serum 
gastrin levels of less than 1500 pg/ml were observed in 2 other 
patients with metastatic ZE-syndrome. Sixty-six out of 72 patients 
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with achíorhydria had increased gastrin levels. In 25 out of 44 
patients with chronic renal failure serum gastrin concentrations 
were higher than the upper limit of the normal range. An elevated 
serum gastrin level of 295 pg/ml was found in a patient with 
suspected antral G-cell hyperplasia. None of 4 patients with 
massive small bowel resection had basal hypergastrinemia. Aspira-
tion of gastric juice resulted in a fall in serum gastrin in all 
9 ZE-patients tested. A decrease in serum gastrin, found in 3 out 
of 4 ZE-patients after total gastrectomy and in one ZE-patient 
following parathyroidectomy, did not reflect tumour regression. 
In 2 patients with extensive liver metastases serum gastrin levels 
increased progressively concomitant with expansive tumour growth. 
Besides the immediate postoperative period the serum gastrin level 
was a useful parameter in evaluating the effect of treatment on 
tumour growth. 
Chapter 5 Serum gastrin response to acute and chronic hypercal-
cemia; studies with emphasis on the significance of 
calcium stimulated serum gastrin levels to the diag-
nosis of the Zol1 inger-El1 i son syndrome 
Calcium infusion over 3 hours (5 mg/kg.h) provoked a more 
than 50% increase in serum gastrin in 14 out of 16 ZE-patients 
and in 3 out of 6 patients with achlorhydria. In none of 15 normal 
subjects, 10 duodenal ulcer patients, 9 stomal ulcer patients and 
5 patients with total gastrectomy was a more than 50% rise in serum 
gastrin observed. No marked differences in the gastrin response to 
calcium were found in ZE-patients before and after total gastrectomy 
and in ZE-patients with and without evidence of metastatic lesions. 
In 2 patients with total gastrectomy and in 4 patients with antrec-
tomy without gastrinoma calcium infusion induced a small rise in 
serum gastrin, indicating calcium stimulated release of extragas-
tric gastrin. Serum gastrin levels in 44 patients with chronic 
hypercalcemia (72 + 24 pg/ml, mean + S.D.) were not significantly 
different from the levels in 100 normal subjects (66 + 18 pg/ml; 
ρ >0.1 0 ) . However, in a patient with ZE-syndrome and in two 
patients with achlorhydria serum gastrin values were markedly 
185 
higher during chronic hypercalcemia than during normocalcemia. 
Chapter 6 The significance of secretin stimulated serum gastrin 
levels in patients with hyperparathyroidism from 
families with Multiple Endocrine Adenomatosis type I 
(MEA I) 
Fasting serum gastrin levels ranged from 40 to 26100 pg/ml 
in 23 patients with hyperparathyroidism from 6 MEA I-families. 
Six patients with marked hypergastrinemia of more than 250 pg/ml 
and 3 patients with slightly elevated serum gastrin levels 
between 142 and 250 pg/ml had positive secretin stimulation tests 
(i.e., more than 50% increase in serum gastrin after 1 U secretin 
GIH/kg.30 sec i . V . ) . The diagnosis of ZE-syndrome could be con-
firmed in these 9 patients by means of histologically proven 
gastrinoma in 2, persistent elevated serum gastrin levels after 
total gastrectomy in one, basal gastric acid hypersecretion in 
9, positive calcium stimulation tests in 9 and negative meal 
stimulation tests in all 6 patients tested. No false positive 
secretin stimulation tests were observed in 34 normal subjects, 
23 non-affected members of the MEA I-families, 14 duodenal and 
10 stomal ulcer patients, 7 patients with non-MEA I hyperpara-
thyroidism and 11 patients with achlorhydria. Two out of 6 IE-
patients without MEA I-evidence had negative secretin stimulation 
tests in spite of histologically proven gastrinoma. The serum 
gastrin response to intraduodenal instillation of hydrochloric 
acid was similar to the effect of secretin infusion studied in 
the same patient with ZE-syndrome and hyperparathyroidism. 
It is concluded that the secretin stimulation test is an easy, 
fast and safe test to diagnose asymptomatic and symptomatic 
ZE-syndrome in patients with hyperparathyroidism from MEA I-
families. 
Chapter 7 Fasting and postprandial serum gastrin levels in 
subjects with and without previous gastric surgery 
Fasting and postprandial serum gastrin levels were measured 
186 
in 12 normal subjects, 16 patients with duodenal ulcer, 9 with 
Billroth I antrectomy, 7 with Billroth II antrectomy, 7 with 
total gastrectomy, 9 with achlorhydria, 9 with ZE-syndrome without 
previous gastric surgery and one with ZE-syndrome and total 
gastrectomy. In all patients with ZE-syndrome or achlorhydria 
basal serum gastrin values were higher than in the other groups 
studied. Postprandial serum gastrin levels were significantly 
higher in duodenal ulcer patients, lower in patients with Billroth 
II antrectomy and total gastrectomy, and not significantly 
different in patients with Billroth I antrectomy in comparison 
with those obtained in normal subjects. Patients with achlorhydria 
had an early, steep and long-standing postprandial increase in 
serum gastrin. A gradual and progressive rise in serum gastrin 
was found in non-operated ZE-patients. Levels at 90, 120 and 150 
minutes after feeding were significantly higher than basal value. 
The patient with ZE-syndrome and total gastrectomy had a pronoun-
ced increase in serum gastrin, peaking at 30 minutes after inges-
tion of the test meal. 
Integrated gastrin response to the standard test meal was signi-
ficantly greater in patients with duodenal ulcer, achlorhydria 
and ZE-syndrome and significantly smaller in patients with 
Billroth II antrectomy and total gastrectomy in comparison with 
normal subjects. The integrated gastrin output in patients with 
Billroth I antrectomy was not significantly different from normal. 
Chapter 8 A comparative study of the value of the calcium, 
secretin and meal stimulated increase in serum gastrin 
to the diagnosis of the Zoll inger-El1 i son syndrome 
To evaluate the significance of provocation tests to the 
diagnosis of the ZE-syndrome calcium, 15 mg/kg.3 h, and secretin 
GIH, 1 U/kg.30 sec, stimulation tests were performed in 15 patients 
with the ZE-syndrome. In all 9 patients without previous gastric 
surgery meal stimulated serum gastrin levels were measured too. 
These tests were also performed in normal subjects and in patients 
with duodenal ulcer, antrectomy, total gastrectomy and achlorhydria. 
All tests were considered positive if a more than 50% increase in 
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serum gastrin was found. 
The results indicate that secretin stimulation is the most 
valuable provocation test to the diagnosis of ZE-syndrome for 
the following reasons: 
a. a small number (2 out of 15) of false negative test results 
in ZE-patients; b. no false positive tests in 69 patients without 
gastrinoma; c. easy and fast to perform and d. no adverse reac­
tions. The 2 ZE-patients with negative secretin stimulation tests 
also had negative calcium provocation tests in spite of histolo­
gically proven gastrinoma. 
In 11 patients with the ZE-syndrome and basal serum gastrin levels 
of less than 1000 pg/ml a good correlation (r=0.841; ρ <0.01) 
was obtained between the percentual increase in serum gastrin 
after stimulation with calcium and secretin. 
Meal stimulated serum gastrin levels proved only to be helpful 
in patients without previous gastric surgery. 
Chapter 9 Prevalence of endocrine abnormalities in patients 
with the Zol1 inger-El1 i son syndrome and in their 
fami 1 i es 
In 7 out of 10 patients with the ZE-syndrome coexisting 
endocrine disease was detected. Six had evidence of Multiple 
Endocrine Adenomatosis type I (MEA I) and one had Cushing's 
syndrome probably caused by the production of ACTH or an ACTH-
like substance by the pancreatic tumour. 
A total of 109 family members, including all living first 
degree relatives of at least 15 years of age, were investigated 
for endocrine disease. All 6 patients with ZE-syndrome as compo­
nent of MEA I had relatives with endocrinopathies. No endocrine 
abnormalities were detected in the families of 4 ZE-patients 
without MEA I-evidence. This study revealed 4 new cases of 
pituitary tumour, 17 of hyperparathyroidism, 7 of the ZE-syndrome 
and one of insulinoma in the 6 MEA I-families studied. These 
newly diagnosed endocrinopathies were very often asymptomatic. 
Analysis of the pedigrees indicates that the MEA I-entity is 
inherited as an autosomal dominant disorder with high penetrance 
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and some variability in expressivity. It is stressed that detailed 
endocrine studies have to be done in all ZE-patients and in their 
relatives. 
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STELLINGEN 
Een daling van het serum gastrinegehalte na een totale maag-
resectie bij een Zol1inger-El1 i son patient is niet bewijzend 
voor tumorregressie. 
Di t proefschri ft . 
ledere patient met het Zol1inger-El1 i son syndroom dient te 
worden onderzocht op andere endocriene afwijkingen. 
Di t proefschrift . 
Het verdient aanbeveling om iedere patient met primaire 
hyperparathyreoidie te onderzoeken op andere endocriene afwij-
kingen. 
Boey JH, Cooke TJC, Gilbert JM, Sweeney EC, Taylor S. Lancet 
2: 781, 1975-
Het verhoogde serum cal ei toninegehalte bij sommige patiënten 
met het Zol1 inger-El1 i son syndroom wordt niet veroorzaakt door 
een medullair schiIdkliercarcinoom en is evenmin gerelateerd 
aan de mate van hypergastrinemie. 
Sizemcre GW, Go VLW, Kaolan EL, fanzenbacher LJ, Holtermuller 
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